0001689548-24-000060.txt : 20240513 0001689548-24-000060.hdr.sgml : 20240513 20240513082105 ACCESSION NUMBER: 0001689548-24-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Praxis Precision Medicines, Inc. CENTRAL INDEX KEY: 0001689548 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39620 FILM NUMBER: 24937002 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-300-8460 MAIL ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 10-Q 1 prax-20240331.htm 10-Q prax-20240331
false2024Q10001689548December 310.06670.06670.06670.0667xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureprax:platformprax:candidateprax:segmentprax:securityprax:obligation00016895482024-01-012024-03-3100016895482024-05-0900016895482024-03-3100016895482023-12-3100016895482023-01-012023-03-3100016895482023-11-282023-11-280001689548us-gaap:CommonStockMember2023-12-310001689548us-gaap:AdditionalPaidInCapitalMember2023-12-310001689548us-gaap:RetainedEarningsMember2023-12-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001689548us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001689548prax:FollowOnOfferingMember2024-01-012024-03-310001689548us-gaap:CommonStockMemberprax:FollowOnOfferingMember2024-01-012024-03-310001689548prax:FollowOnOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001689548prax:AtTheMarketOfferingMember2024-01-012024-03-310001689548us-gaap:CommonStockMemberprax:AtTheMarketOfferingMember2024-01-012024-03-310001689548prax:AtTheMarketOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001689548us-gaap:CommonStockMemberprax:LicenseAndCollaborationAgreementMember2024-01-012024-03-310001689548prax:LicenseAndCollaborationAgreementMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001689548prax:LicenseAndCollaborationAgreementMember2024-01-012024-03-310001689548us-gaap:CommonStockMember2024-01-012024-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001689548us-gaap:RetainedEarningsMember2024-01-012024-03-310001689548us-gaap:CommonStockMember2024-03-310001689548us-gaap:AdditionalPaidInCapitalMember2024-03-310001689548us-gaap:RetainedEarningsMember2024-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001689548us-gaap:CommonStockMember2022-12-310001689548us-gaap:AdditionalPaidInCapitalMember2022-12-310001689548us-gaap:RetainedEarningsMember2022-12-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100016895482022-12-310001689548us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001689548prax:AtTheMarketOfferingMember2023-01-012023-03-310001689548us-gaap:CommonStockMember2023-01-012023-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001689548us-gaap:RetainedEarningsMember2023-01-012023-03-310001689548us-gaap:CommonStockMember2023-03-310001689548us-gaap:AdditionalPaidInCapitalMember2023-03-310001689548us-gaap:RetainedEarningsMember2023-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100016895482023-03-310001689548prax:FollowOnOfferingMember2023-01-012023-03-310001689548prax:LicenseAndCollaborationAgreementMember2023-01-012023-03-310001689548prax:FollowOnOfferingMemberus-gaap:SubsequentEventMember2024-04-012024-04-300001689548us-gaap:MoneyMarketFundsMember2024-03-310001689548us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001689548us-gaap:CorporateDebtSecuritiesMember2024-03-310001689548us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-03-310001689548us-gaap:OtherDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMember2023-12-310001689548us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001689548us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001689548us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001689548us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-03-310001689548us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-03-310001689548us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001689548us-gaap:FairValueMeasurementsRecurringMember2024-03-310001689548prax:OfficeSpaceInBostonMassachusettsMember2021-05-310001689548prax:UCBMemberus-gaap:LicenseMember2022-12-310001689548prax:UCBMemberus-gaap:LicenseMember2024-01-012024-03-310001689548prax:UCBMemberus-gaap:LicenseMember2024-03-310001689548us-gaap:LicenseMemberprax:TenaciaMember2024-01-040001689548prax:TenaciaMember2024-01-042024-01-040001689548prax:TenaciaMember2024-01-0400016895482024-01-040001689548prax:TenaciaMember2024-01-012024-01-310001689548us-gaap:LicenseMemberprax:TenaciaMember2024-01-310001689548prax:TenaciaMember2024-03-310001689548prax:TenaciaMember2024-01-012024-03-310001689548prax:FollowOnOfferingMember2023-06-210001689548us-gaap:OverAllotmentOptionMember2023-06-212023-06-210001689548prax:FollowOnOfferingMemberprax:PreFundedWarrantMember2023-06-210001689548us-gaap:WarrantMemberprax:FollowOnOfferingMember2023-06-210001689548prax:FollowOnOfferingMember2023-06-212023-06-210001689548srt:MaximumMemberprax:PreFundedWarrantMember2024-01-012024-03-310001689548us-gaap:WarrantMember2024-01-012024-03-310001689548prax:FollowOnOfferingMember2024-01-162024-01-160001689548prax:FollowOnOfferingMember2024-01-160001689548us-gaap:OverAllotmentOptionMember2024-01-162024-01-160001689548prax:FollowOnOfferingMemberprax:PreFundedWarrantMember2024-01-160001689548us-gaap:WarrantMemberprax:FollowOnOfferingMember2024-01-160001689548us-gaap:EmployeeStockOptionMember2024-03-310001689548us-gaap:EmployeeStockOptionMember2023-12-310001689548prax:PreFundedWarrantMemberprax:June2023FollowOnOfferingMember2024-03-310001689548prax:PreFundedWarrantMemberprax:June2023FollowOnOfferingMember2023-12-310001689548prax:PreFundedWarrantMemberprax:January2024FollowOnOfferingMember2024-03-310001689548prax:PreFundedWarrantMemberprax:January2024FollowOnOfferingMember2023-12-310001689548us-gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockIncentivePlanMember2024-03-310001689548us-gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockIncentivePlanMember2023-12-310001689548prax:TwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:StockCompensationPlanMember2024-03-310001689548prax:TwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:StockCompensationPlanMember2023-12-310001689548prax:InducementPlanMemberus-gaap:StockCompensationPlanMember2024-03-310001689548prax:InducementPlanMemberus-gaap:StockCompensationPlanMember2023-12-310001689548us-gaap:RestrictedStockMember2024-03-310001689548us-gaap:RestrictedStockMember2023-12-310001689548prax:InducementPlanMember2024-03-310001689548prax:A2020EmployeeStockIncentivePlanMember2024-03-310001689548prax:A2020EmployeeStockIncentivePlanMember2023-12-310001689548prax:A2017EmployeeStockIncentivePlanMember2024-03-310001689548prax:A2017EmployeeStockIncentivePlanMember2023-12-310001689548prax:TwentyTwentyEmployeeStockPurchasePlanMember2024-03-310001689548prax:TwentyTwentyEmployeeStockPurchasePlanMember2023-12-310001689548us-gaap:RestrictedStockMember2024-01-012024-03-310001689548prax:UnvestedRestrictedStockUnitsMember2024-03-310001689548prax:UnvestedRestrictedStockUnitsMember2024-01-012024-03-310001689548us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001689548us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001689548us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001689548us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001689548us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001689548us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001689548us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001689548us-gaap:RestrictedStockMember2024-01-012024-03-310001689548us-gaap:RestrictedStockMember2023-01-012023-03-310001689548us-gaap:EmployeeStockMember2024-01-012024-03-310001689548us-gaap:EmployeeStockMember2023-01-012023-03-310001689548prax:FollowOnOfferingMemberus-gaap:SubsequentEventMember2024-04-022024-04-020001689548prax:FollowOnOfferingMemberus-gaap:SubsequentEventMember2024-04-020001689548us-gaap:OverAllotmentOptionMemberus-gaap:SubsequentEventMember2024-04-022024-04-020001689548prax:FollowOnOfferingMemberus-gaap:SubsequentEventMemberprax:PreFundedWarrantMember2024-04-020001689548us-gaap:WarrantMemberprax:FollowOnOfferingMemberus-gaap:SubsequentEventMember2024-04-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number: 001-39620
PRAXIS PRECISION MEDICINES, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 47-5195942
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
99 High Street, 30th Floor
Boston, MA
02110
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 617-300-8460
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange
on which registered
Common Stock, par value $0.0001 per sharePRAXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒   No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
 Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐   No  ☒
As of May 9, 2024, the registrant had 17,107,887 shares of common stock, $0.0001 par value per share, outstanding.


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
•the success, cost and timing of our product candidate development activities and clinical trials;
•our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;
•the ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements and collaboration agreements;
•the ability and willingness of our third-party research institution collaborators to continue research and development activities relating to our product candidates;
•our ability to commercialize our product candidates, if approved, in light of the intellectual property rights of others;
•our ability to obtain funding for our operations, including funding necessary to complete further development and, if approved, commercialization of our product candidates;
•the commercialization of our product candidates, if approved;
•our plans to research, develop and, if approved, commercialize our product candidates;
•future agreements with third parties in connection with the commercialization of our product candidates, if approved, and any other approved product;
•the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
•the rate and degree of market acceptance of our product candidates, if approved;
•the pricing and reimbursement of our product candidates, if approved;
•regulatory developments in the United States and foreign countries;
•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
•the success of competing therapies that are or may become available;
•our ability to attract and retain key scientific or management personnel; and
•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the sections titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking


statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.
The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.
This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.


Table of Contents

  Page
PART I.
Item 1.
Item 2.
Item 3.
Item 4.
PART II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts in thousands, except share and per share data)
March 31, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$151,980 $81,300 
Marketable securities55,436 — 
Prepaid expenses and other current assets4,388 3,580 
Total current assets211,804 84,880 
Long-term marketable securities35,873 — 
Property and equipment, net476 588 
Operating lease right-of-use assets1,840 2,064 
Other non-current assets416 416 
Total assets$250,409 $87,948 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$9,404 $5,815 
Accrued expenses6,976 7,416 
Operating lease liabilities1,158 1,126 
Current portion of deferred revenue1,256 1,392 
Total current liabilities18,794 15,749 
Long-term liabilities:
Non-current portion of operating lease liabilities1,066 1,369 
Non-current portion of deferred revenue866 1,161 
Total liabilities20,726 18,279 
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023
— — 
Common stock, $0.0001 par value; 150,000,000 shares authorized; 13,258,047 shares issued and outstanding as of March 31, 2024, and 8,791,877 shares issued and outstanding as of December 31, 2023
13 13 
Additional paid-in capital923,141 723,577 
Accumulated other comprehensive income3 — 
Accumulated deficit(693,474)(653,921)
Total stockholders’ equity229,683 69,669 
Total liabilities and stockholders’ equity$250,409 $87,948 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(Amounts in thousands, except share and per share data)
Three Months Ended
March 31,
20242023
Collaboration revenue$431 $683 
Operating expenses:
Research and development26,984 25,504 
General and administrative15,333 13,270 
Total operating expenses42,317 38,774 
Loss from operations(41,886)(38,091)
Other income:
Other income, net2,333 636 
Total other income2,333 636 
Net loss$(39,553)$(37,455)
Net loss per share attributable to common stockholders, basic and diluted1
$(2.84)$(10.58)
Weighted average common shares outstanding, basic and diluted1
13,904,374 3,540,185 
1 Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(Amounts in thousands)
Three Months Ended
March 31,
20242023
Net loss$(39,553)$(37,455)
Change in unrealized gains on marketable securities, net of tax3 154 
Comprehensive loss$(39,550)$(37,301)
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(Amounts in thousands, except share data)
Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other
Comprehensive Income		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 20238,791,877 $13 $723,577 $(653,921)$— $69,669 
Stock-based compensation expense— — 14,475 — — 14,475 
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $10,836
3,802,025 — 161,649 — — 161,649 
Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of $376
209,852 — 6,169 — — 6,169 
Issuance of common stock from a collaboration and license agreement443,253 — 17,265 — — 17,265 
Vesting of restricted stock units11,095 — — — — — 
Shares withheld for taxes for vesting of restricted stock units(3,689)— (137)— — (137)
Issuance of common stock upon exercise of stock options3,634 — 143 — — 143 
Change in unrealized gain on marketable securities, net of tax— — — — 3 3 
Net loss— — — (39,553)— (39,553)
Balance at March 31, 202413,258,047 $13 $923,141 $(693,474)$3 $229,683 

Common Stock1
Additional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other
Comprehensive Loss		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 20223,292,163 $5 $606,918 $(530,644)$(173)$76,106 
Stock-based compensation expense— — 7,593 — — 7,593 
Issuance of common stock from at-the-market public offerings, net of commission costs of $560
560,253 1 18,095 — — 18,096 
Vesting of restricted stock units11,516 — — — — — 
Shares withheld for taxes for vesting of restricted stock units(2,875)— (127)— — (127)
Issuance of common stock upon exercise of stock options2,970 — 101 — — 101 
Change in unrealized loss on marketable securities, net of tax— — — — 154 154 
Net loss— — — (37,455)— (37,455)
Balance at March 31, 20233,864,027 $6 $632,580 $(568,099)$(19)$64,468 
1 Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Amounts in thousands)
Three Months Ended
March 31,
20242023
Cash flows from operating activities:
Net loss$(39,553)$(37,455)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense112 106 
Stock-based compensation expense14,475 7,593 
Non-cash operating lease expense224 201 
Amortization of premiums and discounts on marketable securities, net(84)45 
Non-cash collaboration and license agreement expense2,500 — 
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(808)1,771 
Accounts payable3,589 2,314 
Accrued expenses(608)(6,498)
Operating lease liabilities(271)(240)
Deferred revenue(431)(683)
Other(2)— 
Net cash used in operating activities(20,857)(32,846)
Cash flows from investing activities:
Purchases of marketable securities(91,220)— 
Maturities of marketable securities— 34,000 
Net cash (used in) provided by investing activities(91,220)34,000 
Cash flows from financing activities:
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs161,649 — 
Issuance of common stock from collaboration and license agreement14,765 — 
Proceeds from at-the-market offerings, net of issuance and commission costs6,337 18,096 
Payments of tax withholdings related to vesting of restricted stock units(137)(127)
Proceeds from exercise of stock options and employee stock purchase plan purchases143 101 
Net cash provided by financing activities182,757 18,070 
Increase in cash, cash equivalents and restricted cash70,680 19,224 
Cash, cash equivalents and restricted cash, beginning of period81,716 62,031 
Cash, cash equivalents and restricted cash, end of period$152,396 $81,255 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents151,980 80,839 
Restricted cash416 416 
Total cash, cash equivalents and restricted cash$152,396 $81,255 
Supplemental disclosures of non-cash activities:
Issuance costs from at-the-market offering included in accrued expenses$168 $— 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

PRAXIS PRECISION MEDICINES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Nature of the Business
Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system ("CNS"), disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using its understanding of shared biological targets and circuits in the brain. Each platform has multiple programs currently, with significant potential for additional program and indication expansion:
•Cerebrum™, the Company's small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies
•Solidus™, the Company's antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology
The Company's platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For the Company's most advanced product candidate under the Cerebrum™ platform, ulixacaltamide (formerly known as PRAX-944), it expects to announce topline results from the ongoing Phase 3 Essential3 clinical trials in essential tremor in the second half of 2024. Within the Company's PRAX-628 program, it announced positive results from its Photo-Paroxysmal Response ("PPR") study in the first quarter of 2024 and plans to initiate the first of two efficacy studies of PRAX-628 in focal onset seizures in the second half of 2024, with topline results expected in 2025. The Company plans to initiate a second PRAX-628 efficacy study in focal onset seizures in the first half of 2025, with topline results expected in the first half of 2026. The Company's PRAX-562 Phase 2 EMBOLD study was initiated in the first quarter of 2023, with cohorts in SCN2A-DEE and SCN8A-DEE; topline results are expected for both cohorts in the third quarter of 2024. For the Company's most advanced product candidate under the Solidus™ platform, elsunersen (formerly known as PRAX-222), it shared results from Part 1 of the EMBRAVE study in the fourth quarter of 2023, and is currently completing multiple global regulatory interactions in anticipation of starting the pivotal phase of the program later in 2024.
Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, from the sale of common stock through an initial public offering and at-the-market offerings under its shelf registration statement, and from follow-on public offerings of common stock and pre-funded warrants to purchase common stock. From inception through March 31, 2024, the Company raised $785.3 million in aggregate cash proceeds from these transactions, net of issuance costs. In April 2024, the Company raised net proceeds of $215.8 million from a follow-on public offering of common stock and pre-funded warrants.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.
6

Liquidity
In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
The Company has incurred recurring losses since its inception, including a net loss of $39.6 million for the three months ended March 31, 2024. In addition, as of March 31, 2024, the Company had an accumulated deficit of $693.5 million. The Company expects to continue to generate operating losses for the foreseeable future.
The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2024 of $243.3 million will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.
Reverse Stock Split
On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the "Effective Time").
As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.
Marketable Securities Classification
The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.
The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and
7

losses in accumulated other comprehensive loss, a component of stockholders’ equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more-likely-than-not that the Company will hold these assets through to their maturity dates.
Unaudited Interim Condensed Consolidated Financial Information
The accompanying condensed consolidated balance sheet as of March 31, 2024, the condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 and the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. Financial statement disclosures for the three months ended March 31, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.
The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Common Stock Warrants
The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480, Distinguishing Liabilities from Equity (ASC 480) and ASC No. 815, Derivatives and Hedging (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.
Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.
8

Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements
On November 27, 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.
On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.
3. Cash Equivalents and Marketable Securities
The following is a summary of the Company's investment portfolio as of March 31, 2024. The Company did not hold any cash equivalents or marketable securities as of December 31, 2023 (in thousands):
As of March 31, 2024
Gross UnrealizedEstimated
CostGainsLossesFair Value
Cash equivalents:
Money market funds$15,971 $— $— $15,971 
Debt securities issued by U.S. government agencies17,889 — — 17,889 
Corporate debt securities12,009 — (1)12,008 
Commercial paper2,450 — (1)2,449 
Available-for-sale marketable securities:
Debt securities issued by U.S. government agencies59,722 12 — 59,734 
Corporate debt securities26,602 — (2)26,600 
Commercial paper1,934 — (3)1,931 
Other debt securities3,046 — (2)3,044 
Total cash equivalents and marketable securities$139,623 $12 $(9)$139,626 
As of March 31, 2024, the Company had 33 securities with a total fair market value of $42.6 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. The Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.
Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):
9

March 31, 2024December 31, 2023
Within one year$87,782 $— 
After one year through five years35,873 — 
Total$123,655 $— 
Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three months ended March 31, 2024 and 2023.
4. Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:
•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;
•Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.
The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of December 31, 2023:
As of March 31, 2024
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$15,971 $— $— $15,971 
Debt securities issued by U.S. government agencies17,889 — — 17,889 
Corporate debt securities— 12,008 — 12,008 
Commercial paper— 2,449 — 2,449 
Available-for-sale marketable securities:
Debt securities issued by U.S. government agencies59,734 — — 59,734 
Corporate debt securities— 26,600 — 26,600 
Commercial paper— 1,931 — 1,931 
Other debt securities— 3,044 — 3,044 
$93,594 $46,032 $— $139,626 
5. Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2024December 31, 2023
Accrued external research and development expenses$4,717 $2,957 
Accrued personnel-related expenses1,661 3,716 
Accrued other expenses598 743 
Total accrued expenses$6,976 $7,416 
10

6. Commitments and Contingencies
In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023. This lease qualifies as an operating lease.
7. Collaboration and License Agreements
UCB Option and License Agreement
In December 2022, the Company entered into an Option and License Agreement (“the Collaboration Agreement”) with UCB Biopharma SRL (“UCB”) for the discovery of small molecule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a $5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to $98.5 million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement.
The Company concluded that UCB is a customer, and as such, the arrangement falls within the scope of Topic 606. At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be $5.0 million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right.
The Company recognizes revenue for its research services performance obligation over time using an input method over the duration of the research services. During the three months ended March 31, 2024, the Company recognized $0.4 million in collaboration revenue related to the Collaboration Agreement in the condensed consolidated statement of operations. As of March 31, 2024, $2.1 million was included in deferred revenue in the condensed consolidated balance sheet, of which $1.3 million was classified as current.
Tenacia Collaboration and License Agreement
On January 4, 2024, the Company entered into an exclusive collaboration and license Agreement (“the License Agreement”) with Tenacia Biotechnology (Shanghai) Co., Ltd. (“Tenacia”), a China-based portfolio company of Bain Capital, which provides Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company also entered into a Stock Purchase Agreement (“the Stock Purchase Agreement”) with BCPE Tenet Holdings Cayman, Ltd. (“BCPE”), a related party of Tenacia. Pursuant to the terms of the License Agreement, the Company was entitled to an up-front, non-refundable and non-creditable cash payment of $5.0 million, net of certain tax withholdings. In addition, the Company is eligible to receive $264.0 million in success-based development and commercialization milestone payments as well as tiered royalties on net sales. Pursuant to the terms of the Stock Purchase Agreement, the Company issued and sold 443,253 shares of its common stock to BCPE at a price per share of $22.5605 for aggregate gross proceeds of $10.0 million. The per share price was based on a 20% premium over the 30-day volume-weighted average price.
Under the terms of the License Agreement, the Company granted to Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing.
The Company concluded that the License Agreement and the Stock Purchase Agreement is a combined arrangement since they were executed at the same time and in contemplation of each other with the same counterparty or a related party thereof and the combined arrangement falls within the scope of Topic 606.
11

The Company’s obligations under the arrangement comprise a single promise, or one performance obligation, related to the exclusive development and commercialization license granted to Tenacia. Total proceeds associated with the combined arrangement at inception were $14.8 million consisting of the following: (i) $10.0 million gross proceeds from the sale of common stock under the Stock Purchase Agreement and (ii) $4.8 million, net of tax, related to the up-front payment under the License Agreement, both of which were received in January 2024. During the three months ended March 31, 2024, the Company had not achieved any development or sales milestones or earned any royalties under the License Agreement.
The Company recorded the common stock sold to BCPE at its issuance date fair value of $38.95 per share, or $17.3 million in the aggregate, which exceeded the proceeds received which were calculated based on the 20% premium over the prior 30-day volume-weighted average price. Accordingly, there is no transaction price allocable to the performance obligation as of March 31, 2024. The Company accounted for the excess of the fair value of the equity securities issued over the total proceeds received as consideration paid to a customer for which no distinct good or service was transferred in exchange. As a result, the transaction gives rise to negative revenue on a cumulative basis in the amount of $2.5 million, which was recorded in research and development expense in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2024. For agreements where the licenses are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time that the Company effectively grants the license, as the licenses or assignments represent functional intellectual property.
As of March 31, 2024, the Company did not have any receivables or deferred revenue related to the arrangement with Tenacia. The Company did not recognize any contract assets related to costs to obtain a contract with a customer or costs to fulfill a contract with a customer through March 31, 2024 because no qualifying costs were incurred. During the three months ended March 31, 2024, the Company did not recognize any revenue associated with the combined arrangement.
8. Common Stock and Preferred Stock
Reverse Stock Split
On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023.
As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the period prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.
Common Stock
As of March 31, 2024 and December 31, 2023, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value.
As of March 31, 2024 and December 31, 2023, the Company did not hold any treasury shares.
Follow-On Public Offerings
June 2023 Public Offering
On June 21, 2023, the Company completed a public offering of: (i) an aggregate of 4,296,646 shares of its common stock at a public offering price of $14.25 per share, including the underwriters’ full exercise of their option to purchase 619,979 additional shares of common stock, and (ii) pre-funded warrants to purchase 470,000 shares of common stock at a public offering price of $14.2485 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0015 per share exercise price for each underlying share. Total net proceeds generated from the offering were approximately $63.4 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.
12

The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause either the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 9.99%, or the combined voting power of the securities beneficially owned by such holder, together with its affiliates, to exceed 9.99%. A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company. The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. In the event of certain fundamental transactions where the consideration payable to the holders of shares of common stock consists solely of cash and/or marketable securities, the pre-funded warrants will automatically be deemed to be exercised in full pursuant to a cashless exercise effective immediately prior to and contingent upon the consummation of such transaction. As of March 31, 2024, none of the pre-funded warrants had been exercised and all remain outstanding.
January 2024 Public Offering
On January 16, 2024, the Company completed a public offering of: (i) an aggregate of 3,802,025 shares of its common stock at a public offering price of $35.50 per share, including the underwriters' full exercise of their option to purchase 633,750 additional shares of commons stock, and (ii) pre-funded warrants to purchase 1,056,725 shares of common stock at a public offering price of $35.4999 per share of common stock underlying the warrants. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $161.6 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.
The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause either the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%), or the combined voting power of the securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%). A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company. The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. As of March 31, 2024, none of the pre-funded warrants had been exercised and all remained outstanding.
The Company determined that the pre-funded warrants related to both the June 2023 and January 2024 public offerings are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity’s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity.
Shares Reserved for Future Issuance
The Company has reserved the following shares of common stock for future issuance:
13

March 31,
2024		December 31,
2023
Shares reserved for exercise of outstanding stock options1,084,026 666,163 
Shares reserved for exercise of pre-funded warrants related to the June 2023 Financing470,000 470,000 
Shares reserved for exercise of pre-funded warrants related to the January 2024 Financing1,056,725 — 
Shares reserved for future awards under the 2020 Stock Option and Incentive Plan111,028 148,264 
Shares reserved for future awards under the 2020 Employee Stock Purchase Plan141,029 53,111 
Shares reserved for future awards under the 2024 Inducement Plan996,950 — 
Shares reserved for vesting of restricted stock units97,601 47,145 
Total shares of authorized common stock reserved for future issuance3,957,359 1,384,683 
Preferred Stock
As of March 31, 2024 and December 31, 2023, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, $0.0001 par value.
9. Stock-Based Compensation
2024 Inducement Plan
In January 2024, the Board of Directors ("the Board") adopted the 2024 Inducement Plan (the "Inducement Plan") without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules ("Rule 5635(c)(4)"). In accordance with Rule 5635(c)(4), the Inducement Plan allows the Company to grant awards only to a newly hired employee who was not previously an employee or non-employee director or to an employee who is being rehired following a bona fide period of non-employment if such award is a material inducement to such employee entering into employment. The total number of shares of common stock authorized for issuance under the Inducement Plan as of March 31, 2024 was 1,000,000 shares.
2020 Stock Option and Incentive Plan
The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of March 31, 2024 and December 31, 2023 was 1,100,833 shares and 661,240 shares, respectively.
2017 Stock Incentive Plan
The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan") as of March 31, 2024 and December 31, 2023 was 395,850 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.
2020 Employee Stock Purchase Plan
The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of March 31, 2024 and December 31, 2023 was 175,145 shares and 87,227 shares, respectively.
Restricted Stock Units
The following table summarizes the Company’s restricted stock unit activity:
SharesWeighted
Average
Grant Date
Fair Value
Unvested as of December 31, 202347,145 $202.27 
Issued65,333 43.35 
Vested(11,346)316.60 
Forfeited(3,531)35.63 
Unvested as of March 31, 202497,601 $88.63 
14

As of March 31, 2024, total unrecognized compensation cost related to unvested restricted stock units was $7.8 million, which is expected to be recognized over a weighted-average period of 2.34 years.
Stock Options
The following table summarizes the Company’s stock option activity:
Number of
Shares		Weighted
Average
Exercise Price
per Share		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic Value
(In years)(In thousands)
Outstanding as of December 31, 2023666,163 $160.19 
Granted428,850 43.36 
Exercised(3,634)39.30 $38 
Cancelled or Forfeited(7,353)124.58 
Outstanding as of March 31, 20241,084,026 $114.62 8.38$14,197 
Exercisable as of March 31, 2024689,361 $129.09 8.06$7,632 
Vested and expected to vest as of March 31, 20241,084,026 $114.62 8.38$14,197 
Valuation of Stock Options
The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three months ended March 31, 2024:
Three Months Ended
March 31,
2024
Risk-free interest rate3.88 %
Expected term (in years)6.01
Expected volatility88.75 %
Expected dividend yield— %
Weighted average grant-date fair value per share$32.70 
As of March 31, 2024, total unrecognized compensation cost related to unvested stock options was $24.8 million, which is expected to be recognized over a weighted-average period of 1.88 years.
Stock-Based Compensation
Stock-based compensation expense was allocated as follows (in thousands):
Three Months Ended
March 31,
20242023
Research and development$5,598 $2,223 
General and administrative8,877 5,370 
Total stock-based compensation expense$14,475 $7,593 
10. Net Loss per Share
The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:
15

Three Months Ended
March 31,
20242023
Outstanding stock options1,084,026 712,737 
Unvested restricted stock units97,601 50,317 
Potential shares issuable under the 2020 ESPP27,827 11,984 
1,209,454 775,038 
Common shares issuable upon exercise of the pre-funded warrants that were sold in connection with the June 2023 and the January 2024 underwritten public offering are included in the calculation of basic weighted average number of common shares outstanding for the three months ended March 31, 2024. Consistent with the guidance in ASC 260-10-45-13, the underlying common shares are issuable for little to no consideration and there are no vesting conditions or contingencies associated with the warrants. Accordingly, the aggregate number of common shares underlying the pre-funded warrants have been considered outstanding for purposes of the calculation of basic net loss per share from the date of issuance.
11. Related Party Transactions
On September 11, 2019, the Company entered into a Cooperation and License Agreement (the “License Agreement”) with RogCon Inc. (“RogCon”). Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon's intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Pursuant to the terms of the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the associated research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. One of the founders of RogCon became the Company's General Counsel in June 2020. The Company continues to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. Expenses incurred during all periods presented were not material.
12. Subsequent Events
April 2024 Financing
On April 2, 2024 the Company completed a public offering of: (i) an aggregate of 3,849,558 shares of its common stock at a public offering price of $56.50 per share, including the underwriters' full exercise of their option to purchase 530,973 additional shares of common stock, and (ii) pre-funded warrants to purchase 221,238 shares of common stock at a public offering price of $56.4999 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $215.8 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.
16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (the "SEC") on March 5, 2024. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2023, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We are a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. We are applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using our understanding of shared biological targets and circuits in the brain. Each platform currently has multiple programs, with significant potential for additional program and indication expansion:
•Cerebrum™, our small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies
•Solidus™, our antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology
Our platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, we have established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For our most advanced product candidate under the Cerebrum™ platform, ulixacaltamide (formerly known as PRAX-944), we expect to announce topline results from the Phase 3 Essential3 clinical trials in essential tremor, or ET, in the second half of 2024. Within our PRAX-628 program, we announced positive results from our Phase 2a Photo-Paroxysmal Response study in the first quarter of 2024 and plan to initiate the first of two efficacy studies of PRAX-628 in focal onset seizures in the second half of 2024, with topline results expected in 2025. We plan to initiate a second PRAX-628 efficacy study in focal onset seizures in the first half of 2025, with topline results expected in the first half of 2026. Our PRAX-562 Phase 2 EMBOLD study was initiated in the first quarter of 2023, with cohorts in SCN2A-DEE and SCN8A-DEE; topline results are expected for both cohorts in the third quarter of 2024. For our most advanced product candidate under the Solidus™ platform, elsunersen (formerly known as PRAX-222), we shared results from Part 1 of the EMBRAVE study in the fourth quarter of 2023, and are currently completing multiple global regulatory interactions in anticipation of starting the pivotal phase of the program later in 2024.
We were incorporated in 2015 and commenced operations in 2016. Since inception, we have devoted substantially all of our resources to developing our preclinical and clinical product candidates, building our intellectual property, or IP, portfolio, business planning, raising capital and providing general and administrative support for these operations. We employ a “virtual” research and development model, relying heavily upon external consultants, collaborators, contract development and manufacturing organizations and contract research organizations, or CROs, to conduct our preclinical and clinical activities. Since inception, we have financed our operations primarily with proceeds from the sale and issuance of equity securities.
We are a development stage company and we have not generated any revenue from product sales, and do not expect to do so for several years, if at all. All of our product candidates are still in preclinical and clinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the
17

successful development and eventual commercialization of one or more of our product candidates, if approved. We have incurred recurring operating losses since inception, including a net loss of $39.6 million for the three months ended March 31, 2024. As of March 31, 2024, we had an accumulated deficit of $693.5 million. We expect to incur significant expenses and operating losses for the foreseeable future as we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will be maintained or increased in connection with our ongoing activities, as we:
•advance our lead product candidate, ulixacaltamide, through the Phase 3 Essential3 clinical trial program for ET;
•advance our PRAX-562 product candidate in the EMBOLD clinical trial;
•advance elsunersen (formerly PRAX-222) into the pivotal stage of the program;
•advance our PRAX-628 product candidate into efficacy clinical trials for focal onset seizures;
•advance our preclinical candidates to clinical trials;
•further invest in our pipeline;
•further invest in our manufacturing capabilities;
•seek regulatory approval for our product candidates;
•maintain, expand, protect and defend our IP portfolio;
•acquire or in-license technology;
•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and
•when needed, increase our headcount to support our development efforts and any future commercialization efforts.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of March 31, 2024, we had cash, cash equivalents and marketable securities of $243.3 million. We expect that our cash, cash equivalents, and marketable securities as of March 31, 2024, together with proceeds from our follow-on public offering in April 2024. will be sufficient to fund our operating expenditures and capital expenditure requirements necessary to advance our research efforts and clinical trials into 2027. The analysis included consideration of our current financial needs and ongoing research and development plans. We have based this estimate on assumptions that may provide to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and Capital Resources.”
Reverse Stock Split
On November 28, 2023, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of our
18

common stock, or the Reverse Stock Split. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023, or the Effective Time.
As a result of the Reverse Stock Split, every 15 shares of our issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders thereof. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock.
No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price per share of the common stock (as adjusted for the Reverse Stock Split) on the Nasdaq Global Select Market on November 28, 2023, the last trading day immediately preceding the Effective Time.
Financial Operations Overview
Revenue
We have not generated any revenue from the sale of products since inception and do not expect to generate any revenue from the sale of products for several years, if at all. As discussed in Note 7 to our condensed consolidated financial statements, we entered into an Option and License Agreement, or the Collaboration Agreement, with UCB Biopharma SRL, or UCB, in December 2022. We recognized $0.4 million of collaboration revenue from the Collaboration Agreement during the three months ended March 31, 2024.
Operating Expenses
Research and Development Expenses
The nature of our business and primary focus of our activities generate a significant amount of research and development costs. Research and development expenses represent costs incurred by us for the following:
•discovery efforts leading to development candidates;
•clinical development costs for our product candidates; and
•costs to develop our manufacturing technology and infrastructure.
The costs above comprise the following categories:
•personnel-related expenses, including salaries, benefits and stock-based compensation expense;
•expenses incurred under agreements with third parties, such as consultants, investigative sites and CROs, that conduct our preclinical and clinical studies and in-licensing arrangements;
•costs incurred to maintain compliance with regulatory requirements;
•costs incurred with third-party contract development and manufacturing organizations to acquire, develop and manufacture materials for preclinical and clinical studies; and
•depreciation, amortization and other direct and allocated expenses, including rent and other operating costs, such as information technology, incurred as a result of our research and development activities.
We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated balance sheets as prepaid expenses or accrued expenses. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
19

As a company operating in a virtual environment, a significant portion of our research and development costs have been external costs incurred by third-parties. We track direct external research and development expenses to specific platforms and product candidates upon commencement. Due to the number of ongoing studies and our ability to use resources across platforms, indirect or shared operating costs incurred for our research and development platforms, such as personnel, facility costs and certain consulting costs, are not recorded or maintained on a platform-specific basis.
The following table reflects our research and development expenses, including direct expenses summarized by platform and indirect or shared operating costs recognized as research and development expenses during each period presented (in thousands):
Three Months Ended
March 31,
20242023
Cerebrum™
$12,785 $11,135 
Solidus™
1,190 3,602 
Personnel-related (including stock-based compensation)10,952 8,126 
Other indirect research and development expenses2,057 2,641 
Total research and development expenses$26,984 $25,504 
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will be maintained or increase in the foreseeable future as we advance our product candidates through the development phase, and as we continue to discover and develop additional product candidates, build manufacturing capabilities and expand into additional therapeutic areas.
At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:
•our ability to add and retain key research and development personnel;
•the timing and progress of preclinical and clinical development activities;
•the number and scope of preclinical and clinical programs we decide to pursue;
•our ability to successfully complete clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;
•our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;
•our successful enrollment in and completion of clinical trials;
•the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations;
•our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our product candidates;
•our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;
•the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;
•our ability to obtain and maintain patent, trade secret and other IP protection and regulatory exclusivity for our product candidates, if approved;
20

•our receipt of marketing approvals from applicable regulatory authorities;
•our ability to commercialize products, if approved, whether alone or in collaboration with others; and
•the continued acceptable safety profiles of our product candidates.
A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete our clinical development activities. We may never obtain regulatory approval for any of our product candidates. Drug commercialization will take several years and require significant development costs.
General and Administrative Expense
General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, finance, legal, commercial and administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; commercial-related costs to support market assessments and scenario planning; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for office rent and other operating costs, such as information technology. Costs to secure and defend our IP are expensed as incurred and are classified as general and administrative expenses. These costs relate to the operation of the business and are unrelated to the research and development function or any individual platform or product candidate.
We anticipate that our general and administrative expenses may increase in the future as we increase our headcount, when needed, to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to incur additional IP-related expenses as we file patent applications to protect innovations arising from our research and development activities.
Other Income
Other Income, Net
Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts.
Income Taxes
Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three months ended March 31, 2024 and 2023.
Results of Operations
Comparison of the Three Months Ended March 31, 2024 and 2023
The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):
21

Three Months Ended
March 31,		Change
20242023
Collaboration revenue$431 $683 $(252)
Operating expenses:
Research and development26,984 25,504 1,480 
General and administrative15,333 13,270 2,063 
Total operating expenses42,317 38,774 3,543 
Loss from operations(41,886)(38,091)(3,795)
Other income:
Other income, net2,333 636 1,697 
Total other income2,333 636 1,697 
Net loss$(39,553)$(37,455)$(2,098)
Collaboration Revenue
The $0.3 million decrease in collaboration revenue is associated with a decrease in the revenue recorded under the Collaboration Agreement with UCB that was executed in December 2022. Changes in revenue recognized each period reflect timing of research services provided and costs incurred.
Research and Development Expense
The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):
Three Months Ended
March 31,		Change
20242023
Cerebrum™
$12,785 $11,135 $1,650 
Solidus™
1,190 3,602 (2,412)
Personnel-related (including stock-based compensation)10,952 8,126 2,826 
Other indirect research and development expenses2,057 2,641 (584)
Total research and development expenses$26,984 $25,504 $1,480 
The $1.5 million increase in research and development expenses was primarily attributable to the following:
•$2.8 million increase in personnel-related costs, primarily due to increased stock-based compensation expense;
•$1.7 million increase in expense related to our Cerebrum™ platform, driven primarily by:
◦a $5.2 million increase in spend for our ulixacaltamide program due to Essential3 study activity;
◦a $1.6 million decrease in spend for our PRAX-628 program due to prior year clinical-related spend;
◦a $1.0 million decrease in activities for our earlier stage assets due to prioritization of clinical-stage programs; and
◦a $0.7 million decrease in spend for our PRAX-562 program.
•$2.4 million decrease in expense related to our Solidus™ platform, primarily related to prior year toxicology and clinical pharmacology spend for elsunersen; and
•$0.6 million decrease in indirect expenses, none of which were individually significant.
General and Administrative Expense
The $2.0 million increase in general and administrative expenses was primarily attributable to the following:
22

•$2.9 million increase in personnel-related costs mainly due to increased stock-based compensation expense; and
•$0.9 million decrease in consulting expenses and professional fees.
Other Income
Other income for the three months ended March 31, 2024 and 2023 was comprised of interest income on our cash, cash equivalents, and marketable securities and investment premium and discount amortization.
Liquidity and Capital Resources
Sources of Liquidity
Since our inception, we have incurred significant losses in each period. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all.
To date, we have financed our operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, common stock and pre-funded warrants through follow-on public offerings and common stock from at-the-market offerings under our shelf registration statement. From inception through March 31, 2024, we have raised $785.3 million in aggregate cash proceeds from such transactions, net of issuance costs. As of March 31, 2024, we had cash and cash equivalents and marketable securities of $243.3 million.
In November 2021, we entered into an Open Market Sale Agreement, or the 2021 Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of $125.0 million of common stock from time to time in at-the-market offerings for which Jefferies acted as sales agent. We terminated the 2021 Sales Agreement in June 2023.
On June 21, 2023, we completed a public offering of: (i) an aggregate of 4,296,646 shares of common stock at a public offering price of $14.25 per share, including the underwriters' full exercise of their option to purchase 619,979 additional shares of common stock, and (ii) pre-funded warrants to purchase 470,000 shares of common stock at a public offering price of $14.2485 per share. The purchase prices per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0015 per share exercise price for each underlying share. Total net proceeds generated from the offering were approximately $63.4 million, after deducting underwriting discounts, commissions and other offering expenses payable by us.
In December 2023, we entered into an Open Market Sale Agreement, or the 2023 Sales Agreement, with Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of $75.0 million of common stock in at-the-market offerings. The 2023 Sales Agreement was terminated in January 2024. During the three months ended March 31, 2024, we issued and sold an aggregate of 192,190 shares under the 2023 Sales Agreement for aggregate net proceeds of $5.3 million, after deducting commissions and offering expenses payable by us.
On January 16, 2024, we completed a public offering of: (i) an aggregate of 3,802,025 shares of our common stock at a public offering price of $35.50 per share, including the underwriters' full exercise of their option to purchase 633,750 additional shares of common stock, and (ii) pre-funded warrants to purchase 1,056,725 shares of common stock at a public offering price of $35.4999 per share of common stock underlying the warrants. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $161.6 million, after deducting underwriting discounts, commissions and other offering expenses payable by us.
In March 2024, we entered into an Open Market Sale Agreement, or the 2024 Sales Agreement, with Jefferies, to provide for the offering, issuance, and sale of up to an aggregate amount of $150.0 million of common stock in at-the-market offerings. During the three months ended March 31, 2024, we issued and sold an aggregate of 17,662 shares under the 2024 Sales Agreement for aggregate net proceeds of $0.9 million, after deducting commissions and offering expenses payable by us.
23

On April 2, 2024, we completed a public offering of: (i) an aggregate of 3,849,558 shares of our common stock at a public offering price of $56.50 per share, including the underwriters' full exercise of their option to purchase 530,973 additional shares of common stock, and (ii) pre-funded warrants to purchase 221,238 shares of common stock at a public offering price of $56.4999 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $215.8 million, after deducting underwriting discounts, commissions and other offering expenses payable by us.
Cash Flows
The following table provides information regarding our cash flows for each period presented (in thousands):
Three Months Ended
March 31,
20242023
Net cash (used in) provided by:
Operating activities$(20,857)$(32,846)
Investing activities(91,220)34,000 
Financing activities182,757 18,070 
Net increase in cash, cash equivalents and restricted cash$70,680 $19,224 
Operating Activities
Our cash flows from operating activities are greatly influenced by our use of cash for operating expenses and working capital requirements to support our business. We have historically experienced negative cash flows from operating activities as we have invested in developing our portfolio, drug discovery efforts and related infrastructure. The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in operating assets and liabilities, which are primarily the result of increased expenses and timing of vendor payments.
During the three months ended March 31, 2024, net cash used in operating activities of $20.9 million was primarily due to our $39.6 million net loss, partially offset by $1.5 million in changes in operating assets and liabilities primarily related to an increase in accounts payable and $17.2 million of non-cash charges primarily related to stock-based compensation.
During the three months ended March 31, 2023, net cash used in operating activities of $32.8 million was primarily due to our $37.5 million net loss and $3.3 million in changes in operating assets and liabilities primarily related to a decrease in accrued expenses, partially offset by $7.9 million of non-cash charges primarily related to stock-based compensation.
Investing Activities
During the three months ended March 31, 2024, net cash used in investing activities of $91.2 million was related to purchases of marketable securities.
During the three months ended March 31, 2023, net cash provided by investing activities of $34.0 million was related to maturities of marketable securities.
Financing Activities
During the three months ended March 31, 2024, net cash provided by financing activities of $182.8 million consisted primarily of net proceeds from our January 2024 follow-on public offering, our at-the-market offerings and our collaboration and license agreement with Tenacia.
During the three months ended March 31, 2023, net cash provided by financing activities of $18.1 million consisted of net proceeds from at-the-market offerings.
Plan of Operation and Future Funding Requirements
24

We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:
•advance the clinical development of our clinical-stage product candidates within our Cerebrum™ and Solidus™ platforms;
•advance the development of any additional product candidates;
•conduct research and continue preclinical development of potential product candidates;
•make strategic investments in manufacturing capabilities;
•maintain our IP portfolio and opportunistically acquire complementary IP;
•seek to obtain regulatory approvals for our product candidates;
•potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;
•when needed, add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company; and
•experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.
We are unable to estimate the exact amount of our working capital requirements, but based on our current operating plan, we believe that our cash, cash equivalents, and marketable securities as of March 31, 2024, together with proceeds from our April 2024 public offering, will be sufficient to fund our operating expenses and capital expenditure requirements into 2027. However, we have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect.
Because of the numerous risks and uncertainties associated with product development and potential collaborations with third parties for the development of our product candidates, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to:
•the scope, progress, results and costs of preclinical studies and clinical trials for our platforms and product candidates;
•the number and characteristics of product candidates and technologies that we develop or may in-license;
•the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
•the costs necessary to obtain regulatory approvals, if any, for products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;
•the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our IP rights and defending any IP-related claims;
•the continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements;
•the costs we incur in maintaining business operations;
•the costs associated with being a public company;
25

•the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval;
•the effect of competing technological and market developments; and
•the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such acquisitions or investments in businesses.
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.
Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. Market volatility could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially result in dilution to the holders of our common stock.
If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no changes to our critical accounting policies from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Significant Judgments and Estimates” included in our Annual Report on Form 10-K filed with the SEC on March 5, 2024, other than as disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Recently Issued Accounting Pronouncements
We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.
26

Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because cash, cash equivalents and marketable securities we may hold at any time may be in the form of money market funds or marketable debt securities or may be invested in U.S. Treasury and U.S. government agency obligations. However, because of the low risk profile of the instruments in our portfolio at any given time, an immediate change in market interest rates of 100 basis points would not have a material impact on our financial position or results of operations.
Item 4. Controls and Procedures.
Management’s Evaluation of Our Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
As of the date of this Quarterly Report on Form 10-Q, we are not party to any material legal matters or claims. We may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors.
There have been no material changes from the risk factors previously disclosed in the section entitled "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Recent Sales of Unregistered Equity Securities
Other than as previously disclosed on our Current Report on Form 8-K filed with the SEC on January 10, 2024, we did not make any sales of unregistered securities during the three months ended March 31, 2024.
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
(a)     Disclosure in lieu of reporting on a Current Report on Form 8-K.
None.
(b)     Material changes to the procedures by which security holders may recommend nominees to the board of directors.
None.
(c)    Insider Trading Arrangements and Policies.
During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.


28

Item 6. Exhibits.
Exhibit
Number		Description
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
*Filed herewith.
**    The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

29

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 PRAXIS PRECISION MEDICINES, INC.
Date: May 13, 2024By: /s/ Marcio Souza
  Marcio Souza
  Chief Executive Officer and Director (Principal Executive Officer)
Date: May 13, 2024By: /s/ Timothy Kelly
  Timothy Kelly
  Chief Financial Officer (Principal Financial Officer)
30
 EX-31.1 2 exhibit31120240331.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marcio Souza, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
May 13, 2024
By: /s/ MARCIO SOUZA
  Marcio Souza
  Chief Executive Officer
  (Principal Executive Officer)


 EX-31.2 3 exhibit31220240331.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Timothy Kelly, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
May 13, 2024
 By: /s/ TIMOTHY KELLY
   Timothy Kelly
   Chief Financial Officer
   (Principal Financial Officer)


 EX-32.1 4 exhibit32120230331.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc. (the “Company”) for the quarter ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:
 
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
May 13, 2024
 By: /s/ MARCIO SOUZA
   Marcio Souza
   Chief Executive Officer
   (Principal Executive Officer)
Date:
May 13, 2024
 By: /s/ TIMOTHY KELLY
   Timothy Kelly
   Chief Financial Officer
   (Principal Financial Officer)


 EX-101.SCH 5 prax-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Collaboration License Agreements link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Common Stock and Preferred Stock link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Common Stock and Preferred Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Nature of the Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Cash Equivalents and Marketable Securities - Investment Profile (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Cash Equivalents and Marketable Securities - Investment Profile (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Collaboration License Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 prax-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 prax-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 prax-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Over-Allotment Option Over-Allotment Option [Member] Pay vs Performance Disclosure [Line Items] Summary of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Total accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement Investments, Debt and Equity Securities [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Weighted average remaining contractual term exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt securities Corporate Debt Securities [Member] Total other income Nonoperating Income (Expense) Commitments and contingencies (Note 6) Commitments and Contingencies Common Stock Warrants Common Stock, Warrants [Policy Text Block] Common Stock, Warrants Insider Trading Policies and Procedures [Line Items] Number of shares exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Summary of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Tenacia Tenacia [Member] Tenacia Proceeds from issuance or sale of equity Proceeds from Issuance or Sale of Equity Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Common Stock and Preferred Stock Equity [Text Block] Aggregate intrinsic value vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Proceeds from stock offerings, net of issuance costs Proceeds from Issuance of Common Stock Summary of Common Stock Reserved For Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance Deferred revenue Increase (Decrease) in Contract with Customer, Liability Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Net loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Supplemental disclosures of non-cash activities: Supplemental Cash Flow Elements [Abstract] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Treasury stock (in shares) Treasury Stock, Common, Shares Level 3 Fair Value, Inputs, Level 3 [Member] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Debt securities issued by U.S. government agencies US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Available-for-sale marketable securities Investments, Fair Value Disclosure Weighted average grant-date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Potential shares issuable under the 2020 ESPP Employee Stock [Member] Debt securities, available-for-sale, amortized cost, current Debt Securities, Available-for-Sale, Amortized Cost, Current Cash Equivalents and Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Upfront payment Contract with Customer, Liability Issuance of common stock upon exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Executive Category: Executive Category [Axis] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Sale of stock, volume-weighted average price, premium Sale Of Stock, Volume-Weighted Average Price, Premium Sale Of Stock, Volume-Weighted Average Price, Premium Equity Components [Axis] Equity Components [Axis] Warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses Increase (Decrease) in Accrued Liabilities Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Change in unrealized gains on marketable securities, net of tax Change in unrealized gain on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Frequency [Axis] Measurement Frequency [Axis] Warrant Warrant [Member] Non-current portion of operating lease liabilities Operating Lease, Liability, Noncurrent Issuance costs from at-the-market offering included in accrued expenses Stock Issuance Costs Incurred But Not Yet Paid Stock Issuance Costs Incurred But Not Yet Paid Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation expense Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Shares withheld for taxes for vesting of restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Payables and Accruals [Abstract] Payables and Accruals [Abstract] Collaboration revenue Revenues Product and Service [Domain] Product and Service [Domain] Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Unvested Restricted Stock Units Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Weighted average remaining contractual term outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Accrued personnel-related expenses Accrued Personnel Related Expenses Current Accrued Personnel Related Expenses, Current. Related Party Transactions Related Party Transactions Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating lease liabilities Operating Lease, Liability, Current License License [Member] Entity Shell Company Entity Shell Company Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Accrued external research and development expenses Accrued External Research And Development Expenses Current Accrued External Research And Development Expenses, Current. Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] Sale of stock (in USD per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Current portion of deferred revenue Contract with Customer, Liability, Current Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Assets Assets, Fair Value Disclosure Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Collaboration License Agreements Collaborative Arrangement Disclosure [Text Block] Shares reserved for exercise of outstanding stock options Outstanding stock options Employee Stock Option [Member] Weighted-average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition January 2024 Follow-On Offering January 2024 Follow-On Offering [Member] January 2024 Follow-On Offering Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total unrecognized compensation cost related to unvested restricted stock units Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Cash equivalents, at carrying value Cash Equivalents, at Carrying Value Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Weighted Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Subsequent Event Subsequent Event [Member] Follow-On Offering Follow-On Offering [Member] Follow-On Offering Number of performance obligations Number Of Performance Obligations Number Of Performance Obligations Income Statement [Abstract] Income Statement [Abstract] June 2023 Follow-On Offering June 2023 Follow-On Offering [Member] June 2023 Follow-On Offering Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Canceled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Sale of stock, value transferred Sale Of Stock, Value Transferred Sale Of Stock, Value Transferred Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities. Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Unvested beginning balance (in dollars per share) Unvested ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] UCB UCB [Member] UCB Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Vesting of restricted stock awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Name Outstanding Recovery, Individual Name Other debt securities Other Debt Obligations [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from collaboration arrangement Proceeds From Collaboration Arrangement Proceeds From Collaboration Arrangement Current assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash equivalents, accumulated gross unrealized loss, current, before tax Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Other Other Operating Activities, Cash Flow Statement Asset Class [Domain] Asset Class [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Number of securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Name of Property [Domain] Name of Property [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Non-cash collaboration and license agreement expense Collaboration And License Agreement, Noncash Expense Collaboration And License Agreement, Noncash Expense Total liabilities Liabilities Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Securities, unrealized loss position, fair value Debt Securities, Available-for-Sale, Unrealized Loss Position Cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-Term Investments Total shares of authorized common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Non-current portion of deferred revenue Contract with Customer, Liability, Noncurrent Long-term liabilities: Liabilities, Noncurrent [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, $0.0001 par value; 150,000,000 shares authorized; 13,258,047 shares issued and outstanding as of March 31, 2024, and 8,791,877 shares issued and outstanding as of December 31, 2023 Common Stock, Value, Issued Unaudited Interim Condensed Consolidated Financial Information Unaudited Interim Condensed Consolidated Financial Information [Policy Text Block] Unaudited interim condensed consolidated financial information General and administrative General and Administrative Expense After one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Non-cash operating lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Shares reserved for future awards under the 2024 Inducement Plan Inducement Plan Inducement Plan [Member] Inducement Plan Number of platforms Number Of Platforms Number Of Platforms Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period Total current assets Assets, Current Revenue from Contract with Customer [Abstract] Restricted cash Restricted Cash All Individuals All Individuals [Member] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Percentage of ownership held by sole owner and affiliates Percentage of Ownership Held by Sole Owner And Affiliates Percentage of Ownership Held by Sole Owner And Affiliates PEO Name PEO Name Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Schedule Of Common Stock Reserved For Future Issuance [Line Items] Schedule Of Common Stock Reserved For Future Issuance [Line Items] Schedule Of Common Stock Reserved For Future Issuance Line items Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Marketable securities Debt securities, available-for-sale, current Debt Securities, Available-for-Sale, Current Accrued other expenses Other Accrued Liabilities, Current Issued (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value Nature of the Business Nature of Operations [Text Block] Cash equivalents, accumulated gross unrealized gain, current, before tax Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Shares reserved for vesting of restricted stock units Unvested restricted stock units Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Milestone payments Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Subsequent Events [Abstract] Percentage increase in annual base rent Percentage Increase In Annual Base Rent Percentage Increase In Annual Base Rent. Preferred stock, issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Share-based payment arrangement Share-Based Payment Arrangement [Member] Title Trading Arrangement, Individual Title Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Long-term marketable securities Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Net Loss per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Cash equivalents, fair value disclosure Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Document Fiscal Year Focus Document Fiscal Year Focus Cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost Stock issuance costs Stock Issuance Costs Stock Issuance Costs Property and equipment, net Property, Plant and Equipment, Net Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Payments of tax withholdings related to vesting of restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Summary of Financial Assets Measured At Fair Value On A Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Accumulated Deficit Retained Earnings [Member] Sale of stock, volume-weighted average price, duration Sale Of Stock, Volume-Weighted Average Price, Duration Sale Of Stock, Volume-Weighted Average Price, Duration Summary of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization of premiums and discounts on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Other income: Nonoperating Income (Expense) [Abstract] Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Number of product candidates Number Of Product Candidates Number Of Product Candidates Unrecognized compensation expense related to unvested stock based awards Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Aggregate intrinsic value exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Shares reserved for future awards under the 2020 Stock Option and Incentive Plan Twenty Twenty Employee Stock Incentive Plan [Member] Twenty Twenty Employee Stock Incentive Plan Warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Arrangement Duration Trading Arrangement Duration At-The-Market Offering At-The-Market Offering [Member] At-The-Market Offering Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Office Space in Boston Massachusetts Office Space in Boston Massachusetts [Member] Office Space in Boston Massachusetts Weighted average remaining contractual term vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Sale of stock, value transferred in excess of consideration received Sale Of Stock, Value Transferred In Excess Of Consideration Received Sale Of Stock, Value Transferred In Excess Of Consideration Received Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Accounts payable Increase (Decrease) in Accounts Payable Common stock, authorized (in shares) Common Stock, Shares Authorized Total available-for-sale securities Debt Securities, Available-for-Sale Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Change in ownership notice, term Notice of Change, Term Notice of Change, Term Award Timing Disclosures [Line Items] Sale of stock, shares, aggregate authorized amount (in shares) Sale Of Stock, Shares, Aggregate Authorized Amount Sale Of Stock, Shares, Aggregate Authorized Amount Stockholders' equity note, stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in capital Additional Paid in Capital Schedule Of Common Stock Reserved For Future Issuance [Table] Schedule Of Common Stock Reserved For Future Issuance [Table] Schedule Of Common Stock Reserved For Future Issuance Table Forfeitures (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Aggregate intrinsic value outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Percentage change in ownership Change in Percentage of Ownership Change in Percentage of Ownership Adjustment to Compensation, Amount Adjustment to Compensation Amount Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Issuance of common stock Stock Issued During Period, Value, New Issues Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Amendment Flag Amendment Flag Money market funds Money Market Funds [Member] 2020 Employee Stock Incentive Plan 2020 Employee Stock Incentive Plan [Member] 2020 Employee Stock Incentive Plan Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Shares withheld for taxes for vesting of restricted stock units (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Other-than-temporary impairment loss, debt securities, available-for-sale Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale Shares reserved for future awards under the 2020 Employee Stock Purchase Plan 2020 Employee Stock Purchase Plan 2020 Employee Stock Purchase Plan [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Operating expenses: Operating Expenses [Abstract] Company Selected Measure Amount Company Selected Measure Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name 2017 Stock Incentive Plan 2017 Employee Stock Incentive Plan [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Subsequent Events Subsequent Events [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Recurring Fair Value, Recurring [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Transaction price Revenue, Remaining Performance Obligation, Amount Total operating expenses Operating Expenses Increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Cash equivalents and debt securities, available-for-sale, fair value disclosure Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Loss from operations Operating Income (Loss) Proceeds from exercise of stock options and employee stock purchase plan purchases Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Maximum percentage of voting power Percentage of Ownership Held by Sole Owner Percentage of Ownership Held by Sole Owner Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale [Table Text Block] Name of Property [Axis] Name of Property [Axis] EX-101.PRE 9 prax-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
May 09, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-39620  
Entity Registrant Name PRAXIS PRECISION MEDICINES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-5195942  
Entity Address, Address Line One 99 High Street  
Entity Address, Address Line Two 30th Floor  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02110  
City Area Code 617  
Local Phone Number 300-8460  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol PRAX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   17,107,887
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001689548  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 151,980 $ 81,300
Marketable securities 55,436 0
Prepaid expenses and other current assets 4,388 3,580
Total current assets 211,804 84,880
Long-term marketable securities 35,873 0
Property and equipment, net 476 588
Operating lease right-of-use assets 1,840 2,064
Other non-current assets 416 416
Total assets 250,409 87,948
Current liabilities:    
Accounts payable 9,404 5,815
Accrued expenses 6,976 7,416
Operating lease liabilities 1,158 1,126
Current portion of deferred revenue 1,256 1,392
Total current liabilities 18,794 15,749
Long-term liabilities:    
Non-current portion of operating lease liabilities 1,066 1,369
Non-current portion of deferred revenue 866 1,161
Total liabilities 20,726 18,279
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023 0 0
Common stock, $0.0001 par value; 150,000,000 shares authorized; 13,258,047 shares issued and outstanding as of March 31, 2024, and 8,791,877 shares issued and outstanding as of December 31, 2023 13 13
Additional paid-in capital 923,141 723,577
Accumulated other comprehensive income 3 0
Accumulated deficit (693,474) (653,921)
Total stockholders’ equity 229,683 69,669
Total liabilities and stockholders’ equity $ 250,409 $ 87,948
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 13,258,047 8,791,877
Common stock, outstanding (in shares) 13,258,047 8,791,877
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Collaboration revenue $ 431 $ 683
Operating expenses:    
Research and development 26,984 25,504
General and administrative 15,333 13,270
Total operating expenses 42,317 38,774
Loss from operations (41,886) (38,091)
Other income:    
Other income, net 2,333 636
Total other income 2,333 636
Net loss $ (39,553) $ (37,455)
Net loss per share attributable to common stockholders, basic (in dollars per share) [1] $ (2.84) $ (10.58)
Net loss per share attributable to common stockholders, diluted (in dollars per share) [1] $ (2.84) $ (10.58)
Weighted average common shares outstanding, basic (in shares) [1] 13,904,374 3,540,185
Weighted average common shares outstanding, diluted (in shares) [1] 13,904,374 3,540,185
[1] Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)
Nov. 28, 2023
Income Statement [Abstract]  
Stockholders' equity note, stock split, conversion ratio 0.0667
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net loss $ (39,553) $ (37,455)
Change in unrealized gains on marketable securities, net of tax 3 154
Comprehensive loss $ (39,550) $ (37,301)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Follow-On Offering
At-The-Market Offering
License And Collaboration Agreement
Common Stock
Common Stock
Follow-On Offering
Common Stock
At-The-Market Offering
Common Stock
License And Collaboration Agreement
Additional Paid-In Capital
Additional Paid-In Capital
Follow-On Offering
Additional Paid-In Capital
At-The-Market Offering
Additional Paid-In Capital
License And Collaboration Agreement
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022 [1]         3,292,163                  
Beginning balance at Dec. 31, 2022 $ 76,106       $ 5 [1]       $ 606,918       $ (530,644) $ (173)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Stock-based compensation expense 7,593               7,593          
Stock issuance costs     $ 560                      
Issuance of common stock (in shares) [1]         560,253                  
Issuance of common stock 18,096       $ 1 [1]       18,095          
Vesting of restricted stock awards (in shares) [1]         11,516                  
Shares withheld for taxes for vesting of restricted stock units (in shares) [1]         (2,875)                  
Shares withheld for taxes for vesting of restricted stock units (127)               (127)          
Issuance of common stock upon exercise of stock options (in shares) [1]         2,970                  
Issuance of common stock upon exercise of stock options 101               101          
Change in unrealized gain on marketable securities, net of tax 154                         154
Net loss (37,455)                       (37,455)  
Ending balance (in shares) at Mar. 31, 2023 [1]         3,864,027                  
Ending balance at Mar. 31, 2023 $ 64,468       $ 6 [1]       632,580       (568,099) (19)
Beginning balance (in shares) at Dec. 31, 2023 8,791,877       8,791,877                  
Beginning balance at Dec. 31, 2023 $ 69,669       $ 13       723,577       (653,921) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Stock-based compensation expense 14,475               14,475          
Stock issuance costs   $ 10,836 376                      
Issuance of common stock (in shares)           3,802,025 209,852 443,253            
Issuance of common stock   $ 161,649 $ 6,169 $ 17,265           $ 161,649 $ 6,169 $ 17,265    
Vesting of restricted stock awards (in shares)         11,095                  
Shares withheld for taxes for vesting of restricted stock units (in shares)         (3,689)                  
Shares withheld for taxes for vesting of restricted stock units $ (137)               (137)          
Issuance of common stock upon exercise of stock options (in shares) 3,634       3,634                  
Issuance of common stock upon exercise of stock options $ 143               143          
Change in unrealized gain on marketable securities, net of tax 3                         3
Net loss $ (39,553)                       (39,553)  
Ending balance (in shares) at Mar. 31, 2024 13,258,047       13,258,047                  
Ending balance at Mar. 31, 2024 $ 229,683       $ 13       $ 923,141       $ (693,474) $ 3
[1] Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Follow-On Offering    
Stock issuance costs $ 10,836  
At-The-Market Offering    
Stock issuance costs $ 376 $ 560
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (39,553) $ (37,455)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 112 106
Stock-based compensation expense 14,475 7,593
Non-cash operating lease expense 224 201
Amortization of premiums and discounts on marketable securities, net (84) 45
Non-cash collaboration and license agreement expense 2,500 0
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (808) 1,771
Accounts payable 3,589 2,314
Accrued expenses (608) (6,498)
Operating lease liabilities (271) (240)
Deferred revenue (431) (683)
Other (2) 0
Net cash used in operating activities (20,857) (32,846)
Cash flows from investing activities:    
Purchases of marketable securities (91,220) 0
Maturities of marketable securities 0 34,000
Net cash (used in) provided by investing activities (91,220) 34,000
Cash flows from financing activities:    
Payments of tax withholdings related to vesting of restricted stock units (137) (127)
Proceeds from exercise of stock options and employee stock purchase plan purchases 143 101
Net cash provided by financing activities 182,757 18,070
Increase in cash, cash equivalents and restricted cash 70,680 19,224
Cash, cash equivalents and restricted cash, beginning of period 81,716 62,031
Cash, cash equivalents and restricted cash, end of period 152,396 81,255
Reconciliation of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 151,980 80,839
Restricted cash 416 416
Total cash, cash equivalents and restricted cash 152,396 81,255
Supplemental disclosures of non-cash activities:    
Issuance costs from at-the-market offering included in accrued expenses 168 0
Follow-On Offering    
Cash flows from financing activities:    
Proceeds from stock offerings, net of issuance costs 161,649 0
License And Collaboration Agreement    
Cash flows from financing activities:    
Proceeds from stock offerings, net of issuance costs 14,765 0
At-The-Market Offering    
Cash flows from financing activities:    
Proceeds from stock offerings, net of issuance costs $ 6,337 $ 18,096
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Nature of the Business
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business Nature of the Business
Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system ("CNS"), disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using its understanding of shared biological targets and circuits in the brain. Each platform has multiple programs currently, with significant potential for additional program and indication expansion:
•Cerebrum™, the Company's small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies
•Solidus™, the Company's antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology
The Company's platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For the Company's most advanced product candidate under the Cerebrum™ platform, ulixacaltamide (formerly known as PRAX-944), it expects to announce topline results from the ongoing Phase 3 Essential3 clinical trials in essential tremor in the second half of 2024. Within the Company's PRAX-628 program, it announced positive results from its Photo-Paroxysmal Response ("PPR") study in the first quarter of 2024 and plans to initiate the first of two efficacy studies of PRAX-628 in focal onset seizures in the second half of 2024, with topline results expected in 2025. The Company plans to initiate a second PRAX-628 efficacy study in focal onset seizures in the first half of 2025, with topline results expected in the first half of 2026. The Company's PRAX-562 Phase 2 EMBOLD study was initiated in the first quarter of 2023, with cohorts in SCN2A-DEE and SCN8A-DEE; topline results are expected for both cohorts in the third quarter of 2024. For the Company's most advanced product candidate under the Solidus™ platform, elsunersen (formerly known as PRAX-222), it shared results from Part 1 of the EMBRAVE study in the fourth quarter of 2023, and is currently completing multiple global regulatory interactions in anticipation of starting the pivotal phase of the program later in 2024.
Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, from the sale of common stock through an initial public offering and at-the-market offerings under its shelf registration statement, and from follow-on public offerings of common stock and pre-funded warrants to purchase common stock. From inception through March 31, 2024, the Company raised $785.3 million in aggregate cash proceeds from these transactions, net of issuance costs. In April 2024, the Company raised net proceeds of $215.8 million from a follow-on public offering of common stock and pre-funded warrants.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.
Liquidity
In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
The Company has incurred recurring losses since its inception, including a net loss of $39.6 million for the three months ended March 31, 2024. In addition, as of March 31, 2024, the Company had an accumulated deficit of $693.5 million. The Company expects to continue to generate operating losses for the foreseeable future.
The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2024 of $243.3 million will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.
Reverse Stock Split
On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the "Effective Time").
As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.
Marketable Securities Classification
The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.
The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and
losses in accumulated other comprehensive loss, a component of stockholders’ equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more-likely-than-not that the Company will hold these assets through to their maturity dates.
Unaudited Interim Condensed Consolidated Financial Information
The accompanying condensed consolidated balance sheet as of March 31, 2024, the condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 and the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. Financial statement disclosures for the three months ended March 31, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.
The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Common Stock Warrants
The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480, Distinguishing Liabilities from Equity (ASC 480) and ASC No. 815, Derivatives and Hedging (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.
Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.
Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements
On November 27, 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.
On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash Equivalents and Marketable Securities
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Cash Equivalents and Marketable Securities Cash Equivalents and Marketable Securities
The following is a summary of the Company's investment portfolio as of March 31, 2024. The Company did not hold any cash equivalents or marketable securities as of December 31, 2023 (in thousands):
As of March 31, 2024
Gross UnrealizedEstimated
CostGainsLossesFair Value
Cash equivalents:
Money market funds$15,971 $— $— $15,971 
Debt securities issued by U.S. government agencies17,889 — — 17,889 
Corporate debt securities12,009 — (1)12,008 
Commercial paper2,450 — (1)2,449 
Available-for-sale marketable securities:
Debt securities issued by U.S. government agencies59,722 12 — 59,734 
Corporate debt securities26,602 — (2)26,600 
Commercial paper1,934 — (3)1,931 
Other debt securities3,046 — (2)3,044 
Total cash equivalents and marketable securities$139,623 $12 $(9)$139,626 
As of March 31, 2024, the Company had 33 securities with a total fair market value of $42.6 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. The Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.
Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):
March 31, 2024December 31, 2023
Within one year$87,782 $— 
After one year through five years35,873 — 
Total$123,655 $— 
Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three months ended March 31, 2024 and 2023.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:
•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;
•Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.
The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of December 31, 2023:
As of March 31, 2024
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$15,971 $— $— $15,971 
Debt securities issued by U.S. government agencies17,889 — — 17,889 
Corporate debt securities— 12,008 — 12,008 
Commercial paper— 2,449 — 2,449 
Available-for-sale marketable securities:
Debt securities issued by U.S. government agencies59,734 — — 59,734 
Corporate debt securities— 26,600 — 26,600 
Commercial paper— 1,931 — 1,931 
Other debt securities— 3,044 — 3,044 
$93,594 $46,032 $— $139,626 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2024December 31, 2023
Accrued external research and development expenses$4,717 $2,957 
Accrued personnel-related expenses1,661 3,716 
Accrued other expenses598 743 
Total accrued expenses$6,976 $7,416 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023. This lease qualifies as an operating lease.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Collaboration License Agreements
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Collaboration License Agreements Collaboration and License Agreements
UCB Option and License Agreement
In December 2022, the Company entered into an Option and License Agreement (“the Collaboration Agreement”) with UCB Biopharma SRL (“UCB”) for the discovery of small molecule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a $5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to $98.5 million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement.
The Company concluded that UCB is a customer, and as such, the arrangement falls within the scope of Topic 606. At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be $5.0 million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right.
The Company recognizes revenue for its research services performance obligation over time using an input method over the duration of the research services. During the three months ended March 31, 2024, the Company recognized $0.4 million in collaboration revenue related to the Collaboration Agreement in the condensed consolidated statement of operations. As of March 31, 2024, $2.1 million was included in deferred revenue in the condensed consolidated balance sheet, of which $1.3 million was classified as current.
Tenacia Collaboration and License Agreement
On January 4, 2024, the Company entered into an exclusive collaboration and license Agreement (“the License Agreement”) with Tenacia Biotechnology (Shanghai) Co., Ltd. (“Tenacia”), a China-based portfolio company of Bain Capital, which provides Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company also entered into a Stock Purchase Agreement (“the Stock Purchase Agreement”) with BCPE Tenet Holdings Cayman, Ltd. (“BCPE”), a related party of Tenacia. Pursuant to the terms of the License Agreement, the Company was entitled to an up-front, non-refundable and non-creditable cash payment of $5.0 million, net of certain tax withholdings. In addition, the Company is eligible to receive $264.0 million in success-based development and commercialization milestone payments as well as tiered royalties on net sales. Pursuant to the terms of the Stock Purchase Agreement, the Company issued and sold 443,253 shares of its common stock to BCPE at a price per share of $22.5605 for aggregate gross proceeds of $10.0 million. The per share price was based on a 20% premium over the 30-day volume-weighted average price.
Under the terms of the License Agreement, the Company granted to Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing.
The Company concluded that the License Agreement and the Stock Purchase Agreement is a combined arrangement since they were executed at the same time and in contemplation of each other with the same counterparty or a related party thereof and the combined arrangement falls within the scope of Topic 606.
The Company’s obligations under the arrangement comprise a single promise, or one performance obligation, related to the exclusive development and commercialization license granted to Tenacia. Total proceeds associated with the combined arrangement at inception were $14.8 million consisting of the following: (i) $10.0 million gross proceeds from the sale of common stock under the Stock Purchase Agreement and (ii) $4.8 million, net of tax, related to the up-front payment under the License Agreement, both of which were received in January 2024. During the three months ended March 31, 2024, the Company had not achieved any development or sales milestones or earned any royalties under the License Agreement.
The Company recorded the common stock sold to BCPE at its issuance date fair value of $38.95 per share, or $17.3 million in the aggregate, which exceeded the proceeds received which were calculated based on the 20% premium over the prior 30-day volume-weighted average price. Accordingly, there is no transaction price allocable to the performance obligation as of March 31, 2024. The Company accounted for the excess of the fair value of the equity securities issued over the total proceeds received as consideration paid to a customer for which no distinct good or service was transferred in exchange. As a result, the transaction gives rise to negative revenue on a cumulative basis in the amount of $2.5 million, which was recorded in research and development expense in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2024. For agreements where the licenses are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time that the Company effectively grants the license, as the licenses or assignments represent functional intellectual property.
As of March 31, 2024, the Company did not have any receivables or deferred revenue related to the arrangement with Tenacia. The Company did not recognize any contract assets related to costs to obtain a contract with a customer or costs to fulfill a contract with a customer through March 31, 2024 because no qualifying costs were incurred. During the three months ended March 31, 2024, the Company did not recognize any revenue associated with the combined arrangement.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Stock and Preferred Stock
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
Common Stock and Preferred Stock Common Stock and Preferred Stock
Reverse Stock Split
On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023.
As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the period prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.
Common Stock
As of March 31, 2024 and December 31, 2023, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value.
As of March 31, 2024 and December 31, 2023, the Company did not hold any treasury shares.
Follow-On Public Offerings
June 2023 Public Offering
On June 21, 2023, the Company completed a public offering of: (i) an aggregate of 4,296,646 shares of its common stock at a public offering price of $14.25 per share, including the underwriters’ full exercise of their option to purchase 619,979 additional shares of common stock, and (ii) pre-funded warrants to purchase 470,000 shares of common stock at a public offering price of $14.2485 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0015 per share exercise price for each underlying share. Total net proceeds generated from the offering were approximately $63.4 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.
The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause either the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 9.99%, or the combined voting power of the securities beneficially owned by such holder, together with its affiliates, to exceed 9.99%. A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company. The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. In the event of certain fundamental transactions where the consideration payable to the holders of shares of common stock consists solely of cash and/or marketable securities, the pre-funded warrants will automatically be deemed to be exercised in full pursuant to a cashless exercise effective immediately prior to and contingent upon the consummation of such transaction. As of March 31, 2024, none of the pre-funded warrants had been exercised and all remain outstanding.
January 2024 Public Offering
On January 16, 2024, the Company completed a public offering of: (i) an aggregate of 3,802,025 shares of its common stock at a public offering price of $35.50 per share, including the underwriters' full exercise of their option to purchase 633,750 additional shares of commons stock, and (ii) pre-funded warrants to purchase 1,056,725 shares of common stock at a public offering price of $35.4999 per share of common stock underlying the warrants. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $161.6 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.
The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause either the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%), or the combined voting power of the securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%). A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company. The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. As of March 31, 2024, none of the pre-funded warrants had been exercised and all remained outstanding.
The Company determined that the pre-funded warrants related to both the June 2023 and January 2024 public offerings are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity’s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity.
Shares Reserved for Future Issuance
The Company has reserved the following shares of common stock for future issuance:
March 31,
2024		December 31,
2023
Shares reserved for exercise of outstanding stock options1,084,026 666,163 
Shares reserved for exercise of pre-funded warrants related to the June 2023 Financing470,000 470,000 
Shares reserved for exercise of pre-funded warrants related to the January 2024 Financing1,056,725 — 
Shares reserved for future awards under the 2020 Stock Option and Incentive Plan111,028 148,264 
Shares reserved for future awards under the 2020 Employee Stock Purchase Plan141,029 53,111 
Shares reserved for future awards under the 2024 Inducement Plan996,950 — 
Shares reserved for vesting of restricted stock units97,601 47,145 
Total shares of authorized common stock reserved for future issuance3,957,359 1,384,683 
Preferred Stock
As of March 31, 2024 and December 31, 2023, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, $0.0001 par value.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
2024 Inducement Plan
In January 2024, the Board of Directors ("the Board") adopted the 2024 Inducement Plan (the "Inducement Plan") without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules ("Rule 5635(c)(4)"). In accordance with Rule 5635(c)(4), the Inducement Plan allows the Company to grant awards only to a newly hired employee who was not previously an employee or non-employee director or to an employee who is being rehired following a bona fide period of non-employment if such award is a material inducement to such employee entering into employment. The total number of shares of common stock authorized for issuance under the Inducement Plan as of March 31, 2024 was 1,000,000 shares.
2020 Stock Option and Incentive Plan
The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of March 31, 2024 and December 31, 2023 was 1,100,833 shares and 661,240 shares, respectively.
2017 Stock Incentive Plan
The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan") as of March 31, 2024 and December 31, 2023 was 395,850 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.
2020 Employee Stock Purchase Plan
The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of March 31, 2024 and December 31, 2023 was 175,145 shares and 87,227 shares, respectively.
Restricted Stock Units
The following table summarizes the Company’s restricted stock unit activity:
SharesWeighted
Average
Grant Date
Fair Value
Unvested as of December 31, 202347,145 $202.27 
Issued65,333 43.35 
Vested(11,346)316.60 
Forfeited(3,531)35.63 
Unvested as of March 31, 202497,601 $88.63 
As of March 31, 2024, total unrecognized compensation cost related to unvested restricted stock units was $7.8 million, which is expected to be recognized over a weighted-average period of 2.34 years.
Stock Options
The following table summarizes the Company’s stock option activity:
Number of
Shares		Weighted
Average
Exercise Price
per Share		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic Value
(In years)(In thousands)
Outstanding as of December 31, 2023666,163 $160.19 
Granted428,850 43.36 
Exercised(3,634)39.30 $38 
Cancelled or Forfeited(7,353)124.58 
Outstanding as of March 31, 20241,084,026 $114.62 8.38$14,197 
Exercisable as of March 31, 2024689,361 $129.09 8.06$7,632 
Vested and expected to vest as of March 31, 20241,084,026 $114.62 8.38$14,197 
Valuation of Stock Options
The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three months ended March 31, 2024:
Three Months Ended
March 31,
2024
Risk-free interest rate3.88 %
Expected term (in years)6.01
Expected volatility88.75 %
Expected dividend yield— %
Weighted average grant-date fair value per share$32.70 
As of March 31, 2024, total unrecognized compensation cost related to unvested stock options was $24.8 million, which is expected to be recognized over a weighted-average period of 1.88 years.
Stock-Based Compensation
Stock-based compensation expense was allocated as follows (in thousands):
Three Months Ended
March 31,
20242023
Research and development$5,598 $2,223 
General and administrative8,877 5,370 
Total stock-based compensation expense$14,475 $7,593 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:
Three Months Ended
March 31,
20242023
Outstanding stock options1,084,026 712,737 
Unvested restricted stock units97,601 50,317 
Potential shares issuable under the 2020 ESPP27,827 11,984 
1,209,454 775,038 
Common shares issuable upon exercise of the pre-funded warrants that were sold in connection with the June 2023 and the January 2024 underwritten public offering are included in the calculation of basic weighted average number of common shares outstanding for the three months ended March 31, 2024. Consistent with the guidance in ASC 260-10-45-13, the underlying common shares are issuable for little to no consideration and there are no vesting conditions or contingencies associated with the warrants. Accordingly, the aggregate number of common shares underlying the pre-funded warrants have been considered outstanding for purposes of the calculation of basic net loss per share from the date of issuance.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Party Transactions
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
On September 11, 2019, the Company entered into a Cooperation and License Agreement (the “License Agreement”) with RogCon Inc. (“RogCon”). Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon's intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Pursuant to the terms of the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the associated research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. One of the founders of RogCon became the Company's General Counsel in June 2020. The Company continues to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. Expenses incurred during all periods presented were not material.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
April 2024 Financing
On April 2, 2024 the Company completed a public offering of: (i) an aggregate of 3,849,558 shares of its common stock at a public offering price of $56.50 per share, including the underwriters' full exercise of their option to purchase 530,973 additional shares of common stock, and (ii) pre-funded warrants to purchase 221,238 shares of common stock at a public offering price of $56.4999 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $215.8 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net loss $ (39,553) $ (37,455)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.
Reverse Stock Split
On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the "Effective Time").
As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.
Marketable Securities Classification
The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.
The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and
losses in accumulated other comprehensive loss, a component of stockholders’ equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more-likely-than-not that the Company will hold these assets through to their maturity dates.
Unaudited Interim Condensed Consolidated Financial Information
Unaudited Interim Condensed Consolidated Financial Information
The accompanying condensed consolidated balance sheet as of March 31, 2024, the condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 and the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. Financial statement disclosures for the three months ended March 31, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.
The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Common Stock Warrants
Common Stock Warrants
The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480, Distinguishing Liabilities from Equity (ASC 480) and ASC No. 815, Derivatives and Hedging (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.
Net Loss per Share
Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements
On November 27, 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.
On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash Equivalents and Marketable Securities (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Debt Securities, Available-for-Sale
The following is a summary of the Company's investment portfolio as of March 31, 2024. The Company did not hold any cash equivalents or marketable securities as of December 31, 2023 (in thousands):
As of March 31, 2024
Gross UnrealizedEstimated
CostGainsLossesFair Value
Cash equivalents:
Money market funds$15,971 $— $— $15,971 
Debt securities issued by U.S. government agencies17,889 — — 17,889 
Corporate debt securities12,009 — (1)12,008 
Commercial paper2,450 — (1)2,449 
Available-for-sale marketable securities:
Debt securities issued by U.S. government agencies59,722 12 — 59,734 
Corporate debt securities26,602 — (2)26,600 
Commercial paper1,934 — (3)1,931 
Other debt securities3,046 — (2)3,044 
Total cash equivalents and marketable securities$139,623 $12 $(9)$139,626 
Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):
March 31, 2024December 31, 2023
Within one year$87,782 $— 
After one year through five years35,873 — 
Total$123,655 $— 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Summary of Financial Assets Measured At Fair Value On A Recurring Basis
The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of December 31, 2023:
As of March 31, 2024
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$15,971 $— $— $15,971 
Debt securities issued by U.S. government agencies17,889 — — 17,889 
Corporate debt securities— 12,008 — 12,008 
Commercial paper— 2,449 — 2,449 
Available-for-sale marketable securities:
Debt securities issued by U.S. government agencies59,734 — — 59,734 
Corporate debt securities— 26,600 — 26,600 
Commercial paper— 1,931 — 1,931 
Other debt securities— 3,044 — 3,044 
$93,594 $46,032 $— $139,626 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses (Tables)
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Summary of Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2024December 31, 2023
Accrued external research and development expenses$4,717 $2,957 
Accrued personnel-related expenses1,661 3,716 
Accrued other expenses598 743 
Total accrued expenses$6,976 $7,416 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Stock and Preferred Stock (Tables)
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
Summary of Common Stock Reserved For Future Issuance
The Company has reserved the following shares of common stock for future issuance:
March 31,
2024		December 31,
2023
Shares reserved for exercise of outstanding stock options1,084,026 666,163 
Shares reserved for exercise of pre-funded warrants related to the June 2023 Financing470,000 470,000 
Shares reserved for exercise of pre-funded warrants related to the January 2024 Financing1,056,725 — 
Shares reserved for future awards under the 2020 Stock Option and Incentive Plan111,028 148,264 
Shares reserved for future awards under the 2020 Employee Stock Purchase Plan141,029 53,111 
Shares reserved for future awards under the 2024 Inducement Plan996,950 — 
Shares reserved for vesting of restricted stock units97,601 47,145 
Total shares of authorized common stock reserved for future issuance3,957,359 1,384,683 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Restricted Stock Activity
The following table summarizes the Company’s restricted stock unit activity:
SharesWeighted
Average
Grant Date
Fair Value
Unvested as of December 31, 202347,145 $202.27 
Issued65,333 43.35 
Vested(11,346)316.60 
Forfeited(3,531)35.63 
Unvested as of March 31, 202497,601 $88.63 
Summary of Stock Option Activity
The following table summarizes the Company’s stock option activity:
Number of
Shares		Weighted
Average
Exercise Price
per Share		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic Value
(In years)(In thousands)
Outstanding as of December 31, 2023666,163 $160.19 
Granted428,850 43.36 
Exercised(3,634)39.30 $38 
Cancelled or Forfeited(7,353)124.58 
Outstanding as of March 31, 20241,084,026 $114.62 8.38$14,197 
Exercisable as of March 31, 2024689,361 $129.09 8.06$7,632 
Vested and expected to vest as of March 31, 20241,084,026 $114.62 8.38$14,197 
Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model
The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three months ended March 31, 2024:
Three Months Ended
March 31,
2024
Risk-free interest rate3.88 %
Expected term (in years)6.01
Expected volatility88.75 %
Expected dividend yield— %
Weighted average grant-date fair value per share$32.70 
Summary of Stock-Based Compensation Expense
Stock-based compensation expense was allocated as follows (in thousands):
Three Months Ended
March 31,
20242023
Research and development$5,598 $2,223 
General and administrative8,877 5,370 
Total stock-based compensation expense$14,475 $7,593 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share
The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:
Three Months Ended
March 31,
20242023
Outstanding stock options1,084,026 712,737 
Unvested restricted stock units97,601 50,317 
Potential shares issuable under the 2020 ESPP27,827 11,984 
1,209,454 775,038 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Nature of the Business - Additional Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
Apr. 02, 2024
USD ($)
Jan. 16, 2024
USD ($)
Jun. 21, 2023
USD ($)
Apr. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
platform
candidate
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Cash and Cash Equivalents [Line Items]              
Number of platforms | platform         2    
Number of product candidates | candidate         4    
Proceeds from issuance or sale of equity         $ 785,300    
Net loss         39,553 $ 37,455  
Accumulated deficit         693,474   $ 653,921
Cash, cash equivalents, and marketable securities         243,300    
Follow-On Offering              
Cash and Cash Equivalents [Line Items]              
Proceeds from stock offerings, net of issuance costs   $ 161,600 $ 63,400   $ 161,649 $ 0  
Subsequent Event | Follow-On Offering              
Cash and Cash Equivalents [Line Items]              
Proceeds from stock offerings, net of issuance costs $ 215,800     $ 215,800      
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies (Details)
 3 Months Ended
Nov. 28, 2023
Mar. 31, 2024
segment
Accounting Policies [Abstract]    
Stockholders' equity note, stock split, conversion ratio 0.0667  
Number of reportable segments   1
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash Equivalents and Marketable Securities - Investment Profile (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Debt securities, available-for-sale, current $ 55,436 $ 0
Cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost 139,623  
Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 12  
Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax (9)  
Cash equivalents and debt securities, available-for-sale, fair value disclosure 139,626  
Money market funds    
Debt Securities, Available-for-sale [Line Items]    
Cash equivalents, at carrying value 15,971  
Cash equivalents, accumulated gross unrealized gain, current, before tax 0  
Cash equivalents, accumulated gross unrealized loss, current, before tax 0  
Cash equivalents, fair value disclosure 15,971  
Debt securities issued by U.S. government agencies    
Debt Securities, Available-for-sale [Line Items]    
Cash equivalents, at carrying value 17,889  
Cash equivalents, accumulated gross unrealized gain, current, before tax 0  
Cash equivalents, accumulated gross unrealized loss, current, before tax 0  
Cash equivalents, fair value disclosure 17,889  
Debt securities, available-for-sale, amortized cost, current 59,722  
Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 12  
Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax 0  
Debt securities, available-for-sale, current 59,734  
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Cash equivalents, at carrying value 12,009  
Cash equivalents, accumulated gross unrealized gain, current, before tax 0  
Cash equivalents, accumulated gross unrealized loss, current, before tax (1)  
Cash equivalents, fair value disclosure 12,008  
Debt securities, available-for-sale, amortized cost, current 26,602  
Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 0  
Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax (2)  
Debt securities, available-for-sale, current 26,600  
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Cash equivalents, at carrying value 2,450  
Cash equivalents, accumulated gross unrealized gain, current, before tax 0  
Cash equivalents, accumulated gross unrealized loss, current, before tax (1)  
Cash equivalents, fair value disclosure 2,449  
Debt securities, available-for-sale, amortized cost, current 1,934  
Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 0  
Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax (3)  
Debt securities, available-for-sale, current 1,931  
Other debt securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, available-for-sale, amortized cost, current 3,046  
Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 0  
Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax (2)  
Debt securities, available-for-sale, current $ 3,044  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash Equivalents and Marketable Securities - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
USD ($)
security
Mar. 31, 2023
USD ($)
Investments, Debt and Equity Securities [Abstract]    
Number of securities | security 33  
Securities, unrealized loss position, fair value $ 42,600,000  
Other-than-temporary impairment loss, debt securities, available-for-sale $ 0 $ 0
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Within one year $ 87,782,000 $ 0
After one year through five years 35,873,000 0
Total available-for-sale securities $ 123,655,000 $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets $ 139,626,000 $ 0
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 93,594,000  
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 46,032,000  
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 15,971,000  
Money market funds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 15,971,000  
Money market funds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Money market funds | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Debt securities issued by U.S. government agencies    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 17,889,000  
Available-for-sale marketable securities 59,734,000  
Debt securities issued by U.S. government agencies | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 17,889,000  
Available-for-sale marketable securities 59,734,000  
Debt securities issued by U.S. government agencies | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Available-for-sale marketable securities 0  
Debt securities issued by U.S. government agencies | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Available-for-sale marketable securities 0  
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 12,008,000  
Available-for-sale marketable securities 26,600,000  
Corporate debt securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Available-for-sale marketable securities 0  
Corporate debt securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 12,008,000  
Available-for-sale marketable securities 26,600,000  
Corporate debt securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Available-for-sale marketable securities 0  
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 2,449,000  
Available-for-sale marketable securities 1,931,000  
Commercial paper | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Available-for-sale marketable securities 0  
Commercial paper | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 2,449,000  
Available-for-sale marketable securities 1,931,000  
Commercial paper | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0  
Available-for-sale marketable securities 0  
Other debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale marketable securities 3,044,000  
Other debt securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale marketable securities 0  
Other debt securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale marketable securities 3,044,000  
Other debt securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale marketable securities $ 0  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accrued external research and development expenses $ 4,717 $ 2,957
Accrued personnel-related expenses 1,661 3,716
Accrued other expenses 598 743
Total accrued expenses $ 6,976 $ 7,416
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies - Additional Information (Details)
May 31, 2021
Office Space in Boston Massachusetts  
Loss Contingencies [Line Items]  
Percentage increase in annual base rent 2.00%
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Collaboration License Agreements - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Jan. 04, 2024
USD ($)
obligation
$ / shares
shares
Jan. 31, 2024
USD ($)
Mar. 31, 2024
USD ($)
$ / shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
obligation
Disaggregation of Revenue [Line Items]            
Number of performance obligations | obligation 1         1
Collaboration revenue     $ 431 $ 683    
Current portion of deferred revenue     1,256   $ 1,392  
UCB | License            
Disaggregation of Revenue [Line Items]            
Upfront payment     2,100     $ 5,000
Milestone payments           98,500
Transaction price           $ 5,000
Collaboration revenue     400      
Current portion of deferred revenue     $ 1,300      
Tenacia            
Disaggregation of Revenue [Line Items]            
Number of shares issued in transaction (in shares) | shares 443,253          
Sale of stock (in USD per share) | $ / shares $ 22.5605   $ 38.95      
Proceeds from stock offerings, net of issuance costs $ 10,000 $ 10,000        
Sale of stock, volume-weighted average price, premium 20.00%   20.00%      
Sale of stock, volume-weighted average price, duration 30 days   30 days      
Proceeds from collaboration arrangement   14,800        
Sale of stock, value transferred     $ 17,300      
Sale of stock, value transferred in excess of consideration received     $ 2,500      
Tenacia | License            
Disaggregation of Revenue [Line Items]            
Upfront payment $ 5,000 $ 4,800        
Milestone payments $ 264,000          
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Stock and Preferred Stock - Additional Information (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 16, 2024
USD ($)
$ / shares
shares
Nov. 28, 2023
Jun. 21, 2023
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
$ / shares
shares
Schedule Of Common Stock Reserved For Future Issuance [Line Items]            
Stockholders' equity note, stock split, conversion ratio   0.0667        
Common stock, authorized (in shares)       150,000,000   150,000,000
Common stock, par value (in dollars per share) | $ / shares       $ 0.0001   $ 0.0001
Treasury stock (in shares)       0   0
Preferred stock, authorized (in shares)       10,000,000   10,000,000
Preferred stock, par value (in dollars per share) | $ / shares       $ 0.0001   $ 0.0001
Pre-Funded Warrant | Maximum            
Schedule Of Common Stock Reserved For Future Issuance [Line Items]            
Maximum percentage of voting power       4.99%    
Percentage of ownership held by sole owner and affiliates       9.99%    
Percentage change in ownership       19.99%    
Warrant            
Schedule Of Common Stock Reserved For Future Issuance [Line Items]            
Change in ownership notice, term       61 days    
Follow-On Offering            
Schedule Of Common Stock Reserved For Future Issuance [Line Items]            
Common stock, authorized (in shares)     4,296,646      
Sale of stock (in USD per share) | $ / shares $ 35.50   $ 14.25      
Proceeds from stock offerings, net of issuance costs | $ $ 161,600   $ 63,400 $ 161,649 $ 0  
Sale of stock, shares, aggregate authorized amount (in shares) 3,802,025          
Follow-On Offering | Pre-Funded Warrant            
Schedule Of Common Stock Reserved For Future Issuance [Line Items]            
Sale of stock (in USD per share) | $ / shares $ 35.4999   $ 14.2485      
Warrants (in shares) 1,056,725   470,000      
Follow-On Offering | Warrant            
Schedule Of Common Stock Reserved For Future Issuance [Line Items]            
Warrants (in dollars per share) | $ / shares $ 0.0001   $ 0.0015      
Over-Allotment Option            
Schedule Of Common Stock Reserved For Future Issuance [Line Items]            
Number of shares issued in transaction (in shares) 633,750   619,979      
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) - shares
Mar. 31, 2024
Dec. 31, 2023
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 3,957,359 1,384,683
Shares reserved for exercise of outstanding stock options    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 1,084,026 666,163
Pre-Funded Warrant | June 2023 Follow-On Offering    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 470,000 470,000
Pre-Funded Warrant | January 2024 Follow-On Offering    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 1,056,725 0
Share-based payment arrangement | Shares reserved for future awards under the 2020 Stock Option and Incentive Plan    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 111,028 148,264
Share-based payment arrangement | Shares reserved for future awards under the 2020 Employee Stock Purchase Plan    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 141,029 53,111
Share-based payment arrangement | Shares reserved for future awards under the 2024 Inducement Plan    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 996,950 0
Shares reserved for vesting of restricted stock units    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Total shares of authorized common stock reserved for future issuance (in shares) 97,601 47,145
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Unvested Restricted Stock Units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total unrecognized compensation cost related to unvested restricted stock units $ 7.8  
Weighted-average period (in years) 2 years 4 months 2 days  
Shares reserved for exercise of outstanding stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted-average period (in years) 1 year 10 months 17 days  
Unrecognized compensation expense related to unvested stock based awards $ 24.8  
Inducement Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares) 1,000,000  
2020 Employee Stock Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares) 1,100,833 661,240
2017 Stock Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares) 395,850 395,850
2020 Employee Stock Purchase Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares) 175,145 87,227
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Unvested restricted stock units
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Shares  
Beginning balance (in shares) | shares 47,145
Issued (in shares) | shares 65,333
Vested (in shares) | shares (11,346)
Forfeited (in shares) | shares (3,531)
Ending balance (in shares) | shares 97,601
Weighted Average Grant Date Fair Value  
Unvested beginning balance (in dollars per share) | $ / shares $ 202.27
Issued (in dollars per share) | $ / shares 43.35
Vested (in dollars per share) | $ / shares 316.60
Forfeitures (in dollars per shares) | $ / shares 35.63
Unvested ending balance (in dollars per share) | $ / shares $ 88.63
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-Based Compensation - Summary of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
$ / shares
shares
Number of Shares  
Beginning balance (in shares) | shares 666,163
Granted (in shares) | shares 428,850
Exercised (in shares) | shares (3,634)
Canceled or forfeited (in shares) | shares (7,353)
Ending balance (in shares) | shares 1,084,026
Number of shares exercisable (in shares) | shares 689,361
Vested and expected to vest (in shares) | shares 1,084,026
Weighted Average Exercise Price per Share  
Beginning balance (in dollars per share) | $ / shares $ 160.19
Granted (in dollars per share) | $ / shares 43.36
Exercised (in dollars per share) | $ / shares 39.30
Cancelled or forfeited (in dollars per share) | $ / shares 124.58
Ending balance (in dollars per share) | $ / shares 114.62
Exercisable (in dollars per share) | $ / shares 129.09
Vested and expected to vest (in dollars per share) | $ / shares $ 114.62
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Weighted average remaining contractual term outstanding 8 years 4 months 17 days
Weighted average remaining contractual term exercisable 8 years 21 days
Weighted average remaining contractual term vested and expected to vest 8 years 4 months 17 days
Aggregate intrinsic value exercised | $ $ 38
Aggregate intrinsic value outstanding | $ 14,197
Aggregate intrinsic value exercisable | $ 7,632
Aggregate intrinsic value vested and expected to vest | $ $ 14,197
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)
 3 Months Ended
Mar. 31, 2024
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Risk-free interest rate 3.88%
Expected term (in years) 6 years 3 days
Expected volatility 88.75%
Expected dividend yield 0.00%
Shares reserved for exercise of outstanding stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Weighted average grant-date fair value per share (in dollars per share) $ 32.70
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 14,475 $ 7,593
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 5,598 2,223
General and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 8,877 $ 5,370
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 1,209,454 775,038
Outstanding stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 1,084,026 712,737
Unvested restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 97,601 50,317
Potential shares issuable under the 2020 ESPP    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 27,827 11,984
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Apr. 02, 2024
Jan. 16, 2024
Jun. 21, 2023
Apr. 30, 2024
Mar. 31, 2024
Mar. 31, 2023
Follow-On Offering            
Subsequent Event [Line Items]            
Sale of stock, shares, aggregate authorized amount (in shares)   3,802,025        
Sale of stock (in USD per share)   $ 35.50 $ 14.25      
Proceeds from stock offerings, net of issuance costs   $ 161,600 $ 63,400   $ 161,649 $ 0
Follow-On Offering | Pre-Funded Warrant            
Subsequent Event [Line Items]            
Sale of stock (in USD per share)   $ 35.4999 $ 14.2485      
Warrants (in shares)   1,056,725 470,000      
Follow-On Offering | Warrant            
Subsequent Event [Line Items]            
Warrants (in dollars per share)   $ 0.0001 $ 0.0015      
Over-Allotment Option            
Subsequent Event [Line Items]            
Number of shares issued in transaction (in shares)   633,750 619,979      
Subsequent Event | Follow-On Offering            
Subsequent Event [Line Items]            
Sale of stock, shares, aggregate authorized amount (in shares) 3,849,558          
Sale of stock (in USD per share) $ 56.50          
Proceeds from stock offerings, net of issuance costs $ 215,800     $ 215,800    
Subsequent Event | Follow-On Offering | Pre-Funded Warrant            
Subsequent Event [Line Items]            
Sale of stock (in USD per share) $ 56.4999          
Warrants (in shares) 221,238          
Subsequent Event | Follow-On Offering | Warrant            
Subsequent Event [Line Items]            
Warrants (in dollars per share) $ 0.0001          
Subsequent Event | Over-Allotment Option            
Subsequent Event [Line Items]            
Number of shares issued in transaction (in shares) 530,973          
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

)-O./"CA:EM@M^&M>X@$?0/^JM-#-_H!!: 5=4<"0A3[S59+E> MV'@7\)-"JT[&R%:R%^+93C8D\0(K! PR;0G8/ YP#XQ9D-'XW3.]84N;>#H^ MTK^ZVDTM>ZS@7K!?E.@R\3YXB$".&Z9WHOT&?3TSR\L$4^X7M5UL]-%#6:.T MJ/ID8U!1WCWQ2W\.)PF&4I.GTXTY7@(2/4E,*"_02DK,"S#'KE7L:[.#C?.SGK;N:.$%6H0> M!->E0E\X ?)OOF_,!KWPJ+<.1X$/6-ZA:'*#PB"LV>Z%-[W+#TGPL0-H \SX7 M0A\G=H/A\Y/^ 5!+ P04 " "@0JU8@A@H^2D/ #A+@ &0 'AL+W=O M[IR^G+X-5M MU7P.2^=:<[A;IS-9=.J M.#D_/7UVLK*^/'KS2GZ[:MZ\JKJV\*6[:DSH5BO;K-^ZHKI]?71VE'[XZ!?+ MEC^2NY7K@R^*DWCYJ^/+LZ^??N2ZV7!W[V[#:// MAB>95=5G?OF0OSXZI4"N<%E+"A9_;MRE*PH2@A@_1YI'/4MN''].U+^7L^,L M,QO<957\P^?M\O71BR.3N[GMBO9C=?LG%\_SE/2RJ@CRO[G5M<\>'YFL"VVU MBILAP13V,-KPXW;/A/&XX%[F5D4CYSK;VS:NFNC4-5X,:/\A193>$ M\R6-.JQKWUSK<8PU=Q<^T7IYSZS96LNLJSJRM:7"W-5%3[S+IA'Z=,W MKTY:L":!DRRR>:MLSO>P>6Q^J,IV&]'AX+O<=[Z.TZ\#\O9J%MX#?_VG5@I?=D-SW&TK>AMIE[ M?81@":ZY<4=O?O^[LV>GWQV0]DDO[9-#U-^\M<$'VNR*M,O6TL-W"?D59,Q/ M2X=@R:I5;>: M:_(1@2]6KH&GFD>__]V+\_/3[_YX<7$E'\^^^V9J+LHU <,UKLQQ!LY M#T0L<]ODP5Q6N423Z#3)>7%]F<0T6&@NKC_)>4CE^XOKMU/1?AA%XE@OR3&[ MH&I5%2L')8)3/L1:,(JP;I>-H8H@8!EBW["#.PI-#SH<5.M2+T GZY M#\"I*-&/4+$Y3ZK[90%@Z*++7:_)2_6Z/P1R?0Q#EATV?'1UU;0&IR02F[/3 MXS]/3(7UE-Z6M =MF\/QD&2F6'_C&HAVW5;99W,-8[?FKQ3NQJUFV'3^0D[U M>#+F"0$+^J&Y=$VKEG/1U><*>TN]@Z^;SY'&(-S9,6QV?/84/JIG#'+&(&?$)@^E M(G1AROCD$6D>[=#(T3?J;+N4-7.97;G(E6YO6_/TV]-34T]7TXEY;^$%#9 " MZ7E"L]S3;&3[OB? I>1X$7 (H V29CKP#@$FAK^M#G,C867XJD2G9AYA[7' MM?7*H*S*8VQR(0AFB$B4:,Q,46?.= %#PVGK*K3':I=X!OM%9U>I&^(+1,RK MVS(Y7NE(!@N6%:38IK_?FKGG$> ]ZD1"JA-S08H(;_\!KT'5&UJ,& &DH9ZZ MWE&W3E\443%V1< *HKD:3#9_39"#)[X"3 +LJQYK-_U%H*6H0H('0/3?.MO M]6"J^YCPMU'R:5(T*IH7Z=R[U,/:$(O:IM(2D56>#U,BX&>$*"V.:.V0 HB] ME]%]LB%9)@!967A0>4,3,0S=70:/,9D-2\H/73FN(5$X6)FKAG(WP_(2A4:G MD!BU^VEZ#8NBS@Y=LYZ,T)-K?=N1>YB8$;@H/=FW0#PVI8 6*NM2DH9 #]A4 MC!+D99R<^\J%[@.,JNRR:]'8W,7G#'Z8R,Y U%P.I4:9H=U>+/\"L MJZIQ$?ZQ&J4QB*N3B0?'$_KP&9(4R1?43+U=PV!7+![;K]R4:8G8I4O-"H]: M.Y>RP;&<"DJ=;@/RN:=[#=Y!Q0)[$@\Y"#NE%O],L'.'@HAK"O\S"*(\FJ2H M06STB'7#5D1I24TAE)CJ1U)0(?;.KZ!OTZ+NR:5V6GM71#\#4R?HT4@-16\ M;C*(ZP;:"S3*+HDV]="#9Q 7'SQ&V-WS92+>C?4%E2V)*]@"0'5Q[[<-2H2+ M1L*; (]@L3Y!#[XYB[ID9@NIVK1Q98$QB:>4>D+LW)6(GD(<$( IV6$!O:LZ M "M!ZTL46-VJ4P_1FD)TXI;L/&%6K@1Q^14AK.XEH$>J,#<+NK/GWQD'C5%? M'Q/7>]QXL/T5SY[";50M@3&Z\28%#2'W7EZ\K^^QEPL2IQ6"Q:@E*8K4#5W3 MR/E&//88?W<,,4B\JI"@1X7 ;!1] DO!GL?PP=6$ %( AN2;]-0Y01@;8>>( MVS%JUF);H:P P*@_+OQGA_S,X#\F4$A+S6%"=-E< MU;Z,;>[*EBAJI$Q)I1T2I;'YO[N8028HD7VV[+-!52*/EG3Z@F4)8$[*FF$# M2FO6:FS'DOHDZ?3";.%L5'D8R8VZQ&O.WQL<6OJ'U*;]JC!0W;3AUSG== 0+ MPUECV=VQ&?A*;QJ<6&K<2NJY/CG#6F,>#3V7KD-FK.?400#95-6>N8' 5J.S M&REM.9E1WTUZ?MAT@Q(F-_#L!+$I/%&JU9)/T. M-*2Y&HS/E*2E10JFV/U(*I390X=$%,G@)WU\*!\]Z_/1L\/Y(8CX[U%]KYCC M=F68AU$0%6]-GAXR<]HQ#I2A6O2",(YOJ6H_.Y;>D;FT*NC25[5&CJ3^46,[ MU(VQWV2+J]E?RUH[\X54*QJ3@Q_&<[ [D;YIYR83"XU\-+!YR.$3R.\2DTY5 MLDS,.\&G89T,_]1CIAMC^OUZBN**JQ8SQ9.Q6"U2>:1C&$5;9X6?)9L=:"#)I8[&NB!M' M:LO8V:HYUOM N61+P!$N,:6U=V-;IEZ0[43LT0J )V%D.O)Q'GE'%Z;J+'C3 M(^Z" G2A743F&[01'$-E=*VYS2)#'J'Q3NA?#NO=!BN>JQDU!: MH'J'H7\I4W=S<7UI?JRFYLF+TXEYQU%%B35AR<#[RRCZ19OOMOJH_8!QO]M.R=%C6?OO/.S1@L1AD MI^53N(P[\[[KDO$Y1YOC,B<@O1%C##LT/0/1PRNV$*O8A$.*.H[K")P M.@+ 0#$B"5#-D1BJ."CB=NGB]-X-1V8@S)&I^UGNYLRKGX_A<,BO>0P7BSXO MC*<.D_W4QT!.9XC1%C*48C+J5XONH;!BZR/@[R"93[G/XGLR-P6*-A:E':83 M,]YP%1.-EFV.&&'[T-GA_@&%B;L;YDN[-V5H:XD!(XFVIFS1'#I,VMY.:>A= M@_I4Y)9C67I>H$B9(G-7:Y/N9>*3+#^1:YE45T^'Z-8IF/21PP"CEW>_'C: M4F;I&R,9FZM_LA9'-CHF*-O:M[8XA'KQ[<1"H?H2X?V$'R8GV-2-P%]@] ME(;A#6PF":M(#W1<[B6RZTZ:[S4'BUYBHE_*Z2N]2EX[H$*8%Q?CR7Y"A@@7 MHTN2S1F\^@727,8I6/3JKZ+K[F*L#Q#%D6/CI1#90"JMVV)AP=$?S]F-X&+/ M901O19IBK=?$[GBNMR3)3:< [T)T]K]5*7Q_#G>SV4ACGE)28 M$>_V0+ZN>+FJB;M_O,%SRML.(@+'X/&N@.<:C#?9$*M*9?+.?#G6[ 2JC7;X M9>M)U9>$3>L%$S@1%!O)&='^G)KWUU=7P_TQ'KG\BTZZ/7_7EP;$,(/-O!1P MH]LD>9&!AU MSR3 I"#=[QERR1IG%I,TKA!/#,/5^FZ91]//6RG!9L3$UA^G M%8? YV4//B\/ L='H.C62SE-5>)SILEC%Q3].HI&%^"D'[00V;]RXV+]^?AB M74JK6,A<7'^2^HA/CT^Q[-HMI#[XV'XF;R /NJ^OB M;9QN?3>:(4RW.1BO!$+LH>*L>K$UX=A(PA/>1JZT_4^S8ECRC8D%>AA@ MU?@UC40Y-7'JOC:].[#]I@-BEO+R192UW$O1A[M9@?/3QX;;(CN(&"\SY=HS ML?.C6>Z.8K?7Z"3RU[Z2W8 \MX;W/H7;H:-[!Z DPPL!Q+LY-(+PY] "X.E0 MXDIQI]#7CT%8$*M/]-=0PP DE6$/(O4$G9KE';#-%=\([36KF;:-+6E8]L'( M=WU\J5X=*5VNG^_#1RP-=S7'4_.I)HPCX^C(3[U]VP,,WP!95(U/W7GL M]+6S$C/!)$2VW.B*A%4%[_9._XMJ7&[O,G.]%P6'H0!5\:;O.LI_2ZG#[+,7V9K2.( M>:7$,N M6ELR@FN0#/YQ6JL_B%#/JWVM_\%U!+ P04 " "@0JU8 M<[G@7?4# !%"0 &0 'AL+W=O3#(0:Q,[M1THY]>?<0*!W65Y M."]@CV>^^>9F9[R5ZE&GB ;^Y)G0$RSKAPIN-*=J>F8UF:C N\4Z#+/&=J=X.9W$Z";%";5\$$DF#RU]XAPPSH\L+X)+P(2P39$@0NA'W8NX$5-%J(*+WH% M[XO8H#:Y38 +M[@T51IL6LSN- 5_SY;:*.JD?\XEH?;1.>_#3M=(%RS&B4/C MHU%MT)F^?1/T_/<7(N@T$70NH4\KTD>F+LPVC&>V8.]H$)"&D@E5D"5A#;+L63+I6*AJ!I4GVL4 U^BS'F2U0'_ BNN2!NLM14 M6-T:P>P,"?BDI-;P(.AVR_B_2!V@#:?)I]5<:@.?Z)+3\)64R--'QA7\9%E) MO)_1&]E^Q]V>(JQ*\@E7$'3=83^@Q=LW@S (WS]9[0^K.I[$P[4NR?UR!P_M M11O6M6N2_#"EPAP35:$:M2A+ =^I@]0(X M]O8XWY]4Z&CH]J@CKVQD5W ];#7"'M$4U?U2$BHUWL%J/UBOM+P!9-3&2Y8Q M$=-1]9@G-C],H9V(>ESUBR%XUOXOI^87-RG94#/##IDBHH.^VQ^$)YT[6QFR M:#1,JF2Y3F%%;VTEH=QUW4$_:@SJE-GH([?7[9Y G;L&O9.GC0JXKAYP#;$L MA:E?N4;:?"/,ZJ?QJ%Y_8%"T:SN_&:[(U&_WNPZH^M&N-T86U4.YE(:>W6J9 MTG<.*JM YRLIS6%C'31?3M/_ %!+ P04 " "@0JU8R<\\?+8# #2" M&0 'AL+W=O MX[?8!IQDP08L:)"DW8=A'VCI;!&12)6D[&:_?D=*5IS,<8'MB\4C[YZ[AW?' M\VPGU:,N$ W\J$JAYUYA3#T- IT56#$]D#4*.EE+53%#HMH$NE;(*M!-53'U=(&EW,V]R-MOW/%-8>Q&L)C5;(/W M:+[6MXJDH$?)>85": /" M$C-C$1A]MGB)96F!*(SO':;7N[2&A^L]^K7C3EQ63..E+/_@N2GFWMB#'->L M*#@S&X1L&<6<0 MN[A;1R[**V;88J;D#I35)C2[<%2=-07'A4W*O5%TRLG.+*X95_"-E0W"#3+= M**0;-QH^/K!5B?K3+##DQ>H&68=XT2+&;R F<".%*33\(G+,7]H'%%T?8KP/ M\2(^"7C#U "2R($E/.7%XR<\I7W&=E=*RUO#G"4'.LH^X;=]\$'J3IRV,*ETP7@-\;3GYMAJ:V._&)GA#U M2$_^NB%2\!ZB,W\RBFCAX,J!MS-QPNBVN=4/$5D_P=7 _@(W< MHA+V]0!ZS>D22"4:^>/QI(?:?[OM2ZEJJ2B-E).7T+UB[(?A^+5(MU^A^VDZ>24MMXR7MD@_4V5^UG0+'7=7N,\^I_^%W]G$'R7IO_AUVS_G M%P_]81B^%M_D%_F3)'HE?:&B5V\Z2/PP35])[V&2^&<3NTB'?IC$+Y.=3/QA M/(1C[U9P,&<.%IMY=DVDX&)UY MH-H)V@I&UFYJK:2A&>B6!?WI0&45Z'PMI=D+UD'_-V;Q#U!+ P04 " "@ M0JU89/Q8V9<" #,!0 &0 'AL+W=O8 4AQ]Q8!D;+,UXCYY:(9/S=%J33JU M13MM\^@DX1U3%Q"' XB"*#G!%_>YQHXO?H=OP5Y=;L!$ 2YQQC7\GBVU4?1W M_#F68'&>T'3/6+GU]*M ]OT+?*:)T%)_FWWX,T@&HW!$:S2X&HYZBA:5 MED(@_ZR0,W.H.!RD:0@QP=+>79)RM7<97EW"*(GA41I2P=[F? ;IX&J4TCH: M),1RK'+^08_0-02P,$% @ H$*M M6/18TL=V P &0@ !D !X;"]W;W)K&ULK5;; M;N,V$/V5@1;8MH :W64[:QM(L@F: ML:<=H^%'V@I;%%1"*U)!4G_?H.*5EU M ,?% GVQ>)MSS@QGAI[OI7K2%:*!EZ86>N%5QK270:"+"ANF+V2+@G:V4C7, MT%3M MTJ9*4S:NH@#L,\:!@7WG+NUE9J.9>=J;G E0+=-0U3K]=8R_W"B[S# MP@/?5<8N!,MYRW:X1O-;NU(T"T:4DC9W:\^[ [QSW^F@, MUI.-E$]V;![G_"0=_,HM7R%J[7]CW9[/$@Z+31C:#,2EHN.B_ M[&6(PY'!-'S'(!X,8J>[)W(J/S/#EG,E]Z#L:4*S ^>JLR9Q7-A+61M%NYSL MS/)&-@T%9VUD\01,E+"BJ*!26 YKWS^R38WZAWE@B,X:!<4 ?=U#Q^] )_!% M"E-IN!4EEF_M Y(Y:HT/6J_CLX!?F+J )/(A#N/T#%XR^IXXO.0=/.=@)>L2 ME?X.;K]VW+S"+](@_'FUT491QOQURNT>-3V-:JOH4K>LP(5'9:)1/:.W_/@A MRL-/9S2GH^;T'/IRW15LF7B%BFE0!TI#&UM94WUSL0-=,=JQ HM>H'8"J7_ MM?%!UV70#=:5.Y* M/V.!S0:5FZQ[B)' VN(+JH)KM,#47+2A9'5T#EVVML8U1'XX3?TPSB'/W[(!7Y M/45?V'8(JYH)B"(BB:<0I5,_SM-O)[AMVEJ^(@Y,JXZNE5KE@)Y:]!EDB4]$ MWPJ>DMBRH^0@P3W>;);[LRP\&XYGU,8&CR)/ZT;QP@:ZSY5.< K^;.+G843W MYT=I!H_2L/HH=5EG*JGXWV3T)HM/J3ZD,R0D:^(GV8SN+*$TS*<)G"KYX*A= M-ZAV[E'21-0)TW?N<75\]Z[Z=O_O\?[1I +:<JDL-YH^S!87#5_#/>C/S:W$V6R(DA<5U*H0-9.PNK2NO//KA.R-P9<"=NIH MS"B3I1"/-/F07UHN 8(2,DT1./YLX0;*D@(AC-_[F-:P)3D>CP_1WYG<,975FJQ'%:\+?6=V/T,?3X1QUOGD/_5?X;P!HS^ >.U/QGP(Y<."SR;^:X?3L0+AIP#$R]X+N<-E]#G?,OW M*#'-KJ3D]1K,^->KI=(2]?+;6/)=[' \-M70N6IX!I<6%HD"N05K\>J%%[NO M)Y"' _)P*OKBOBL=)E;L#A!CD6G,P7#(KDC?A=Z/89Z,.H[Y80-L)4HLVJ)> M,TUBZ"NW^ ,4T[A,>N'U_M6+U/>2UPIK=("D#*2V+G17=XCKG)ES5^RKJ10T M^EQOT0,'7%%&;R"#:@GR0'7 PL3VPHB]I)GC)^R#4BV:QY$=!+@:.$'$OG0A M3CS/#L+X%)UC)W89ENP*"K,2V%'@X4+DQ,'W>Z*TLLV@+39/[-CU<,,T)>,) MQJ*!L>A'&>MH^M28\IIB:S+B_\961Y%HOC5'0](OK>$ \0X\#8.K]5K"FFM@ M)Q]JM@WA^;YD6!>.-V?OL?AH@]!/ M[31R#;4Q>_L$,BM4QV$I@^%Q%MK>/#F ,"H1H+WJ&^Q6E$E%,(F6'#1(O&7! M^*PIX[.<,E[1*6T/IW1<.JHSZVB%JBG%'G '(KP6]=FW+_TQFG 8PWAA0M+( MJJM=^I7&2F\D .(R]RC0/?J=3L[9@S$YOFH[ =T5ZO%L16L%PJ*>S"3M&3AI MRGY"/1]4B)FRDV*HX]C!SC>L;D6)%);8$J@7)M&Q9XZM(D=0;%] F3/34?S7 M:#$TB@,]XR?88"]0=!=0)?M.XDYI.ADTG?RK1COVIJ$,:@5C@IP,/B[(;INE MV28[W@:Z;=@.B>7(:\;["^? \DEQW#*?I](T2[SHP5!/DLIAB^_HQCQ37K+( MCN;4&7S;1\/W4..IE\:.YZCB@EXQ].AEV%63!,T#/.L'H=%(_1-XTV_")#*= M+)J/7X:SHX=G!7)MGM<* [:U[MZ@P]?A!7_5/5R_F7?/?Y3WNL!J*F&%KBY* MSF*R>U)W$RT:\XQ="HV/8C/'3FI;2!)$VQ LQEQNGTH]H&6SA81OF@D%:?_ MOD?*UE+4,?I%(JF[YY[G>'>:[;1YLBVB@Q9J>)Y)Q%2UFX6QI%C/=.\$5+@W87DIFOEZCT+MY ME$6'@P>^;9T_2!:SCFUQA>YSMS2T2T:4ADM4EFL%!C?SZ"J[O"Z]?3#XF^/. MOEJ#5[+6^LEO_FCF4>H)H<#:>01&KV>\02$\$-'X;X\9C2&]X^OU ?TN:"./:>32-H,$-ZX5[T+O?<:]GXO%J+6QXPFYOFT90]]9IN7]GGX&8=\[Y 'WD.@P/(C0*O&-46 :]X ^^6&<75UL)R5/OE:FV= MH>+X]YC> :X\#N<;YM)VK,9Y1!UAT3QCM/CUE^P\_7"";#F2+4^A+U9#GX#> MP)5RO.&B]Q4,*ZQ[PQU'RO-++7I*-=P9+>%&RZYW+%0[.?TH]IC"DQR.*WQL M$39:4#\3/'3:(=%C FHM)86V/I2-(3@H1^Q\VS3@>U#J7CD+-!VL8ZKQ_LP! MLKKU!#T2,WI^JG5HD%C28()J$-@"YSXU"SPQ9KU%NG$,_ DR4[2?.E% RVC.U@C MDAJ2_?YP+9?PV!K$[SH@E*U_%/#7*\6!!>C.Z["0Q>FTC-/\'*HLCZNB@L_J M&:WG00DD&;5?#CZ]XI2]BRH^3S.8I'&15; <\S\D'KBU?=#=$X=!(E%(X7:U M7$)>Q=.\@BR++Z8EQ<[3B[B4D6N"&7-.S:A*!&0;GL'&Z"\-JK1V-OK!LZ5^#QAO0 M]XTFN?N-#S#^O1;? %!+ P04 " "@0JU88I.S:38% !V)0 &0 'AL M+W=O^)K0@3ZGB89GW360FQNNET>KDF*^37=D$S^LJ0LQ4*>LE67;QC!41&4)EVS MU^MW4QQGG>FXN/; IF.:BR3.R -#/$]3S'[,2$)WDX[1>;[P)5ZMA;K0G8XW M>$4>B?BZ>6#RK%M3HC@E&8]IAAA93CJWQDU@."J@*/%W3';\X!BIKBPH?5(G M]]&DTU,M(@D)A4)@^;4E=R1)%$FVXUL%[=1UJL##XV>Z7W1>=F:!.;FCR3]Q M)-:3SK"#(K+$>2*^T%U J@X5#0QIPHM/M"O+#JP."G,N:%H%RQ:D<59^X^_5 MC3@(,,T7 LPJP#PWP*H"K',#["K /C? J0*"&@7P7TSZUA4 4,S@T8 M5@'#XNF6CZ-XEBX6>#IF=(>8*BUIZJ 0HHB6CS#.E+N/@LE?8QDGII^PR!E! M=(G$FJ!9SN7OG*/WZ#:*8F473M!]5OY'E&MO72)PG/!WZ V*,_37FN8<9Q$? M=X5LC6)VPZIFKZS9?*%F WVDF5ASY&41B5KB?7V\I8GORKM0WPKS^5;,3"WP M=L.N4<^\0F;/M-'71Q>]??.NI5UW>LP'G%TCH_\JQGT%DTN,:1082X/QSNB4 MU7NU-;X>\Q$KC-'$H$V"A5(#A5*!.,*"M)#GYY-U_0ST&)>$KV$:4ECU_\,J MN-8+W#O,UTCV#A4'WK<\WN*$9(*C?_^41=&]("G_KZ6]LY)KMW-52KKA&QR2 M24?F'$[8EG2FO_]F]'M_M"D'"7,A81XDS(>$S2%A 1"LX:!=.VCKZ--/>;H@ M3(W1SW\XCG[6QVWN:7F7N@<)YN#X6"K"X @C6$ M9 PWSE1RSY2"[*Z C64*M? MJ]77JO7 :$A(Q-&2T13%G.J!0ES(6$> M),PO8?T#M09#Q^KUCOR"K#, @C7\&M1^#?1#EYS.)Y2WS3=FVLA+_8&$N9 P M#Q+F#TZ&)FOD.-:1/H,3RZR![3C-4@%0PQI>#&LOAEHO;L,P3W/Y2D0BM701 MA[%H4T0+N5012)@+"?,@8?[P1)'^R+('QRD,LLY@>")B, +F:0X"7,6BYBTCC+:*BY5"!+F0L(\ M2)@_.GVWMJW3+ 599P $:XAF]/;+:CVM:CY-$KI[_SE#GY=+PN)LU>:2'G*I M3* T%Y3F@=)\4-HES4%I 12M M*:.YE]&\8#;(!0V?Y!2P' ]EWLWDR[R<$=:SQ)!RT9IS]=55GW^1&=F1="E: T'Y0V!Z4%4+2FC/O5=T.__ Z6%9V3%& :SO X0=WIFW.Q=*#K[&?VP0>M M=0Y*"Z!HI4[=@\T<*6&K8F,/EQ;DF2@W,]17Z\U#M\66F:/KOG$S+[< [3'E MCJ2/F*WBC*.$+"6R=SV0'6#E)I_R1-!-L65D086@:7&X)C@B3!60OR\I%<\G MJH)ZJ]7T?U!+ P04 " "@0JU81%]!EI$" "N!@ &0 'AL+W=O< M"5@KHG=51=7S-7!Y6'@3[[APSXH2[8*?Q#4M8 /XM5XK,_,[EHQ5(#23@BC( M%]YR5L"Y)3(R'EM. MKTMI@:?C(_LGY]UXV5(-*\F_LPS+A7?ID0QRNN-X+P^?H?7C!*:2:_N-@YMW#!AO^(&E=EE!H?)IOEZ1.9DPPK!R1.16"BPU^2@RR%[B?:.XDQT> M95^'@X1W6(A$$8]>D9AM]2-2;1Q,&G1$-ASB4.R(JZ:D:.-SK#VU>V M'\NM1F6.Z\\>G=<-W[2?SU[A*UW3%!:>N:,:U!Z\Y/6KR3SXT&?Z/Y&]L#[M MK$^'V),-RO2AE#P#I=\0>-PQ?"9"(HR(MEM$UYSAB*12[$V(:P+4W.2^HC29 MWKM,M@WMDV &P6U5$BW'(X'2?=Y M&J3[VP_=D,U."C3I:M/8\4]:0@6J<)U2$W<\F^[0K7;->.EZD/\[O.GDYK(4 M3&C"(3?08'QA\JJF.S83E+5K,%N)IEVY86E^**!L@-G/I3D&[<0FZ'Y1R2]0 M2P,$% @ H$*M6"QIV1HQ!@ QC( !D !X;"]W;W)K&ULS9M=;]LV%(;_"N$50PLDL432CITY!MIDQ0JL6- LV\6P"UJF M;:&2Z)*4T^S7CY)5T1(5VE;$)#>)OGAXWE?\>$19DWO&OXH5I1)\CZ-$7/96 M4JXO^GT1K&A,Q!E;TT2=63 >$ZEV^;(OUIR2>5XHCOK0\X;]F(1);SK)C]WP MZ82E,@H3>L.!2..8\(>__B"H^S OD5?X7T7NQL@TS*C+&OV&&1#21 I!D#CX3_I5*,HLHN*5!RD,94@%.P:=D0X54-U&"&\X6 MH3K_]EI=&$;BG3I]=WL-WKYY!]Z , %_KE@J5# QZ4N59U9;/RAR^K#-"3Z2 MDZK^#"#_!$ /XH;B5_;BUS0HBZ-J\;YRI[0(EA;!/!YZ--Y,[OAP MYOE.+, MG5/5C4Z%,@[\\[LJ!#Y)&HM_FP1O:\#--61=]4*L24 O>ZHO"LHWM#?]^2=_ MZ/W2)+^C8!4S4&D&LD7?FB%VS""&&2>JW7*N&DF3$=OHPSQZ-L1LIH,!1L-) M?[.KT+S**Z^HI(W+M+$U[;R94]W,5=X2!(3SAS!9 G4PI7G+GQ\BC\2,R_ _ M.@V; 'XW._UJ[ME;<5MX.'_K'B.AO^BZH'C=-\H=Z:75OUFOQ\*TL= MJ_ZHD;VHVJK>!>GY&O5\.^N9Z@\>M(O(>QNW-8&V C44^G8JK,$L"(5(U6V< M/8"[L]LSL&0;RI/\<4<]T2:!NJ11:T<85UCB @I]387^P/G8[G<$;84A+A#0 MUPSH'P>!AX[N)KCYYZ-1G=WLE;<5I^G-/P[?.AW=37 SQC<7T.9K:O/MV.9T M=!_M5^^"X7P-<;X5BYXTNH\/:]PNN QJ+H-V+CMHJ:+Z+&]=NH FL*DI#=:? M6.U9M56M@0W:@>TPU9WU MX6"G#-=5M*HAFN&@$X:##0P'/:\^S=DK;RM.,QQ\.8:#^QG.GEU;]9KAX,LQ M'#09[K3^!&M/KZU\#7'0&<3!!HA3K7M4%^@"XI"&./2\$(=,B(/#H5='%GM6 M;55KB$.O"N+0_H4X>\)M#=$,AUX5PR&3X4Z-)N+D->S.>UC'+V)-B,LZ@G'? M74 A"0":[*FO%%)I^S65;2J8,UNR#V[H4[9K:MH54,TNR$G M[(9,=H-X8+1N%^B&-+JAET,WM!_=[-FU5:_1#;T7EOY&MV0,W1# M)KI!C.O/)?;Z6^K#FMSP\Y(;;GA?.C86'>Q)M16MP0V_*G##^\'-GG!;0S2X MX5<%;K@!W(Q?7;D -ZS!#;L%-]SP:G6,ZH.;/8FV(G=^;F?GMC_DBO)#%M[L M<8YEE:ZB555K>,/NX0UW"F]=1:L:HN$-V^&M\SG I#KDX?I/P>Q)M16MJ0[; MJ>ZYYX#]H&=/N*TA&O2P'?2>>PYH8+_ZP[L]X[:.:/;#=O9[\ARP#3^L]@.# MA3H%P/[.1P;9%QZ?"5^&B0 17:CPWMFY,IQO/YK8[DBVSK\[F#$I69QOKBB9 M4YY=H,XO&),_=K)/&@" #$!P M&0 'AL+W=O*Z#+/J7J> )?KL=?WM@MW;)D9N^#'HX(N80;F MOKA5./-KE)3E(#23@BA8C+WS_MDTLN?=@6\,UKHQ)I;)7,H'.[E*QU[/%@0< M$F,1*#Y6, 7.+1"6\;C!].J4-K YWJ)_=MR1RYQJF$K^G:4F&WL?/9+"@I;< MW,GU%]CP&5J\1'+M_LFZ.GLZ\$A2:B/S33!6D#-1/>G31H=&0-@_$!!L H*= M@" X$!!N D)'M*K,T;J@AL8C)==$V=.(9@=.&Q>-;)BPMS@S"G<9QIEX2G5& M+A]+MJ(;C),J8W @8TBNI3"9)IE>7^N^W>)A7@T %:>UK%83CR5TU&K3G?R&A8,QJV M,GJYPPXI!7HJ9[\@)5QJ30JIF?6M#EE0I@A^;27LHUAEB!H4!T'4L[\=HJVE MO)%H5!.-6HE^-1FHKLFHZ!K("ZG0_PG+"V1F7V_'N(-FBJ^X;FA"5V@9UE6Z MV'VZ&@UGGP+17PKL4F\[4?'Q&X:8@UJZ/J%)(DMA*F.I5^M6=.X<>&=]@BVJ MZB@O,%5_0Y=8,J$)AP5"]DY.\4)4U3.JB9&%L]VY-&CB;IAAFP5E#^#^0DJS MG=@$=>.._P!02P,$% @ H$*M6'8NA7&< @ J 8 !D !X;"]W;W)K M&ULK551;]HP$/XK5C9-G=0V(2& .HC4PJ;U85)5 MUO5AVH,)%V+5L:E]@?;?[^RD&1U0[6$OQ&??]_F[+]QEO-7FP98 R)XJJ>PD M*!'7%V%H\Q(J;L_U&A2=%-I4'"DTJ]"N#?"E!U4RC*-H$%9-6K$IT&V$V7O,5S 'OUC>&HK!C68H*E!5: M,0/%)+CL74Q3E^\3?@C8VITUFQ@"E(Z(I+Q MV'(&W94.N+M^8?_B:Z=:%MS"5,M[L<1R$HP"MH2"UQ)O]?8KM/5X@;F6UO^R M;9L;!2RO+>JJ!9."2JCFR9]:'W8 O?X10-P"XG\%)"T@\84VRGQ9,XX\&QN] M9<9E$YM;>&\\FJH1RKW%.1HZ%83#;,IMR3X_UF+#)2BTC*LE^\;- R!?2&!S MR&LC4(!E9VRJ%1HRON:2XOKVP:Y[#)*#&M& V$&0? MWO4&T:=#!OPGLE=V))T=R5OLV;W 4BBF%;!GX.90K0W!P!.XD;+)1L/AB(9, M- XWNW7L)_[)>"6NWXGKORGNLD PG3:&I='UJF0%C0V_8P_);2C3'15).AHF M^W+W$X_(33NYZ9MROVNDMN(;:AG726G S2=%_Q M?N;?BL.=.>)F.#7?2BC+)!2$B&ULS9Q=;]LV%(;_"N$-0PRQ*+:OYO-\]<@W+#]/MSPI/[E/LPTKRI?9PSS?9IRM M#XTV\=RQ+'^^85$R6UXIT^7,WOVXXV/ MT<-C4;TQ7UYLV0._Y<6G[8>L?#4_J:RC#4_R*$U(QN\O9Z_M5U>A6S4X'/$Y MXD]YXV]2A7*7IE^J%^_6ES.K&A&/^:JH)%CYWYY?\3BNE,IQ?*U%9Z<^JX;- MOW^HOST$7P9SQW)^E<9_1>OB\7(6SLB:W[-=7'Q,GW[G=4!>I;=*X_SP+WFJ MC[5F9+7+BW13-RY'L(F2X__L6YV(1@/;?::!4S=PNC:@=0-Z"/0XLD-8UZQ@ MRXLL?2)9=72I5OUQR,VA=1E-E%33>%MDY:=1V:Y8OF511CZS>,?)#6?Y+N/E M'!4Y.2.WQXDEZ3UY&R4L644L)J_SG)>?UH>N"2M(0Z&:%O*1KW99%B4/Y W+ MHYR\N.8%B^+\UU(3CGW9..Z,?+J])B]^_O5B7I0A50.;K^KAOSD.WWEF^#;S,I&G;#JG;#H'/=J:S9<_4L62-7D?L;LH MCHJ(-U)7)@M24!WU1YID_\O=W^_+#LB[@F_R?U3).8[&58^F.@.\RK=LQ2]G M98GG/-OSV?*7GVS?^DV5*DUB0N+H*7$44U\>DZ4*\=C./[2KSDG[I4T7ON-; MEG4QWS?'+Q\)1PB#=['A]#M%5#0UOWS;XF,2%0[Q2H-ZEEZ^E, MG"8Q(7'^*7'^P&5[;.@M77K5H!P.''YR&'W1=X(XJ"+1UWWG2)"8$ M&IX"#2>UP$.=B=,D)B1N<4K<8N "7T@+W/4MZL@+'.U@X/!M"_#&ZKK$J1(O MT.9]ITJ7FAAL@^7L22WS>CBZDJ=)34P>H)N- @ZRU.N&GI(LZK&;@"<;Z,G& M\>DF3?CW[9*V. Q7I/5V:U,20@\9Z-4 MM+QB^2/A7W?1GL75=D\9L">M>MM;!+9\AL<[&QH,,)B-0YB\^,F_I(W=< MTVF"XFS .#N85BUH!4-=:F+R UM%*"ZU4+8N19,T)H-N&;CO-96"TK,QS5[ M3Z<)X', ^!QK4K7@: 5(76IB\@ @'92Q.M5"+8'1$-[+T"@:)AQ.Q&80#P'$,_!$>^:WQ4D MK^;Q.-]1GN_*V;[[3CZ=WYZ3AW3/LZ3R^@E[X,FJ/$09IU:K3I>:F!( 1<>? M5E5H94Q=:F+R@#$=W"OL5!6!C$E!&"YD3,([&QH,,)^#,]_K/8MB=A?SL_LT M.\O+B.JOB^J]1M4H@Y19L$1!JK!V\4$,#1)8T,%9L/\9H,.^">^S]YHVP8H4 M6)%.BQ6I5E;4I28F#UB1CF=%*K/B,R<$O+.AP0 RTA;S;\0)@:-H%^%-"/3LM4I%I-15UJ8O* ..EX4Y'*IJ)4 M)"8@D0(DTI9+NF/.!/)57RDZ$Q1'@>(H3G%C3P'*K3/>9^]5; (-*: AG=:E M8JKU6K$N-3%Y@)P41\Y.IP#YRK%4)":PT 4L=/%KQF-. ;4T%AW>^]#H@-O< M%FY+LVV:L8*3M7@R4(:C]0JO+C4QU: M0L!]Q[)"F83QSH8&T_AA'V[QC:IPV?IS_.KGB'*0)GC,!1YS6WCLN4+OL,W' MI7LO71-(YP+2N=/R_5RMOI\N-3%Y0(SN>-_/E7T_J19,4)T+5.>:,_Q+C4Q>0"&WGA#SU,8 M>NIO>+RSH<$ ZWGF##U/-O2>^8;'!S$T2& RKX7)NM6]NB9XS@.> M\Z;EVWE:?3M=:F+R&C=_C/?MO';?#N]E:!0 >9XYW\YK]^WPWH=&!Q3FM5!8 MNMGP[' +WI9M>::,0JL-ITM-#!B S9N6#>=IM>%TJ8G) Q[TQMMPGFS#.:ZK MN#*']S7T!BM .M^<&>?+9IR]H(I?;>)C&!HCD)??9LF)U=UA@XXK]EVONM3$ M^ '6_&D9<[Y68TZ7FI@\@$!_O#'GR\:<5 (F",X'@O/-.7)^^X_Q\-Z'1@>( MY;=9<5B!*_?EN&+O-6KD+MG&;;+3Z]7$\06 +$%TS+A JTF MG"XU,7F @L%X$RYHOP,#[V5H% !T@3GW+6B_VQ;O?6AT0%P!3EQ_%H]E57>X M>H[K]%Z9)@@M $(+IN6Q!5H]-EUJ8O( ,< $<5A.R]4$VV",$,@S'!:]^^&6D%5EYJ8/ #5T)R56$NK M'R)81Z>5).>-1W=6STV]8=E#E.0DYO>EO'5>,5UV?!3I\461;@]/\[Q+BR+= M'/Y\Y&S-L^J \O/[-"U^O*@>$'IZ(.SR/U!+ P04 " "@0JU84GACRJ(" M M!P &0 'AL+W=OX[/ MN;:OXRT73S('4&17LDJ.K5RI^MJV99I#2>4%KZ'"F247)578%2M;U@)H9D E MLSW'B>R2%I65Q&9L)I*8KQ4K*I@)(M=E2<7S+3"^'5NN]3)P7ZQRI0?L)*[I M"N:@'NN9P)[=L61%"94L>$4$+,?6C7L]B72\"?A1P%;NM8EVLN#\27>^96/+ MT8* 0:HT \7?!B; F"9"&7]:3JM;4@/WVR_L=\8[>EE0"1/.?A:9RL?6I44R M6-(U4_=\^Q5:/Z'F2SF3YDNV;:QCD70M%2];,"HHBZKYTUV;ASV &QP >"W M>R_ ;P&^,=HH,[:F5-$D%GQ+A(Y&-MTPN3%H=%-4>A?G2N!L@3B5W*2I6$-& MONSP7$B0Y)S,FPTE?$EZLZ=34+1@\@SC'N=3?\8>W<<8*= 5)01O005:6ZRD<$&KWV-EUAA1',DAM+1 MK!&9-709V23!R!W%]F;?9C_(NPK_!;V2'W3R@W?)KT%(7E7 S@4PJHRAPW(; MSG!/B1M%[ANY_2!_Y$;#7;Q3V8T:!/RPPZ@1& M1P4^<(5G@':'XK# J+>;T=4H>J.P'S0*>CFT]XJ9?DBP/*R*2A(&2X0Y%R-T M*)KBW'04KTU]6W"%U=(TUAV(-JT[%073R12=J_'R6G M1C8T?=N+)4H\AXC+8X2SJB_CQ-L>[ 2#QQ/5B^:9TWDMCT MZQ1[#[*)(*/3(LO.4B.53:HRGJU\5;H-:65AY05NC)'^<0[:[69)GCP=W*AU M1^$@KKN$6Z%N_\FRE(TNC#%A4S@H/[2RYR,_GT^ ?';XKV.'!7H1,[IR[ M#\95,TNR( @TU!08)"];6(#6@8AE_-YS)F/( #S'T#]50 M-TL^)J*!5FXTW;C=%]CG*K,C_1J>L?4R@&!,H(MWT"-W7ME4UB-M>\E=9,7=<,RN6 M$E'6W0:!")\3^2)K&(5S#)2SA'L=P6\AJ5Z_RL^R3R]HGHR:)Y%]DYV0-QGD7F\$!LJ^PD*\IT>Z@G/>C?\!0LI5\KBT)#R[#LY ,/CQ_&:S#( M];&E[QSQ@,1MQR\2^.# ]ZUS]&2$*1G?N.H/4$L#!!0 ( *!"K5C#\&PO=V]R:W-H965T:/VT>N-P:UI1%G-),Q"Q#G"YO!^_LFQ!? MJ8"BQ)\QW8O6;Z0.Y9FQ+VKC_>)V8*D6T81&N4(0^;6C=S1)%$FVX]\*.JCK M5('MWR_TH#AX>3#/1- [EOP5+_+U[6 R0 NZ)-LD_\3VO]/J@%S%BU@BBD^T MK\I: Q1M1<[2*EBV((VS\IM\K4Y$*\"UCP3@*@ ?!&!\),"I IR# ,ZI >,J8'QJDZZJ@"+[P_+L%JGQ2$YF4\[VB*O2DJ9^%/DMHF5& MXDQ)\3'G\M]8QN4SF<*$/#-."F%\B".I,HK>K3BE4G"Y0&_11\+5WSN*7GLT M)W$BWJ!7:(C$FG J4)RAIRS.Q87<*7]_7K.M(-E"3(>Y;)^J91A5;;DKVX*/ MM,5&]RS+UP+YV8(N>N(]<[QCB!_*\U*?'/QRGKT MT.M7;Q![3N)5>;Y:IZ'\ZCOH$^IP;+V.OF,W8^X)[V):[>LA^J<3'4/# C/& MH]%)F/!T#.Y)A2';3GTI.$45SK$J8D%64OA5;MD2?:([FFTI^ON#+(K>YS05 M__0T?5YR1_U<-9C3$WR"+:4J9 WX_JM)1/R7<+OIHZ[&;V=+AK M:\+8@G,U 0GS(6$!)"PTG54MT6Z=:->8:'VHY&7?T)=/(^;<[@ 2YI6P<>N< MC)P#K?G=,N.)HY<)(!L5 L&TG([KG([-.=UR+JN^.#%$/6&(P[>K&=:ZS7& +5J.7XJL[QE3''3W=SV0574]N^ M;!K#S\TF),R#A/F0L 2%@+!-'5,:G5,?M*L;P(I&TB8!PGS(6$!)"P$@FFR MN:YEA\G5.1,7O)53OO6S',SY-RL@M(\4)H/2@M :6%%:ROX M>N(>U4#+#+.-&OC,229(:9)NN)PQ]$K R#A; I T#Y3F@]("4%I8T4[L!7"C M RSR#-SSE8!),VK:.W+8]3IWT&K#$!I(11-%T%C!-I&P^C_K@K-U+,E 6H$ M5C1]F=;5!*C%!TH+H6BZ)AJ7SS;;?)]I1J*8].8=TK>Z Z5YH#0?E!: TD(H MFJZ/QARTW9^TCK1!_4)0F@=*\T%I 2@MA*+I\FE\2-ML1#9W$5YNJPJQE<-- MG*&\-2E]+;?+ F_0]^.W]N9VUP<M,+J_=PVD(J%4)2@NA:'KF&[?2-KI:LP?.(DH7 BTY2ZO\LZ69:34F;4N M\6'Z06W'D^KT0>L,0&DA%$U_&JFQ*+'9HCPO^XLM/_K(P0\J(2'.TU+-\V8H>NV=A)I^[%JEHVMWH MT:0S>H!6ZH/2 E!:"$73A=&8F]AL;A[V'R21R]-B>5&:6[V* /4Y06E>1=-F M)U==5PNTT@"4%D+1=$4T3BE!:"T$(JFRZ\N'>PW[-O_/)%Q 93OA=Y M3_@JS@1*Z%(BK6YRPM?JXID1-654#^OV0L?]E0 M%=0O?,[^ U!+ P04 " "@0JU8CDYF_18( 72 &0 'AL+W=OY8DR1KUF:RYO>2JGUFWY?SE8LH_*2KUFN_[+@(J-*?Q3+OEP+1N=E4);V MW<' [V\XU*DYS="2(W64;%MW45 N<>_$[:3!^])<2@/ MG'\I/KR?W_0&18M8RF:J0%#]LF6W+$T+DF['7S6TM\]9!!Z^?Z1'Y<'K@WF@ MDMWR](]DKE8WO:L>F;,%W:3J$]_]RNH#&A6\&4]E^3_9U?L.>F2VD8IG=;!N M09;DU2O]6G\1!P'#IP+<.L ]"G"&3P1X=8#WW S#.F#XW(!1'3 Z"G#=)P+\ M.L _"O">"AC7 >.R6-6W6Y8FH(I.KP7?$5'LK6G%F[*^9;2N2)(74KQ70O\U MT7%J>LNS3"OB7O'9%T+S.;G34F!"L'F][35Y.Y\GA6QH2M[GE?@+$;T*F*)) M*G\F/Y(^D2LJF"1)3C[GB9(7>J-^__N*;Z2FRNN^THTM4O9G=>JY4D83YG2]8IG\L^6HWE4YA^TYBZ'CC5S3&;OIZ;&A3-.;_N,' MQQ_\TB8M)"Q PD(D+$+"8A#,D-1P+ZFAC3XM];/BZ9P)^1-A?VT2]8WD7+$+ M(DMIR76:J LRX_E6[U(.V$5_V28D:Z:N0JI@DQ)6S#^VT\'EP/?'U_WMH420 M.4,D+$+"8A#,D,AH+Y&152)U3U/*X8+0C5IQD?Q7=S:O](A8]6UMO>4[*[6K M')"P D+*]CH0*C.:%#],[4:(=/&STEKE-O?E]OO4.XU%61+TPTKJSWG:4J% M)&LFJLK_3/YW,-*UJ<":K*L*D+ "0LKV-CLK@8#YT@"R)SQV9Q&_BR.SQL_(:M1[LJ_WI%N]_W8_;LW7509(6("$ MA9/G]>/(G/'9G(8$G$%CA0S.B>!UM"GL!O('%8+F2E?Y _V:9)NLK<1V7-<: M0VD!E!9":1&4%J-HIF@._#/G!3R&.BE*6DA: *6%4%H$I<4HFBDMMY&6:^V/ MZJZG&'5F+%=TR0A?D"U72;XD:[YCHE4Z5FAGZ2!I 906UC3',4>"X61R-/I MT\8HFJF*QM-TK/[6],Y0 ]_E3,A5LB8KEL[)@[X,X;HS*C>7?CY=+)(TH:I] MEF+/U5DL4#<32@MKVK%8)J=B@7J5*)HIEL:M=.QVY8%89BN:ZQ<]F]UKIE41 M4%<22@N@M+"F'2G":5$$U)I$T4Q%-.:D8WK8G=>(IRG?O?Z8ZPYH MP82^U&F5!=1EA=("*"V$TB(H+4;13*DTGJTS>8FA"NK<0FD!E!9":1&4%J-H MYJ-BC17LVJW@[[V';\=V%0^4%M2TPYLG0W?B^T/?O-X)H6DC*"U&T4Q=-&ZO M:[7\IOZ')D5N#6WHK.A3_-Z0POW=%QV:%. M+)06HVAFV1LGUK4[L7>"SQB;2[(0/*N+S^OIB;P@.5.%*)+'(6;&I9*%%%H5 M4*7R#ZOAZY8.CC4 =5Y;LOK>\#AI^$3CAL>62,M^1Z@8U7ZS9(U-ZMIM4N-, MO:C/2-V5+Y>"+:EBAYTZS?@F5V?[=N^D__2N!N[@^$2ZM;>L<^6@-BB4%D%I M,8IF*J;Q2EV[5WIZY:%/X=-[PJW2@)JF4%H I8506@2EQ2B:J9_&675'+W Y MXD)-62@M@-)"*"V"TF(4S9168\JZ]F=,__ZT\_391SWM')[3C?GIV?:_RYAX)O[O]6#D_K;) M'O1X4USQUNM*:/EH0>GQ2.FA2=)J'9,S5T3>J6'K>]YX=.RTVQO3620M69W) M9#PY'H>P/[#'_L(>ZL3V#Y8GR9A8EBO/2#(K3/=J_8[]UOWJ-F_+-5V.MH?. MFZA:HZ;!5$OF?*!BF>22I&RAD8/+L?[Z1;4*3?5!\76Y",H#5XIGY=L5HW,F MBAWTWQ>&ULQ5E=;Z-&%/TK(RJMNE(3&+YL MI[:EKM.HJ;J*%;?=AZH/$QC;*,#0F<%.JOWQ>P<(&!O3=35KYR'FX]XS]YZ9 M P<8;QE_%FM*)7I)XE1,C+64V8UIBF!-$R*N6493.+-D/"$2=OG*%!FG)"R2 MDMBT+R9-4H8)305$4L1I\N)\1.^F=FN2B@B_HSH5NQL(]7*$V// M:N<^G!B6JHC&-) *@L#/ALYH'"LDJ..?"M2HQU2)N]MOZ'=%\]#,$Q%TQN)/ M42C7$V-HH) N21[+1[;]A58->0HO8+$H_J-M%6L9*,B%9$F5#!4D45K^DI>* MB)T$[!Y)L*L$^VL3G"K!*1HM*RO:NB623,><;1%7T8"F-@INBFSH)DK5-"XD MA[,1Y,GIC"4)L+F0+'A&) W1'&BDG-.P.G:%%N4,([9$K>A'*BC?0"#PB>YR MF7.*[H7(21I0]/TME22*Q7L $&O"J1B;$NI5HYI!5=N'LC;[2&T?";]&#OX! MV9;M=J3/^M-O:5"G.^UT$UBJJ;)KJNP"SSF"MP )A7E,T<,I1/SU&\"@>TD3 M\7<7!>68;O>82L0W(B,!G1B@TF(88_KN.^Q;/W81H@FL18]3T^/TH4]_9Y+$ MU5RKM4)RN68\^A=X"4JV1,$6?V,+KD%H6;(5U$P#CM#UQ\Z=5RK1;=NT>UM<5$VU^J OE >1(*JEN$R*22( M*$I75;,L4Q>KSK7?.]2I$Z\)K,6*5[/B74 7GDYZ-(&UZ/%K>OR+Z\(_7._6 MT+5L?T\7AW&^[V/_B"P&=8>#W@[AEG%UEZXUY^=11I5">U;A>!J4J!#(BA;;GU&7PZHZ)%O"0X&4KCB2Z^+F8E5KZ"$KGPGA^>4>2$C5 MHR&:QR3MI*"WR)/7C":T-J6-(\7N)62EU9SJ0FM3U-A3W&OOSB,K[U!6&%OV M<%]5'7'NT/;=(])J3";N=YG?0%H_)UG,7BFM%M0\Y\$:\(_KJK?"DQ>-)K0V MGXVEQ8-+Z$JKR]6%UJ:H\;FXUR>>1U?##KV KO8?^#OB/ <4>$16C5G%_6Y5 MNZQ5!F'U52;U$G+Q--:.V79HT;MJU+O#;3ZHUUH;4I:KRQW6LLSZ*D MJH1=A8Q&_LC;?RCJB#OB^^R=%Z?]QK9+(QLJI'I/!NW"<]6_QNM1NW+#M7$(86MVM+K0V18V[M?M?N)Y%&.ZA, :^A?=U<1CF M#K#K[6G#W/D4H[Z#?21\%:4"Q70)>=;U !X^6FIW)$L*[[./#$I65)LKBF! M.X8*@/-+QN3;COK@4W_@FWX!4$L#!!0 ( *!"K5@K!$Z&PO=V]R:W-H965TE^_6SG9 T-/4=$ 0?J./X/#GGR3G' M3]W!EHM'N010Z"E-F!QZ2Z56E[XOPR6D5)[S%3!]9\Y%2I6^% M?K@30R!JE MB4^"H.NG-&;>:&#GIF(TX&N5Q RF LEUFE*QNX:$;X<>]IXG[N+%4ID)?S18 MT07<@WI8386^\@N4*$Z!R9@S)& ^]*[PY9@08V!7_!G#5NZ-D0EEQOFCN9A$ M0R\P'D$"H3(05']L8 Q)8I"T'__DH%[Q3&.X/WY&_\4&KX.940ECGGR+([4< M>GT/13"GZT3=\>VOD ?4,7@A3Z3]C[;YVL!#X5HJGN;&VH,T9MDG?+AX]FU)B)"8Y[J[)#4\GN&KJ(H-D.:H G+$L;<.+D!1>-$GNHE M#_U] M'5 1%7F.ZIHX 6^I.$/3 8E5+F!/0U/:E7-$0AIXN7@EB ][HQQ]P-_BY+MJ&P"JQ MMXO8VQ:]=2S!EE3 V>PPP:Z$H&P!NB4H--NA_753NK/35ULJ(O37;QH2312D M\N\ZJMI-4M406(6J3D%5QYDF?W"E:VW-!(1\P>)_-1/A/F,AETJWSH2:_%%< MK\S32I1I)6U:K8^E5>8 SA+?M/C-J'?>'_B;?0Z<7KZ1@V[!0=?)P3?;=R$Z MHQL0>A]!*Q QC]");C [H$*>UH7EQB29)6JC-&LS!$5T5\?/V GTQM![1>@] MIYNV B3*@2.D6RZ")Q!A+ 'Q.=*;L%2413%;Y*^9K]2QANM\U&N+HB&P"BO] M@I7^)_>/?I-4-016H>JBH.KB VK'C8FM)<+!<^W@WM'B<2*],78ZQOPI,90VWKS HI2QMJTJ5>O@2'?9.T#QJGV\.W,K GY;"3@0F+UF%6$-.$ MLMI G BO3?:FT*KQDC)>\LFM(7>@*;H:0JO258I0[%:AOZ_3&0BSD\ALIZ%K MM>3"UHMI$=EL;8_(D3M[Z8\#^_>R CY":N)2:V*G/AMIO1Z@K^DJX3N 7&)/ M6*A?N/ZN>+PH&E603:%5*2@U).Y\=E$TI ]SNCY";>)2;F*W-GQ/470/BT)7 M1;_5>ED4APN[74S:9?%4G2\%(W8K1A+HW?A_9WFCDK IM&KDI2C$GZT*<:.R ML"FT*EVE,,1N%?>>++\X2-[61:??.>C\WUU7/ MLZ[?(Z3W(M?]O7/9%,3"'E=+_>5DS51V1%O,%D?B5_8@V"^79^?IMU0L8B91 M G-M&ISW]+-%=D2=72B^LJ>\,ZX43^UP"30"81;H^W/.U?.%>4#Q0\'H/U!+ M P04 " "@0JU8=]KD/T\# #@"@ &0 'AL+W=O4K:)4A-]_AB4M5JW6L7+HE5L#/; M))NT#[^S(213",HJ[4W <'?^W<7WYZ9;J9[T"L"0GU4I],Q;&;.^\GV=KZ!B M>B37(/#-0JJ*&5RJI:_7"ECAG*K2#X,@]2O&A9=-W;-;E4UE;4HNX%8175<5 M4[_F4,KMS*/>[L$=7ZZ,?>!GTS5;PCV8;^M;A2N_BU+P"H3F4A %BYEW3:_F M-+8.SN*!PU8?W!.;RJ.43W;QI9AY@26"$G)C0S"\;. &RM)&0HX?;5"OV],Z M'M[OHG]TR6,RCTS#C2R_\\*L9M[$(P4L6%V:.[G]#&U"B8V7RU*[7[)M;0./ MY+4VLFJ=D:#BHKFRGVTA#ARB\(1#V#J$CKO9R%&^9X9E4R6W1%EKC&9O7*K. M&^&XL/_*O5'XEJ.?R>Z-S)\NYIA706YDA7^V9JY<%^2^^:.(7) [T$;QW*"1 M!&3WV#P'9;/V_AY@U<> (N M(E^E,"M-/H@"BK_]?4RTRS;<93L/!P-^96I$(OJ6A$$8DY?$)WK%D+:]#.P0 M=?6,W [1J7KV!&K(&K^XW\\VWY5>LQQF'G:7!K4!+WOU@J;!NP&JN*.*AZ)G MTSB9^IL>G*3#209Q MOFA=X]DXER$Y8DB3*(KZ&=*.(1UD>&B.ZKD,Z1'#!:51G/9#C#N(\2 $"LL" M^+]PC(\YHB2B_1B3#F,RB('M]9RS,3EBN1RGP0F6RX[E@6RV7!R4&34KE$X[J\R/=!]>FX//@>K_:I$A\(0C:(3PD##/59X M;EL^!RL\QHIH.CK1IG2OZG10GG>-6MMO12^;/@,NZH%+1ND)(:-[<:?#ZMZ= M.CCNX^<4,3XZW&M^MF:-F;-[,??I:Q M730I88&NP6B,FJ*:<:I9&+EV(\RC-#@0N=L5CJ"@K &^7TAI=@N[03?49G\ M4$L#!!0 ( *!"K5C.C<5YU 0 $,3 9 >&PO=V]R:W-H965T'4CHDK@MTGZ!Q+&?/^_9_C[;HQT73W+%F$+/>5;(L;-2 M:GWMNC)>L9S*'E^S KXLN,BI@E>Q=.5:,)J81GGF$L\+W9RFA3,9F;)[,1GQ MC5 \?KJ:@5\)NN$Y#+:D)EQ7 MZ*$<*,07R-1"?ZS-EZD.9*KVZ.*6*9IF\B/Z@%PD5U0PB=("/1:IDI=0",]_ MKOA&TB*1(U!G M*GK(QY>(>"1 CP^WZ.+#"_;RS]*37T75-SWY'3U]V>1S)DSD6DR6K*6%H-V" M7HS7?L73M_+\*FBA8 :^E:+?H A( M%/6]=HJPH@BM%'?/3,2I? ='V."X\D,_:,<85!@#*\:-'I ,*+A (+L+EKXG M-(,FTL#O=XQ/5"%%]L@4R3F3)6JP8"\*/!*VTPPKFJ&5IEY=AW7+RH&C\^SM M;,/F1(Z&?HC;T;!7ZZEGA?O&I!XND#S 6D/N@1?%T1:*W\QVZ.+-@<,G:H^M MPO3=9"E FFZ9@*R+CG.^E)9[D<+PKB&X1K=:V?#_H%N8U Z0,Y0KX5E&A33D M)JPZOK6PM_I1]A.=QCCT>GC8$>):^K%5N5]HV3EG@J],&MN>-N_^HX#EP@[;@#7M>UZJH$PBV9Y#79/$9[=%KOGNY-\71'17)YV"K#)GB:)*E^ MI!FZ366<<;G1&>NOZ5PJ 4>2OUL]L^:_,S66U"F,V%-8E23H(4D(IL]W>O+' ML"/7V!OP1S&1(SCH247-RFCSY)6>(K1G>M0#E)=;?3Q "=W;MN"DSG7$FHK> MY<;)#J+5#7M/1S<(?I6^3G3$GNC>0[_M7ERMWMA[/F=0ZNQ([-EQNEP*MJ2* MP>%0B11.]S':TFS#CD, Z+#P6[%+R^%I^ND0=5)G16+/BMT\)S.[DZAY&L(! M'@XZH.J,2.P9\=4@&8WO@FH>C@:AWR&*I,Y^Q)[]NIDLLZ^3,6P,95O@W)-[ MC9R)I;F]D3#_-X4JKSBJTNJ&:%K>B]35R^LE./O#QE&BC"V@J=<;0'Q$>6-3 MOBB^-K MI@A%@:)?;)+B/<]SQ^,=9SMMGFR!Z."YE,K.H\*YZB*.;5Y@R6Q?5ZCHRTJ; MDCF:FG5L*X.,!Z-2QFF2C..2"15EL[!V;[*9WC@I%-X;L)NR9&:_0*EW\V@0 M'1<>Q+IP?B'.9A5;XR.Z#]6]H5G7@XO%(/$&8<='@3M[ M,@;ORE+K)S^YY?,H\8I08NX\!*._+5ZAE!Z)='PY@$8-IS<\'1_1WP;GR9DE MLWBEY2?!73&/IA%P7+&-= ]Z]S<>'!IYO%Q+&WYA=]B;1)!OK-/EP9@4E$+5 M_^SY$(@3@W3T@D%Z,$B#[IHHJ+QFCF4SHW=@_&Y"\X/@:K F<4+Y4WETAKX* MLG/9H]/Y4V]!?G&XTB4=MF4A7#UXI S@&XF@5_"6"0,?F=R$63""]U78>+EC MAEN@D2L0_C),.2 I"!^L4.NPN)",2 A/2[1'.X]64]UICA)>7Z-C0MH_9K$C MQ[R\.#\XL:B=2%]P8D@0RA46;A1'_F_[F +21"4]1F61=@+>,=.'X> -I$EZ M!K]##+9@!FT']+ )^#! #U\*N ?J+?\?\$M#H5LC9;R#Y1Y.]]VS?5@.H8;/ M[P@2;AV6]I^V6-7\9^W\_I9?V(KE.(_H&ELT6XRR5[\-QLF?'=Z=-=Z==:%G M#\(^]58&$81R2/@.#.5"F\P::% GIB\>VRSI)\/I=!9O6Q2,&@6C3@4WSQ5= M> H:T9?P6BC8(S/M6=6--*XM80B<[;N.?MQ(&W^?M*V6=.92N'V;JG%;8*;3 MR:@],).&??)][%QL!4?%82]0\C8%-1"5VA,%[>33AGS:21ZRV<(AX3A0.P%\ M1I,+&RH*]0OKF.*^8MA0772H$K9-7B?5#R;X>>/(^2^^ON<_P;M!\JT=))T' M]2FT,1+-MFBH+]P5]Y9O -C2!"DU=$L,-XUI*?U.:U?8:7C-/3[)J MF/8G_TFL^*27E6C6H6-;R/5&N;JM-:O-J^"R[H7?MM=/"JKB:Z$L2%R1:=*? MT'TW=9>N)TY7H3,NM:,^&X8%O6S0^ WT?:6U.TX\0?-6RKX"4$L#!!0 ( M *!"K5@4PJ ?+ , ,8+ 9 >&PO=V]R:W-H965T,/(@*0Y#%-,C$P(BGS<],4000I%6CFCA3QSB1')_&F"?]B63!P^D0C0C)B*58'8)J?T_)I#A9PF9D9]35HQH# M.;X$2>-$?,*\^\DE.3[Z1(Y(G)&[B"T$S4+1-R7259N:04EM6%"S=U!SR W+ M9"3(519"N)EOHLQ*J[W6.K3W MY0?D:4P^E4FSJF3_AN2'+!. ,(X$LP_(\?6AWK MA^[?,91.A*["PK"@7H50&-5D08';T;CJ2EOZK7;;<_OFLJ[M993G]IPJ:(.S M6W%V]W*^11B$L\<;,U;DVL=R+]-J#.A#8ANA.);KSSC7=.:15!P+; ML,JKK/+>J*8+7+=6K:[;ZVZ5],L@V[9WE'2WHMS=2_DK9,"1M#H[&N+7*!:2 M4_4=;J*Y%^NU)W4@L W9O4IV[YV+NG=(JPX$MF%5RWKN)ZPW*NL2N'X+=[N> MMU77#5&NXUE;A6W6.J(4^%PWB@*IX&D4#4.U6C6C%[H%VUH?JB95=UK/,$6' MB^W /,X$26"&D-:9A^\:+YK&8B)9KONN*9/8Q>EAA(TV,R?5$;5"U M[OX_4$L#!!0 ( *!"K5A84[4 B , .H. 9 >&PO=V]R:W-H965T MV@<3-L +M9M3H]E#T M@9&N;2(2J9&4G?W[75**+-F*L!0JD!>;I'B/SCWWB."='X5\4'L 31ZSE*N% ML]\AH^I*Y,#QR5;(C&J-W$SRKBSG-NUM5S. M1:%3QF$MB2JRC,I_;R$5QX7C.T\+G]ENK\V"NYSG= <;T%_RM<296Z,D+ .N MF.!$PG;AW/C7*S\T 7;'7PR.JC$F)I5[(1[,Y$.R<#S#"%*(M8&@^'> %:2I M04(>_U2@3OU.$]@H$AH; MO%BDROZ28[77:+N=2'(DTNQ'-#*PV-AJS8=R4<:,E/F48IY=_H%,^"J5(#I)L]E0" M^95LRIH2L264:Y:PM#!B$P5Q(9EFH @\QFF10$*V4F0D%EE>:&H+@T% )6=\ M5X(J"_KF/6C*4O46X>V*FKL:^1L6;EQQO2VY!L]P#D3N.;V['NYAW MG7SPE/QMT OXB^ S>35/KS4GKNY;6 MJ[;6=T]:K^L"?OV(P.2#ADQ]ZU*Y9#'J9F'.C6N5TQ@6#AX,"N0!G.7//_D3 M[UV71 .!M00;U8*-^M#;@C7,^8;QRF1ON_(O0<<6U!QSAZ4?>+/1&"UP:*9V MN2^*QEXXK;>U2(]KTN->TG\66FG*$RP:P<\[?B B-\7L_"!ZH5Y:JH' 6EE/ MZJPGK\+;DR$%&PBL)5A4"Q;]"&]'E][VIB,OF)QY^W)?Y =1&'5[>UJ3GO:2 M_L(/H#16$^EIR6(S+#U><*8['=X+^-*"#036RGU6YSY[%0Z?#2G80& MP7SO M=/?P?H3'*]2F>6?1Q///+-ZQ#4]O_QF+^XT;D]_+>BTT('&:5AP)4ZJ@]RF@ MR1,LH]Z#N1%XY&ZS7G?R[\5_:0F'0FNK$9S4"%Z%[2L:0XDV$%I;M--%S^^] M%GVW\<,+1P?1-(C.C7^YS?=GT]&9\=U&UY"!W-EF2N%=ON"ZO$/7JW7#=F/; ME+/U6]/(V6[D!%-V@7A#WC&N2 I;A/2N(N0DR\:JG&B1V][D7FCL=.QPC\TH M2+,!GV\%?FS5Q+R@;F^7_P%02P,$% @ H$*M6*."0L4-!P F$4 !D M !X;"]W;W)K&ULK9Q=;]LV&(7_"N$50PLDMC[] MD24&$DOD.JQ+T*SKQ; +Q:9MH9;DBG+2#?WQHSYBF;;"2,6YB6V9[T-:[P'Y MZE#1Y5.2?A%KSC/R+=K$XJJWSK+MQ6 @YFL>!:*?;'DLOUDF:11D\F.Z&HAM MRH-%$11M!I9A# =1$,:]Z65Q["Z=7B:[;!/&_"XE8A=%0?KO#=\D3U<]L_=\ MX&.X6F?Y@<'T_:O&"VE0<4+?X* M^9,X>$_RG_*0)%_R#^\75STC'Q'?\'F6(P+Y\LAG?+/)27(<7RMH;]]G'GCX M_IE.BQ\O?\Q#(/@LV7P.%]GZJC?ND05?!KM-]C%Y^I57/\C->?-D(XJ_Y*EL M.W)Z9+X361)5P7($41B7K\&WZD0X+P2X M58#;-F!8!0S;#FE4!8R*9)5GMTB-%V3!]#)-GDB:MY:T_$V1WR):9B2, M9ZG\-I1QV?1^]R#XUQV/,^(_RK^"O/5X%H0;\8Z,% M7S3$4WV\K8D?R-.P/Q?6\[FXL;3 ZVW:)X9U1BS#R]+N^ Y+_!HLI&3 MY/EM3&Z72YZ&\:IA3#=:1CZ)7XAM,.=7/3E+"YX^\M[TYY_,H?%+4W*1, \) M\Y$PBH0Q$$R1B+.7B%/0[98S%_G[=]F"O,]X)/YI4HN#5 L2YB%A/A)&D3 & M@BEJMDS3\CR]($"4[ MJ:>WI/3;D7.I>#AX/E8+LU$?"*!+&0#!% M*<.]4H;ME5*((*^"MCPMQ="H!2VQJQ9*V/A0"V[_6 BGC4RG?RP7'SDNBH0Q M$$S)\&B?X9$VPW=I,N=\(<@R3:(JSTE59L@Y(987@#+_H1"[()YS,D]$UE3> MWFA[Z9KU$C8\3.A0MC6.\G[:;&@[QZU\Y,AH\\B[O. GGX,T#>*L*3-:<-?,(&$>$N8C810)8R"8HIO)7C<3;&$X M0:H%"?.0,!\)HT@8 \$4M9A&[8 8\ 5?C^RJF8HV4I=\9S(YFF.]AH;YLN^, MCQ=^Z/@HE,90-#7=!X:7J4UWM6R(U^I[/:9SBLV3"M\TW.'HI,)O:.B,#.-D MB8<.CT)I#$53,VS5&;:Z%PZ::D&/ZYQI),V#TGPHC4)I#$5315,;CJ:-K1I, MJ/L(I7E0F@^E42B-H6BJ:FH/TM2:5NIBLI#S3I"*UTH'J ]9T0XK J,O5POS M>%EI;F>>% Y0^Q!*8RB:FNO:033U%N+M(T_/K^72DD7Y_'"[S?=2&S,,M0:A M- ]*\Z$T"J4Q%$U52^TBFD/P>@(U$:$T#TKSH30*I3$4355-[4R:>FORCUWT M(%>/_&JTVFX78L<7^4Y[)A<:$90W<+QVZ0)U)BO:X17)T+9'[K$UV=3.G$Q& MD^,E!NI.0FD,15/37SN>IM[R/)DTOI-V.^%Z;N>,0RU/*,V'TBB4QE T53VU M[VF"C4\3ZGQ":1Z4YD-I%$IC*)IZSU-M?UH=[$_(SGC5H;J;[4Q<=ZRN!#/] MR+HJ!DKSH30*I3$4355,[:!:>@?U1PSS"GFX8>T.CW>U9_J..PL"2?.A- JE M,11-%41MN%IZPQ6UH5YU<[B';)GN^-C[GNF'TUDF4(NUY6^@T%X9BJ8*H#9/ M+?WMFJWJUM:[]_K.NI8E4)H'I?E0&H72&(JF2JIV5BT'6\Q:4%\52O.@-!]* MHU :0]%4U=0>K=7A-L^VI8E[8HW+TN1T]WVF[[NS)J!.+)1&H32&HJF:J)U8 M2W]#9]L-_PIS>-EB6:9EGURU0*U5*,V'TBB4QE T50:UM6KIK=6V-8JN,('Z MJE":!Z7Y4!J%TAB*INJH]FBM,;@P@7JS4)H'I?E0&H72&(JFJJ;V9BVMB_V]F?ZGCLK NJ[0FD42F,HFOH/CK7O:K_BNYZN1ZWO,-"CNTXI4)H' MI?E0&H72&(JF"JBV86T3NQ#9T#M:H30/2O.A- JE,11-54WMU=IZKQ9SAT'5 MR>&UDFL;DY%]M#;I!]-9)%"G%DJC4!I#T4J1# Z>#Q'Q=%4\^D.0>;Z95SX> M87]T_WB1Z^*A&D?'J7G!RH>$U)CRF24?@G05QH)L^%(BC?Y(2B,M'P-2?LB2 M;?$4BH+OFP8*G>0/Y_3))LN0?[A[%,_P=02P,$% @ H$*M M6#Q5A&-$ P TA0 T !X;"]S='EL97,N>&ULW5AM3]LP$/XK41@32!-I M&TB;T5;:*B%-VB8D^+!OR&V1AY2:\.(+UHF0MEMBA&GQQ&OX\8F&I/^OI9E(LN-LZJ!I[BF&)H[I=AOU0HFI+*Y M70;W>UQ/WP%6(Q#(.&\$=D+G&/9+HC55XL8,[&3K? $%M7V_+(W"J2++=NN89_3'.0H-IW!7,Q_Y5OY-VLM7\08E>Y3ZZ]PL1]@Q M] J]531G"SM>Y(T C+V-LY.RY,LOG$U%0=WB#TXX[)-57#"3BCV9;- J$^.@ M*@P>J=)LLNGYHTAY3Q=ZU4Z+'-?<.4+-_[;.4RJH(GQ3M.G]]USE5RN.NV\E MV7ZK[ KV:JS?W>]=Y-4QB$R.0>11]&3O&$2F1R"R^V;?FH>+C-]G(:/Z)+1Q MW-HZ;#7> ZU@_ G')_Y.FDPGC.NF:A',Y9E5+PX'KH>AV':>EZDA\;TT!@7Y4-& M]H/E\<>DYO*O-$WC.$FPBHY&7@4CK&Y) C]^-DP;1&!Y(-/?U1K?;;Q#]O*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'0M44I;AO4!9PFW0V0 M9HTZR'5!2[1-A")=DG*:_OH=2O4NE8_!7J8ZV:(D^FEHSAM2'QZLNU];>\^^ M-]KX>;8+87\VF?AJ)QOA?[=[:>#,QKI&!#ATVXG?.REJOY,R-'K"I]/9I!'* M9!\_'/M:NDEZ8(.L@K(&&F/#G9(/_K_S\9 =E%=KI55XG&?==RTSUBBC&O5# MUO-LFC&_LP]_6J=^6!.$7E7.:CW/\O[$G71!5<^:5Q'R5JQ]UQ+$^JL D'DV MFT*'&^5\Z*[H^A? >)!P<7_4!OM9Z2#=A0CR#V?;O3+;V T\Q21YC"X.Q\\^ MB&?N_X31;C:JDA>V:AMI0A]')W4$-'ZG]CYC1C1RGGVR!^G84FQE?"CXE:NZ M?\ 9$FXW)F"$^ZJ[A@I>4PMC9:E4#1\W.A1:FDBR!Y @D'Q'R;YY M%@AD,0KD*N+ K0EDB4"6(T(.(GF*0)Z."5DDD#,$9I MOD,@WXT).4L@WR.0[VDA;T1HG61VP\).LO/6*R.]3W/X%$OB4UJZ5=LTPCU& MO)7:&@6W"1/8HJIL:X)*,5'74,M&^!V[_-:J@]!PI6?"U.R+F M ;Y5L-5]%\REDQOI7)<7;95B8GK)B?W2\9VN2F<*QYS"R9VR]O); M"Q>QR\.3_,# MD:TA";*%@R'>/A,)QT3"B46"5@V#Q0#'O,*IO8)5#4-,S"R893KUN> M&?"E 2\PT13$HGEY:<5.V**NU6#Q4F#:*8BU@V?+=%>BP,134.^5H=ER@(EN MEE'OEJ&8Z?9)@;FG&-4]Z09*@;FG&,D])ZS[UZ:8F'N*7^V>GWS]K%JDF)B! MBE]@H%<7LNPDQ<0,5)#OFR%+V>&N.&:@@MA N,_3A%1B%BJ)+81CI@FIQ"Q4 M4EOHM;*CUV6*B5FH)+80@AEG?(J)6:BD7@%AF(,I5*(O;8@MA&%"]RDF9J&2 MV$)X- G^"WMS 56'TH/*O<0,5'8&FAS? M:M=R Z5U?0/=>VBOA*Z6CL6/?LN]/(U;8IM6ZT_0]I>YMJ(^OB0_ON#_^ ]0 M2P,$% @ H$*M6)(LH):X 0 YQP !H !X;"]?[0YI6ZYS;MQ#2?!WW=>HW M;3R<[RR;;E_G\[);A;:>;^M5##H8C$)W/Z-ZG]S/[,U.;?S/Q&:YW,SC1S/_ MWL=#_F-P^&FZ;5K'F*O>K.Y6,4^K<-S=ME.X7*1_GESU/A?3JOM<2!5*!RD$ M:?D@@R K'^00Y.6#AA T+!\T@J!1^: 7"'HI'_0*0:_E@\80-"X?) .4<4"0 M]( U@=:"7 N!UX)@"X'8@F0+@=F": N!VH)L"X';@G +@=R"= N!W8)X"X'> MBGHK@=Z*>BN!WOKPL4V@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@ MMZ+>2J"WH=Y&H+>AWD:@MZ'>1J"W/1R6$.AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1 MZ&VHMQ'H;:BW$>CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.T/A]T$>COJ[01Z.^KM M!'H[ZNT$>COJ[<_4.^73+J9;SW6-[W\FU?G\;+R]_K*\;J*$PPO. ?YKOO\" M4$L#!!0 ( *!"K5B,3^J/N@$ .X< 3 6T-O;G1E;G1?5'EP97-= M+GAM;,W9R6[",!0%T%]!V2)B/)0. C9MMRV+_H";/$A$$ENVH?#W=<(@M:*H MB$J]FT2)[7=?;.EL,G[;6O*]35TU?I(4(=@'QGQ64*U]:BPU<61N7*U#?'0+ M9G6VU MB8C@5:'WO(FO?6F:2>*H\DGO<3>QS9HD MVMJJS'2(XVS=Y-]2!ON$-*[LYOBBM+X?)R3L9$([\G/ ?MWKFIPK<^K-M LO MNHZSV*9B/FPK\NGY$B=Z-/-YF5%NLE4=EZ3>.M*Y+XA"7:6[HOWSR2'N,.VN M_.K\KLRYP#ASYHSU\<0<71YW.))V]<#&0N1">?X3CXFQ]-7?1^UIYY3_,CMN M[X=QR^X\/.MNU^_QUS,^UK^P#P'2AP3I0X'T<0/2QPBDCUN0/NY ^K@'Z8,/ M41I!$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D%2BR"A19!8JL D56 M@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4616*K I% M5H4BJT*15:'(JE!D52BR*A19U7_*^F[,\J__P+7WM-9E<\AGW6_.Z2=02P$" M% ,4 " "@0JU8!T%-8H$ "Q $ @ $ 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( *!"K5@1&UL4$L! A0#% @ H$*M6..P3/+K!0 OQ\ !@ M ("!#@@ 'AL+W=OP0# !%"@ & M @(%>% >&PO=V]R:W-H965T&UL4$L! A0#% M @ H$*M6 '^VCO;! N1$ !@ ("!F!< 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ H$*M6(7TK!K:# M$ID !@ ("!!2( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ H$*M6,/2NA0S# 9AX !D M ("!Z#D 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ H$*M6/\@^ZC9! / P !D ("!M5H 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ H$*M6'_; M-281"@ X!T !D ("!]&4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ H$*M6$Q;+RDG! 1 D !D M ("!O(( 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ H$*M6$ZS&PO=V]R:W-H965T&UL4$L! A0#% M @ H$*M6'.YX%WU P 10D !D ("!/Z, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ H$*M6&*3LVDV!0 =B4 !D M ("!CKH 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ H$*M6'YF3LGH @ Q < !D ("!*\D M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MH$*M6%)X8\JB @ +0< !D ("!F]< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ H$*M6'?:Y#]/ P X H !D M ("!%O8 'AL+W=O=0$ !#$P &0 @(&<^0 >&PO=V]R:W-H M965T&UL4$L! M A0#% @ H$*M6!3"H!\L P Q@L !D ("!, (! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ H$*M M6#Q5A&-$ P TA0 T ( !EA ! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ H$*M6)(L MH):X 0 YQP !H ( !/QD! 'AL+U]R96QS+W=O XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 139 227 1 true 47 0 false 9 false false R1.htm 0000001 - Document - Cover Page Sheet http://praxismedicines.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 9 false false R10.htm 0000010 - Disclosure - Nature of the Business Sheet http://praxismedicines.com/role/NatureoftheBusiness Nature of the Business Notes 10 false false R11.htm 0000011 - Disclosure - Summary of Significant Accounting Policies Sheet http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 0000012 - Disclosure - Cash Equivalents and Marketable Securities Sheet http://praxismedicines.com/role/CashEquivalentsandMarketableSecurities Cash Equivalents and Marketable Securities Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Measurements Sheet http://praxismedicines.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 0000014 - Disclosure - Accrued Expenses Sheet http://praxismedicines.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 0000015 - Disclosure - Commitments and Contingencies Sheet http://praxismedicines.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Collaboration License Agreements Sheet http://praxismedicines.com/role/CollaborationLicenseAgreements Collaboration License Agreements Notes 16 false false R17.htm 0000017 - Disclosure - Common Stock and Preferred Stock Sheet http://praxismedicines.com/role/CommonStockandPreferredStock Common Stock and Preferred Stock Notes 17 false false R18.htm 0000018 - Disclosure - Stock-Based Compensation Sheet http://praxismedicines.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 0000019 - Disclosure - Net Loss per Share Sheet http://praxismedicines.com/role/NetLossperShare Net Loss per Share Notes 19 false false R20.htm 0000020 - Disclosure - Related Party Transactions Sheet http://praxismedicines.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 0000021 - Disclosure - Subsequent Events Sheet http://praxismedicines.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Cash Equivalents and Marketable Securities (Tables) Sheet http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesTables Cash Equivalents and Marketable Securities (Tables) Tables http://praxismedicines.com/role/CashEquivalentsandMarketableSecurities 25 false false R26.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://praxismedicines.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://praxismedicines.com/role/FairValueMeasurements 26 false false R27.htm 9954474 - Disclosure - Accrued Expenses (Tables) Sheet http://praxismedicines.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://praxismedicines.com/role/AccruedExpenses 27 false false R28.htm 9954475 - Disclosure - Common Stock and Preferred Stock (Tables) Sheet http://praxismedicines.com/role/CommonStockandPreferredStockTables Common Stock and Preferred Stock (Tables) Tables http://praxismedicines.com/role/CommonStockandPreferredStock 28 false false R29.htm 9954476 - Disclosure - Stock-Based Compensation (Tables) Sheet http://praxismedicines.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://praxismedicines.com/role/StockBasedCompensation 29 false false R30.htm 9954477 - Disclosure - Net Loss per Share (Tables) Sheet http://praxismedicines.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://praxismedicines.com/role/NetLossperShare 30 false false R31.htm 9954478 - Disclosure - Nature of the Business - Additional Information (Details) Sheet http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails Nature of the Business - Additional Information (Details) Details 31 false false R32.htm 9954479 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies 32 false false R33.htm 9954480 - Disclosure - Cash Equivalents and Marketable Securities - Investment Profile (Details) Sheet http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails Cash Equivalents and Marketable Securities - Investment Profile (Details) Details 33 false false R34.htm 9954481 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details) Sheet http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails Cash Equivalents and Marketable Securities - Narrative (Details) Details 34 false false R35.htm 9954482 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details) Sheet http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details) Details 35 false false R36.htm 9954483 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Details 36 false false R37.htm 9954484 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails Accrued Expenses - Summary of Accrued Expenses (Details) Details 37 false false R38.htm 9954485 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 38 false false R39.htm 9954486 - Disclosure - Collaboration License Agreements - Narrative (Details) Sheet http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails Collaboration License Agreements - Narrative (Details) Details 39 false false R40.htm 9954487 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details) Sheet http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails Common Stock and Preferred Stock - Additional Information (Details) Details 40 false false R41.htm 9954488 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) Sheet http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) Details 41 false false R42.htm 9954489 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 42 false false R43.htm 9954490 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Details 43 false false R44.htm 9954491 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 44 false false R45.htm 9954492 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) Details 45 false false R46.htm 9954493 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Details 46 false false R47.htm 9954494 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) Sheet http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) Details 47 false false R48.htm 9954495 - Disclosure - Subsequent Events (Details) Sheet http://praxismedicines.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://praxismedicines.com/role/SubsequentEvents 48 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - prax-20240331.htm 4 prax-20240331.htm prax-20240331.xsd prax-20240331_cal.xml prax-20240331_def.xml prax-20240331_lab.xml prax-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "prax-20240331.htm": { "nsprefix": "prax", "nsuri": "http://praxismedicines.com/20240331", "dts": { "inline": { "local": [ "prax-20240331.htm" ] }, "schema": { "local": [ "prax-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "prax-20240331_cal.xml" ] }, "definitionLink": { "local": [ "prax-20240331_def.xml" ] }, "labelLink": { "local": [ "prax-20240331_lab.xml" ] }, "presentationLink": { "local": [ "prax-20240331_pre.xml" ] } }, "keyStandard": 192, "keyCustom": 35, "axisStandard": 16, "axisCustom": 0, "memberStandard": 24, "memberCustom": 15, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 4 }, "contextCount": 139, "entityCount": 1, "segmentCount": 47, "elementCount": 444, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 425, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://praxismedicines.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } }, "R3": { "role": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } }, "R4": { "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } }, "R5": { "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical", "longName": "0000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } }, "R7": { "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-28", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "longName": "0000008 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-12", "name": "prax:StockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } }, "R10": { "role": "http://praxismedicines.com/role/NatureoftheBusiness", "longName": "0000010 - Disclosure - Nature of the Business", "shortName": "Nature of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://praxismedicines.com/role/CashEquivalentsandMarketableSecurities", "longName": "0000012 - Disclosure - Cash Equivalents and Marketable Securities", "shortName": "Cash Equivalents and Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://praxismedicines.com/role/FairValueMeasurements", "longName": "0000013 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://praxismedicines.com/role/AccruedExpenses", "longName": "0000014 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://praxismedicines.com/role/CommitmentsandContingencies", "longName": "0000015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://praxismedicines.com/role/CollaborationLicenseAgreements", "longName": "0000016 - Disclosure - Collaboration License Agreements", "shortName": "Collaboration License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://praxismedicines.com/role/CommonStockandPreferredStock", "longName": "0000017 - Disclosure - Common Stock and Preferred Stock", "shortName": "Common Stock and Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://praxismedicines.com/role/StockBasedCompensation", "longName": "0000018 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://praxismedicines.com/role/NetLossperShare", "longName": "0000019 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://praxismedicines.com/role/RelatedPartyTransactions", "longName": "0000020 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://praxismedicines.com/role/SubsequentEvents", "longName": "0000021 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesTables", "longName": "9954472 - Disclosure - Cash Equivalents and Marketable Securities (Tables)", "shortName": "Cash Equivalents and Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://praxismedicines.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://praxismedicines.com/role/AccruedExpensesTables", "longName": "9954474 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://praxismedicines.com/role/CommonStockandPreferredStockTables", "longName": "9954475 - Disclosure - Common Stock and Preferred Stock (Tables)", "shortName": "Common Stock and Preferred Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://praxismedicines.com/role/StockBasedCompensationTables", "longName": "9954476 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://praxismedicines.com/role/NetLossperShareTables", "longName": "9954477 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "longName": "9954478 - Disclosure - Nature of the Business - Additional Information (Details)", "shortName": "Nature of the Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "prax:NumberOfPlatforms", "unitRef": "platform", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "prax:NumberOfPlatforms", "unitRef": "platform", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails", "longName": "9954480 - Disclosure - Cash Equivalents and Marketable Securities - Investment Profile (Details)", "shortName": "Cash Equivalents and Marketable Securities - Investment Profile (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "prax:CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } }, "R34": { "role": "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails", "longName": "9954481 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)", "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "unitRef": "security", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "unitRef": "security", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails", "longName": "9954482 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details)", "shortName": "Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "longName": "9954483 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-75", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails", "longName": "9954484 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "longName": "9954485 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-76", "name": "prax:PercentageIncreaseInAnnualBaseRent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "prax:PercentageIncreaseInAnnualBaseRent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "longName": "9954486 - Disclosure - Collaboration License Agreements - Narrative (Details)", "shortName": "Collaboration License Agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-83", "name": "prax:NumberOfPerformanceObligations", "unitRef": "obligation", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-83", "name": "prax:NumberOfPerformanceObligations", "unitRef": "obligation", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "longName": "9954487 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details)", "shortName": "Common Stock and Preferred Stock - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } }, "R41": { "role": "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "longName": "9954488 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)", "shortName": "Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "longName": "9954489 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-122", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails", "longName": "9954490 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-113", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "longName": "9954491 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "longName": "9954492 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)", "shortName": "Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails", "longName": "9954493 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails", "longName": "9954494 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)", "shortName": "Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://praxismedicines.com/role/SubsequentEventsDetails", "longName": "9954495 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-95", "name": "prax:SaleOfStockSharesAggregateAuthorizedAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-135", "name": "prax:SaleOfStockSharesAggregateAuthorizedAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "prax-20240331.htm", "unique": true } } }, "tag": { "prax_A2017EmployeeStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "A2017EmployeeStockIncentivePlanMember", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Stock Incentive Plan", "label": "2017 Employee Stock Incentive Plan [Member]" } } }, "auth_ref": [] }, "prax_A2020EmployeeStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "A2020EmployeeStockIncentivePlanMember", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Employee Stock Incentive Plan", "label": "2020 Employee Stock Incentive Plan [Member]", "documentation": "2020 Employee Stock Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://praxismedicines.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r15" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r514" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r59" ] }, "prax_AccruedExternalResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued external research and development expenses", "label": "Accrued External Research And Development Expenses Current", "documentation": "Accrued External Research And Development Expenses, Current." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "prax_AccruedPersonnelRelatedExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "AccruedPersonnelRelatedExpensesCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued personnel-related expenses", "label": "Accrued Personnel Related Expenses Current", "documentation": "Accrued Personnel Related Expenses, Current." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r22", "r23", "r51", "r96", "r390", "r409", "r410" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r6", "r23", "r307", "r310", "r336", "r405", "r406", "r614", "r615", "r616", "r621", "r622", "r623" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r565" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r46", "r514", "r701" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r295", "r296", "r297", "r417", "r621", "r622", "r623", "r683", "r702" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r571" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r571" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r571" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r571" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r38", "r39", "r261" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r536", "r547", "r557", "r582" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r539", "r550", "r560", "r585" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r571" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r578" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r543", "r551", "r561", "r578", "r586", "r590", "r598" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r596" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r290", "r298" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r140" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r27" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r27" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r69", "r95", "r116", "r145", "r150", "r154", "r194", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r302", "r304", "r326", "r386", "r441", "r514", "r527", "r650", "r651", "r686" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r90", "r97", "r116", "r194", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r302", "r304", "r326", "r514", "r650", "r651", "r686" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r40" ] }, "prax_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "At-The-Market Offering", "label": "At-The-Market Offering [Member]", "documentation": "At-The-Market Offering" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r172", "r384" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r171", "r383" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total available-for-sale securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r165", "r202", "r379", "r626" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax_CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "terseLabel": "Debt securities, available-for-sale, current", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r161", "r202" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term marketable securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r93", "r161", "r202" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r593" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r594" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r589" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r589" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r589" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r589" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r589" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r589" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r592" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r591" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r590" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r590" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r26", "r92", "r488" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and marketable securities", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r613" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r26", "r57", "r113" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r57" ] }, "prax_CashEquivalentsAccumulatedGrossUnrealizedGainCurrentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CashEquivalentsAccumulatedGrossUnrealizedGainCurrentBeforeTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap_CashEquivalentsAtCarryingValue", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents, accumulated gross unrealized gain, current, before tax", "label": "Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax", "documentation": "Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax" } } }, "auth_ref": [] }, "prax_CashEquivalentsAccumulatedGrossUnrealizedLossCurrentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CashEquivalentsAccumulatedGrossUnrealizedLossCurrentBeforeTax", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap_CashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash equivalents, accumulated gross unrealized loss, current, before tax", "label": "Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax", "documentation": "Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax" } } }, "auth_ref": [] }, "prax_CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax_CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax", "label": "Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax", "documentation": "Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax" } } }, "auth_ref": [] }, "prax_CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax_CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax", "label": "Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax", "documentation": "Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax" } } }, "auth_ref": [] }, "prax_CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax_CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents and debt securities, available-for-sale, fair value disclosure", "label": "Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure", "documentation": "Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails_1": { "parentTag": "prax_CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 1.0 }, "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents, at carrying value", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r612", "r697" ] }, "prax_CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost", "label": "Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost", "documentation": "Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost" } } }, "auth_ref": [] }, "prax_CashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap_CashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents, fair value disclosure", "label": "Cash Equivalents, Fair Value Disclosure", "documentation": "Cash Equivalents, Fair Value Disclosure" } } }, "auth_ref": [] }, "prax_ChangeInPercentageOfOwnership": { "xbrltype": "percentItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "ChangeInPercentageOfOwnership", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage change in ownership", "label": "Change in Percentage of Ownership", "documentation": "Change in Percentage of Ownership" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r569" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r245" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r245" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r570" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r570" ] }, "prax_CollaborationAndLicenseAgreementNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CollaborationAndLicenseAgreementNoncashExpense", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash collaboration and license agreement expense", "label": "Collaboration And License Agreement, Noncash Expense", "documentation": "Collaboration And License Agreement, Noncash Expense" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration License Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r78", "r80", "r86" ] }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails", "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": [ "r655", "r684" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r19", "r42", "r387", "r428" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r62", "r210", "r211", "r483", "r645" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total shares of authorized common stock reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r20" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r621", "r622", "r683", "r700", "r702" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r45", "r429" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r45", "r429", "r447", "r702", "r703" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value; 150,000,000 shares authorized; 13,258,047 shares issued and outstanding as of March\u00a031, 2024, and 8,791,877 shares issued and outstanding as of December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r45", "r389", "r514" ] }, "prax_CommonStockWarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "CommonStockWarrantsPolicyTextBlock", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Warrants", "label": "Common Stock, Warrants [Policy Text Block]", "documentation": "Common Stock, Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r575" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r574" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r576" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r573" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r24", "r101", "r103", "r108", "r380", "r396" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r247", "r248", "r250" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r247", "r248", "r250" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current portion of deferred revenue", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r247", "r248", "r250" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails", "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r508", "r510", "r699" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r117", "r118", "r227", "r233", "r341", "r489", "r491" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax", "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax" } } }, "auth_ref": [] }, "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax", "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails_1": { "parentTag": "prax_CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 2.0 }, "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt securities, available-for-sale, amortized cost, current", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r202", "r627" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities, unrealized loss position, fair value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r75", "r204", "r497" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r76", "r205" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r32" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r249", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r249", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r259", "r263", "r291", "r292", "r294", "r512" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r531" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r564" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r109", "r124", "r125", "r126", "r127", "r128", "r133", "r135", "r137", "r138", "r139", "r143", "r315", "r316", "r381", "r397", "r493" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r109", "r124", "r125", "r126", "r127", "r128", "r135", "r137", "r138", "r139", "r143", "r315", "r316", "r381", "r397", "r493" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://praxismedicines.com/role/NetLossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r132", "r140", "r141", "r142" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost related to unvested restricted stock units", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r293" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r293" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to unvested stock based awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r682" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential shares issuable under the 2020 ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for exercise of outstanding stock options", "verboseLabel": "Outstanding stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r529" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r529" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r529" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r603" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r529" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r529" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r529" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r529" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r88", "r104", "r105", "r106", "r119", "r120", "r121", "r123", "r129", "r131", "r144", "r195", "r196", "r246", "r295", "r296", "r297", "r300", "r301", "r306", "r307", "r308", "r309", "r310", "r311", "r314", "r327", "r328", "r329", "r330", "r331", "r332", "r336", "r405", "r406", "r407", "r417", "r469" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r572" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r536", "r547", "r557", "r582" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r533", "r544", "r554", "r579" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r578" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r318", "r319", "r322" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r318", "r319", "r322" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Assets Measured At Fair Value On A Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r40", "r67" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r8" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r40", "r41" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r228", "r252", "r253", "r254", "r255", "r256", "r257", "r319", "r349", "r350", "r351", "r498", "r499", "r508", "r509", "r510" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r323" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r317" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r228", "r252", "r257", "r319", "r349", "r508", "r509", "r510" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r228", "r252", "r257", "r319", "r350", "r498", "r499", "r508", "r509", "r510" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r228", "r252", "r253", "r254", "r255", "r256", "r257", "r319", "r351", "r498", "r499", "r508", "r509", "r510" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r228", "r252", "r253", "r254", "r255", "r256", "r257", "r349", "r350", "r351", "r498", "r499", "r508", "r509", "r510" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r317", "r323" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r197", "r198", "r199", "r200", "r201", "r203", "r206", "r207", "r229", "r243", "r312", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r395", "r497", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r638", "r639", "r640", "r641" ] }, "prax_FollowOnOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "FollowOnOfferingMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Follow-On Offering", "label": "Follow-On Offering [Member]", "documentation": "Follow-On Offering" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r540", "r551", "r561", "r586" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r540", "r551", "r561", "r586" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r540", "r551", "r561", "r586" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r540", "r551", "r561", "r586" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r540", "r551", "r561", "r586" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r54", "r451" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r53" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r208", "r209", "r454" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r209", "r454" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r377", "r617" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "prax_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "documentation": "Increase (Decrease) in Operating Lease Liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r543", "r551", "r561", "r578", "r586", "r590", "r598" ] }, "prax_InducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "InducementPlanMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for future awards under the 2024 Inducement Plan", "verboseLabel": "Inducement Plan", "label": "Inducement Plan [Member]", "documentation": "Inducement Plan" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r596" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r532", "r602" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r532", "r602" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r532", "r602" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale marketable securities", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r318" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents and Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r68", "r72", "r73", "r87", "r159", "r162", "r324", "r325" ] }, "prax_January2024FollowOnOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "January2024FollowOnOfferingMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2024 Follow-On Offering", "label": "January 2024 Follow-On Offering [Member]", "documentation": "January 2024 Follow-On Offering" } } }, "auth_ref": [] }, "prax_June2023FollowOnOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "June2023FollowOnOfferingMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2023 Follow-On Offering", "label": "June 2023 Follow-On Offering [Member]", "documentation": "June 2023 Follow-On Offering" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r16", "r116", "r194", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r303", "r304", "r305", "r326", "r427", "r494", "r527", "r650", "r686", "r687" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r50", "r70", "r392", "r514", "r620", "r642", "r685" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r18", "r91", "r116", "r194", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r303", "r304", "r305", "r326", "r514", "r650", "r686", "r687" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "prax_LicenseAndCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "LicenseAndCollaborationAgreementMember", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "License And Collaboration Agreement", "label": "License And Collaboration Agreement [Member]", "documentation": "License And Collaboration Agreement" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r654" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r212", "r213", "r214", "r217", "r646", "r647" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r212", "r213", "r214", "r217", "r646", "r647" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r213", "r214", "r215", "r216", "r258", "r376", "r404", "r419", "r420", "r476", "r477", "r478", "r479", "r480", "r485", "r486", "r496", "r500", "r511", "r516", "r652", "r688", "r689", "r690", "r691", "r692", "r693" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r570" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r570" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r589" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails", "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r655" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r597" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r571" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusiness" ], "lang": { "en-us": { "role": { "verboseLabel": "Nature of the Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r77", "r85" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r112" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r112" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r57", "r58", "r59" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "negatedLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r52", "r59", "r71", "r89", "r100", "r102", "r106", "r116", "r122", "r124", "r125", "r126", "r127", "r130", "r131", "r136", "r145", "r149", "r153", "r155", "r194", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r316", "r326", "r394", "r449", "r467", "r468", "r495", "r525", "r650" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r570" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r540", "r551", "r561", "r578", "r586" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r568" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r567" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r578" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r597" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r597" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r55" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r12" ] }, "prax_NoticeOfChangeTerm": { "xbrltype": "durationItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "NoticeOfChangeTerm", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in ownership notice, term", "label": "Notice of Change, Term", "documentation": "Notice of Change, Term" } } }, "auth_ref": [] }, "prax_NumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "NumberOfPerformanceObligations", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of performance obligations", "label": "Number Of Performance Obligations", "documentation": "Number Of Performance Obligations" } } }, "auth_ref": [] }, "prax_NumberOfPlatforms": { "xbrltype": "integerItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "NumberOfPlatforms", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of platforms", "label": "Number Of Platforms", "documentation": "Number Of Platforms" } } }, "auth_ref": [] }, "prax_NumberOfProductCandidates": { "xbrltype": "integerItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "NumberOfProductCandidates", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of product candidates", "label": "Number Of Product Candidates", "documentation": "Number Of Product Candidates" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r625" ] }, "prax_OfficeSpaceInBostonMassachusettsMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "OfficeSpaceInBostonMassachusettsMember", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office Space in Boston Massachusetts", "label": "Office Space in Boston Massachusetts [Member]", "documentation": "Office Space in Boston Massachusetts" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r145", "r149", "r153", "r155", "r495" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r335" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current portion of operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r335" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r334" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r618" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r17" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r94" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized gains on marketable securities, net of tax", "verboseLabel": "Change in unrealized gain on marketable securities, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r98", "r99", "r193" ] }, "us-gaap_OtherDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDebtSecuritiesMember", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails", "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other debt securities", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } }, "auth_ref": [ "r643", "r655", "r684" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r56" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r570" ] }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other-than-temporary impairment loss, debt securities, available-for-sale", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale", "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI)." } } }, "auth_ref": [ "r74" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r538", "r549", "r559", "r584" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Over-Allotment Option", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r566" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of tax withholdings related to vesting of restricted stock units", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r111" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r25", "r110", "r160" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r569" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r568" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r578" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r571" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r567" ] }, "prax_PercentageIncreaseInAnnualBaseRent": { "xbrltype": "percentItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "PercentageIncreaseInAnnualBaseRent", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage increase in annual base rent", "label": "Percentage Increase In Annual Base Rent", "documentation": "Percentage Increase In Annual Base Rent." } } }, "auth_ref": [] }, "prax_PercentageOfOwnershipHeldBySoleOwner": { "xbrltype": "percentItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "PercentageOfOwnershipHeldBySoleOwner", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of voting power", "label": "Percentage of Ownership Held by Sole Owner", "documentation": "Percentage of Ownership Held by Sole Owner" } } }, "auth_ref": [] }, "prax_PercentageOfOwnershipHeldBySoleOwnerAndAffiliates": { "xbrltype": "percentItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "PercentageOfOwnershipHeldBySoleOwnerAndAffiliates", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership held by sole owner and affiliates", "label": "Percentage of Ownership Held by Sole Owner And Affiliates", "documentation": "Percentage of Ownership Held by Sole Owner And Affiliates" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681" ] }, "prax_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "PreFundedWarrantMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/SubsequentEventsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrant", "label": "Pre-Funded Warrant [Member]", "documentation": "Pre-Funded Warrant" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r44", "r231" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r44", "r429" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r44", "r231" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r44", "r429", "r447", "r702", "r703" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March\u00a031, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r44", "r388", "r514" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r613" ] }, "prax_ProceedsFromCollaborationArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "ProceedsFromCollaborationArrangement", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from collaboration arrangement", "label": "Proceeds From Collaboration Arrangement", "documentation": "Proceeds From Collaboration Arrangement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock offerings, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from exercise of stock options and employee stock purchase plan purchases", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r2", "r11" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance or sale of equity", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r412" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r156", "r378", "r398", "r399", "r400", "r401", "r402", "r403", "r487", "r501", "r515", "r604", "r648", "r649", "r653", "r698" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r156", "r378", "r398", "r399", "r400", "r401", "r402", "r403", "r487", "r501", "r515", "r604", "r648", "r649", "r653", "r698" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r385", "r393", "r514" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r566" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r566" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r213", "r214", "r215", "r216", "r251", "r258", "r286", "r287", "r288", "r352", "r376", "r404", "r419", "r420", "r476", "r477", "r478", "r479", "r480", "r485", "r486", "r496", "r500", "r511", "r516", "r519", "r644", "r652", "r689", "r690", "r691", "r692", "r693" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r213", "r214", "r215", "r216", "r251", "r258", "r286", "r287", "r288", "r352", "r376", "r404", "r419", "r420", "r476", "r477", "r478", "r479", "r480", "r485", "r486", "r496", "r500", "r511", "r516", "r519", "r644", "r652", "r689", "r690", "r691", "r692", "r693" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r484", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r484", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r533", "r544", "r554", "r579" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r337", "r338", "r339", "r340", "r342", "r414", "r415", "r416", "r452", "r453", "r454", "r473", "r475" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r117", "r118", "r227", "r233", "r341", "r490", "r491" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r43", "r299", "r694" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r534", "r545", "r555", "r580" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r535", "r546", "r556", "r581" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r612", "r619", "r695", "r697" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares reserved for vesting of restricted stock units", "terseLabel": "Unvested restricted stock units", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r27" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r47", "r64", "r391", "r408", "r410", "r413", "r430", "r514" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r88", "r119", "r120", "r121", "r123", "r129", "r131", "r195", "r196", "r295", "r296", "r297", "r300", "r301", "r306", "r308", "r309", "r311", "r314", "r405", "r407", "r417", "r702" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction price", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r84" ] }, "prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments", "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r107", "r116", "r146", "r147", "r148", "r151", "r152", "r156", "r157", "r158", "r194", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r326", "r382", "r650" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r597" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r597" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock (in USD per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "prax_SaleOfStockSharesAggregateAuthorizedAmount": { "xbrltype": "sharesItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "SaleOfStockSharesAggregateAuthorizedAmount", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, shares, aggregate authorized amount (in shares)", "label": "Sale Of Stock, Shares, Aggregate Authorized Amount", "documentation": "Sale Of Stock, Shares, Aggregate Authorized Amount" } } }, "auth_ref": [] }, "prax_SaleOfStockValueTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "SaleOfStockValueTransferred", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, value transferred", "label": "Sale Of Stock, Value Transferred", "documentation": "Sale Of Stock, Value Transferred" } } }, "auth_ref": [] }, "prax_SaleOfStockValueTransferredInExcessOfConsiderationReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "SaleOfStockValueTransferredInExcessOfConsiderationReceived", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, value transferred in excess of consideration received", "label": "Sale Of Stock, Value Transferred In Excess Of Consideration Received", "documentation": "Sale Of Stock, Value Transferred In Excess Of Consideration Received" } } }, "auth_ref": [] }, "prax_SaleOfStockVolumeWeightedAveragePriceDuration": { "xbrltype": "durationItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "SaleOfStockVolumeWeightedAveragePriceDuration", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, volume-weighted average price, duration", "label": "Sale Of Stock, Volume-Weighted Average Price, Duration", "documentation": "Sale Of Stock, Volume-Weighted Average Price, Duration" } } }, "auth_ref": [] }, "prax_SaleOfStockVolumeWeightedAveragePricePremium": { "xbrltype": "percentItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "SaleOfStockVolumeWeightedAveragePricePremium", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, volume-weighted average price, premium", "label": "Sale Of Stock, Volume-Weighted Average Price, Premium", "documentation": "Sale Of Stock, Volume-Weighted Average Price, Premium" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://praxismedicines.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://praxismedicines.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents [Table]", "label": "Schedule of Cash and Cash Equivalents [Table]", "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances." } } }, "auth_ref": [] }, "prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceLineItems", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]", "label": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]", "documentation": "Schedule Of Common Stock Reserved For Future Issuance Line items" } } }, "auth_ref": [] }, "prax_ScheduleOfCommonStockReservedForFutureIssuanceTable": { "xbrltype": "stringItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTable", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Table]", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table]", "documentation": "Schedule Of Common Stock Reserved For Future Issuance Table" } } }, "auth_ref": [] }, "prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Common Stock Reserved For Future Issuance", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]", "documentation": "Schedule Of Common Stock Reserved For Future Issuance" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r260", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r36" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r66" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r528" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r530" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r280" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeitures (in dollars per shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r280" ] }, "prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period" } } }, "auth_ref": [] }, "prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r275", "r276" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested beginning balance (in dollars per share)", "periodEndLabel": "Unvested ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r275", "r276" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant\u00a0Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r287" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r286" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r288" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r260", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r513" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r269" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r269" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r282" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Canceled or forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r273" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r271" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant-date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r281" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r267", "r268" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r267", "r268" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise\u00a0Price per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r272" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled or forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r273" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r271" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r285" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r35" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r35" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r65" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r283" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r60", "r114" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r21", "r88", "r104", "r105", "r106", "r119", "r120", "r121", "r123", "r129", "r131", "r144", "r195", "r196", "r246", "r295", "r296", "r297", "r300", "r301", "r306", "r307", "r308", "r309", "r310", "r311", "r314", "r327", "r328", "r329", "r330", "r331", "r332", "r336", "r405", "r406", "r407", "r417", "r469" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r119", "r120", "r121", "r144", "r378", "r411", "r418", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r448", "r450", "r451", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r469", "r520" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r119", "r120", "r121", "r144", "r378", "r411", "r418", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r448", "r450", "r451", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r469", "r520" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r537", "r548", "r558", "r583" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r624" ] }, "prax_StockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "StockIssuanceCosts", "crdr": "debit", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance costs", "label": "Stock Issuance Costs", "documentation": "Stock Issuance Costs" } } }, "auth_ref": [] }, "prax_StockIssuanceCostsIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "StockIssuanceCostsIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs from at-the-market offering included in accrued expenses", "label": "Stock Issuance Costs Incurred But Not Yet Paid", "documentation": "Stock Issuance Costs Incurred But Not Yet Paid" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r44", "r45", "r64", "r412", "r469", "r481" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock awards (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r7", "r64" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r44", "r45", "r64", "r272" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r44", "r45", "r64", "r417", "r469", "r481", "r526" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r7", "r21", "r64" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r45", "r48", "r49", "r61", "r431", "r447", "r470", "r471", "r514", "r527", "r620", "r642", "r685", "r702" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStock" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock and Preferred Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r63", "r115", "r230", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r246", "r313", "r472", "r474", "r482" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical", "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity note, stock split, conversion ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r13" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r333", "r344" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r333", "r344" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r333", "r344" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r333", "r344" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r333", "r344" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://praxismedicines.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r343", "r345" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of non-cash activities:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r577" ] }, "prax_TenaciaMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "TenaciaMember", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenacia", "label": "Tenacia [Member]", "documentation": "Tenacia" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r576" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r596" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r598" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r229", "r243", "r312", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r395", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r638", "r639", "r640", "r641" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r599" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r600" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r598" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r598" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r601" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r599" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r33" ] }, "prax_TwentyTwentyEmployeeStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "TwentyTwentyEmployeeStockIncentivePlanMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for future awards under the 2020 Stock Option and Incentive Plan", "label": "Twenty Twenty Employee Stock Incentive Plan [Member]", "documentation": "Twenty Twenty Employee Stock Incentive Plan" } } }, "auth_ref": [] }, "prax_TwentyTwentyEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "TwentyTwentyEmployeeStockPurchasePlanMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for future awards under the 2020 Employee Stock Purchase Plan", "verboseLabel": "2020 Employee Stock Purchase Plan", "label": "2020 Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "prax_UCBMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "UCBMember", "presentation": [ "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UCB", "label": "UCB [Member]", "documentation": "UCB" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails", "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities issued by U.S. government agencies", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r492", "r508", "r696" ] }, "prax_UnauditedInterimCondensedConsolidatedFinancialInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "UnauditedInterimCondensedConsolidatedFinancialInformationPolicyTextBlock", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Interim Condensed Consolidated Financial Information", "label": "Unaudited Interim Condensed Consolidated Financial Information [Policy Text Block]", "documentation": "Unaudited interim condensed consolidated financial information" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r595" ] }, "prax_UnvestedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240331", "localname": "UnvestedRestrictedStockUnitsMember", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested Restricted Stock Units", "label": "Unvested Restricted Stock Units [Member]", "documentation": "Unvested Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r29", "r30", "r31", "r79", "r81", "r82", "r83" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r517", "r518", "r521", "r522", "r523", "r524" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r134", "r139" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r133", "r139" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-8A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 67 0001689548-24-000060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001689548-24-000060-xbrl.zip M4$L#!!0 ( *!"K5@S(K)9GP@ 'LR 6 97AH:6)I=#,Q,3(P,C0P M,S,Q+FAT;>U;;5/;N!;^?G^%+LSMPHP3XKP!@3*30KJ;F1;8$'9[[Y<[BB43 M#;;EE>2$]-?O.9*3&)*4L,N6E](/-+:.I'.D1\]YI"B'0Q-'1X=#3MG1OP[_ M72J1$QED,4\,"12GAC.2:9%D5,JMCF4Z4>)J:$BU4JV3WZ6Z%B/J MRHTP$3^:MG.XXYX/=VPGAP/))D>'3(R(8.\WQ.YNV-AMUCBM[3?K#;^YOU_= M:S1"5F?[S2:E_/_^!E0%QZI\?=\_8GTOG2.;[L=W_KP&NPZ/3(^67OXK)]VB?]LY6!/I? M>I>?.A?$K]&27]^BVZ1]>D+\!LN?+D]/()[^+QUR 4'VNOTN&'>^'/_2/OVY M0]K'?1P*?[]6]YY]H.T+TCXY.^]W3HKS@W'9*:U5JAB+#;7=^] ^[5R4SKY\ MZOQW&F6U4JFN"]M_/,3ZTA"['OE,52 DN9#95^J1@"LCP@DQ0VK>;3;V#A8" M6,DBA>!2RAA09"GB(?2T-UV5(F$PGZT2OGFB@/WRU.GOW_O![6&IE!LX#%TR MI"-.%!\)/H;D8H9"DU\SJ@#XT83T>"J5(3(A'Z6*B5\I_4ID2,X5O0&[<\4# MH064?N9,!-"A]D@W"ZJSV[N/E -,P:C'T_(=2+'$6=7W'-3J-S$ M,0DN)!+$ _1 14)H,B%98E3&(0*0$U99P(Q2$L.3$C0B(0W@E2(RAN1GI+-; M,$AXP+6F:H(F,;WFT&^A30WO&#@#7496ED ?:! (!3($S!*H#IXPKLAX*((A MT1G^F=VB116 H)2 '-N=MOX$5 ])&,FQGB)6 M\2NAC:+0$<67SF_PTBL 3T^=6?#VE6'/KP+VZD^%/>A].?;ZMR;JW>9>U=\] MT#FZLBI2D8..*F2 6?P6I,MP GC #P'ALY-,*3)%2=MH*M>%H&%E:^- M+>Z\L/(5G]RC0-&9.,!B^P0YK8!CAROT9>V.PEL=A= 1QGD7W6"!8N"1A%>M M^3P0:]D2]@;/A2Z;Y7T?Q^&$:]ACP,S9Q'<_K#S,R0'-]/I5,#D..$ D[\FE M6YDI: !X:V2UFX=6/+'MH.Z>\VB1BQ6/J,5&CP5VA<(NEFNU1?1 MOC;%+8!^?7)<&_NP7D:"(:2IE@G%+$ U+ >4J(ASJM@4<[ *!!V(2)@)RH-E MW>(*M/"TR'.+YY9I0>+:9'.3!Y1F*@7D:RMG@D J9AVP8O>*)Z!2(E@ 4,)3 M7%EH D+>@1Q6H$B![W\8F#M2#YX=J7=&-,HL\R$&>!B"#A4CF#V]1$_.9,H: M3.X>ETM,BVJH""RLG9 =R,RL]F"=7$-GUAQ5>GC_)HL,IOK?+E3N1@+\L:#$ M#GX<8+)G!,R##.]:YX[!WX_8L X\YDFSFU[;S:DCU3-L@D]JE MP9E-,78\E;ACM@F@\N\.*O[QAM,>E M;+J:O#GK(0D7$3TG0,3D Q3/@L*>>4=!91NI]$QDV!?09!P+8SC_1HH92) Q M6,X$^&<;V0+< Z-KS!CP/VK]Z6+E?V0"W+<+,TL">SRR_;8O_"X2 H^R4+,* M !YNRW&#'P@.,,EEP&Q_-N;T&O.ZTXPVLUNU:P]OI\=:#P)?OI5RAR)+Z) R MJ*CYC U7 C77R% %T 92UG/B0H.RT%D0(!;$@00V7/W'&V>2Z(B&R&+B\= !2Y*L%(1S35O#7]< "$GD9T MTA*)'2];Z2!O:R"-D3$V=S#"Q #*(_]^V +*%>?7'?;WR[N57;SQ8 ":ADT[ MSB]#E.UEB!W#%LOJY5JUL;*T4O97EGVKU89?KM:;C]YLM;S7V/M+K7ZKK%KV M_P%?:_7RWIHCNV,G34T-IJLF!Q)N?"*=TN3]1FWC#LNT*L22]ZR/%V.:QWQ? MG6IZ@[6*]UN00!96A$R_/ZG:*T8GP%-6H9 9-]P_$FM&Y99X\1K3]X[N,YV\ MV_2;E0._YMD;7G>N4#U:J$\W@1\FMP7FX\_>4T3E9NWO!>6N(3V?F7JW68=L M;?^2S^W>,7)Q=_J]]*\HU>>4!M/4JI_M'C3]78O8"6@INXC=&9.K?"UH+ MQ?MK;_A_P_\KI/OCH> AZ=SP(,-O$LB9.Q)[0_L;VE\AVK?.W;>I-%J$_/8B MYG?L4<$#CZ;N_%(BE=K>2VNY2Q8COO#;B7G6M$<1E7D5.H#4F9G%*O?\W"+_ MZW[\L6-_=/(G4$L#!!0 ( *!"K5C]&<,;L @ *(W 6 97AH:6)I M=#,Q,C(P,C0P,S,Q+FAT;>U;;5,BN1;^?G]%KM:=U2I FA=%=*QB%.]0ZZ"+ M6+OSZ5;HI"5E=Z7(F_33BL2&^XM1P1E(MXEOR.^/ZCN3SF=6I3$9*W/8-*15+ M%?*[5'=B0%VY$2;D)^-VCO?<\_&>[>2X)]GHY)B) 1'L\Y9@0>F %7NL?!CX M%8^6:*]6J=4J/5:LL%JY4OV/MP55P=S5T684\L];D8CS?8[]URNEPD$U,4=# MP4R_[A6+_]JRIB?'@8P-]*>@OOOHFEEHS/![DZ>AN(WK-J0M5W5<[,M0JOIV MT?X[PI)\0",1CNJ_=$7$-6GS(>G(B,:_Y#2-=5YS)0)GJ,5?''P"]^SCT+E\ M .V$(N;C$+P2.MV\[XN>,*3L%4KS'L\&3M4MQ&YD K6@V1G??1ALKE[)^=-F MI]LZ;YTVNJW+-KD\)U>=5ONT==6X(.>M=@,^PJ?+<[!H=LC53>?ZIM'NDN[E MRD W);#.S47SFGAEFO=TG*QA+'84!N=+XUV M\SI_^<=%\_LXRE*QN!9L]Y/__P*K+(VPE2/0GC3]$?F5A^$H1WRNC A&Q/2I M^;1=K1TM!+"216:"2RAC0)'YD ?056V\*D7,8#[K>7SS2A%[A;'3+]_[T?RP M% M5'(86Z=,!)XH/!!]"_![DIQ7V@!I=\X$SYTJ'.D%?L%F+O#MS9WI8V;NR]4PXS!Z$<>AWIDT-[Q@X UV&5I9 'VC@"P4R!,QBJ Z> M,*[(L"_\/M$I_IG6'W+%LT8P@$CH$/0*2I^A,'T(4"?B(XDOG-WB9FP&>'CNSX.T;PYY7 NQ57@M[T/MR['7G M)NK3=JWD'1SI#%V9JD#JD$$@X'%'[]I9;!&JN,4+S+_HA1SGE7 :2\4NH\U MT"P"YD3VQ&<1$F?,WBMR0[@A'$ G@-#\][OT_B6DP;0 M52<-P<+*U^H.=UY8^8I/[E&@Z(P=8+%]@IPV@V.'*_1E[8Z"N8X"Z CC?(AN ML$ Q\$S"J[R_&8BU; E[@TVAR_W"H8?C<,8U[#%@YFSB>QQ6.%DQ0)3 X52!S0XQMI1JS-1VE6J;UBUW2LW!(0-F&1]J./TP*WO@4X^C(; RU.=L.0LOQZWG*.5GQ;MEZ)W> M:^%]@:+W"^7*(M[7)KD%V*]/CVNC'U;,0# $-=4RII@'J(8%@2(5D4X5&Z,. MUH&@/1$*,T*!L*Q;7(,6H!9[;OG,FN,] M@%VJW(T$^&-AB1V\)VBR#8)FQL%NUA?1@\<"F7BT)4LA^@3F11TA?3]5B)&9 MI+VDU4AJ ^_QK!7:TCXT]*<[?R([*ZH$ ';@Q ?6F>.P@^/V1 ,/.^)TXM>N M\ZI/]43A()O:Q<&933-V/+(4,"*AN.-A=KSQP#[W/P_1"RV(3=DVV@51W;@C MB[^];;2'IFR\FG)3WD,:GD7TE (1DT]0/0LZ>^(=!:UMI-(3H6%?0)-1)(SA M_ =)IB=!RF Y$^"?;60'< ^+E?^9"G#?+LPT]NTAR>['[O!% M1 0>:*%N%0 \W)SC-M\7'&"2"8')+FW(Z1UF=J<;;6ZWBM<>X8X/MYX$OFQ# MY8Y&EM A95!1\PD;K@1JII.A"J -Y&S.R0L-VD*G402[PK^X#2;+0DN/ =^E M='BU[=M*Z8 *(5! -3F ![<$"0"S)_,9$G,NP8IX(,,!QRP;T]OL"P:5<2J/ MDE"..)0.^]*Q*)W#.>#R621(8>6LSWSUZ8!B[(8O*^T!3+G*PTB'--&\/OYP M!&2?A'14%[$=+UOI*&NK)XV1$39W-,"D :HD^P;9 LH59QUUBS[#%LDJA[!VL+"T6O)5E/VH5UTMU=?'?;K90K56?O56O M7#BL/;^SI?&4/+G5'Y65"EZE]/P#6RD<'*SG[)Y%F!H;C)=XAGK[!/;-GQ<=31^4U!L2-QO-/ M]>L!^,MH?O_Q,4_S=]4V9Z8^;5= L-F_I-OZ=MG]^IW\VKRX^#X7YIK$^M[7 MY4?\[S/^;#=B;Q^L0OC![\H"R1VE[?K;N[ M: .^\!.SJ6RRY['%:17: ^V4FL4JC_PJ+?OK?B.W9W^;]U]02P,$% @ MH$*M6!!*/SV5!0 MS, !8 !E>&AI8FET,S(Q,C R,S S,S$N:'1M[5MM M3]M($/Y^OV(NZ"A(L;&=A)"7(J7!J%$AH4FXMO?EM+$W9(7C==<;B/OK;W9M MTT"@I2=:*!@A<#([L_/RS.QX9+=G4^/M_M/\T##C@WF).0PF>H$12 M'Q8Q"\_@@T_CT=O MTIYP/]EO^^P"F/^ZQ)Q=JT&]NF/5O$K5JS0F7L5V?-MJU!I>G3C6OW8)67%Y MRA/+)*"O2W,6&C.J]F]6';->BV3KDOERUK0MZZ^27KK?GO)0XGX"^=/+5,R: M,$F7TB !.PN;VJ12RIJ3/1YPT=RP]$]+48PIF;,@:;X:LSF-H4\O8OKC9:IR'>4$+*2Y";:CE':7,S9A$BJ.:5_7>-5P M(L[0=LDCY$*Q*[I[Z&PJ'DGYKCL<]PY[WO]L[Z1R!^]'M MGHY[?[OX-2YQA]#I'ZS0#WO]#E[B54X_.1V.3CO],8P'=WKBJ5AN[\&I.3*[ M)HS[$K-*D-G!)V#PXYCM;I\'I$PT9_LUC9,N="[?$YW 8J>\.&8"&^VN6'O6JV*74X+*8EAR@(D M7FDVHMY",,G0!23TP5UZ,Q*>4:S \SF+M2KXJU;Z6*YA1@5%=5>U22W*E2GK MM0O40,2(-MQ*L4P2\*B0;)J4(5J(>$$P-)+#"KI3EZ7ZIA!'98G/(W5(K/)D M*S6$4!5M!!$3@KXR!LN )M#QI*(H""EUB"PK/K5P0F.9,3$!YR&_1&>P$H=<"=R(^([^-Y:01TJB28M1OH-^R]1\/^EKV=Z_WKMV]= M\\RN6:DJ/ZB89QDW7028?AZF3J# ?I4 @GY>,$%5+Q$K:-P XA;9!DPON[;E M;U_![6O.7.5+ACF[4:DBFAHME4V_9Q2=)QE%%F*5FQ.=^5AA)6&JMK"T-.4A M)DR5V$C06$6SK,@D" #94!D28*SC",,;IT5JRD(2>NI[%.@S+5K50%RU"%(P M\(@*O6>9]SJ;T&))D$M"<.N$"*Z.!W@Q(%--F?M'R61P%)&FR4/M$ M,[4R61,N)9\K<:T+544]$F1GN09-2LXZU$;#W*M55),JL3.5?KYQUK^:NG_= MD?XZK6I6[/J=5,NT[Z1]2VK%-FNUN\G_6ZQ9VZL]N%2[8C;V'EY9)P_)#TO] M%@W[^*KS\([%]JE^/V5W-,)$OB!/XPSU/F95$&.NO"Y52C<*7],"6Z_*]WCA M2S-/?H_'B9:*:_6N3-7)M:+ HU]_=N@;XP,LM+J7@JOR^'U/W-.JM,J5?D9G M=D_KCDF2=P5I.WWCQO]!\?&C7GD,A]SH51_,J,<#\)OD^JU $:?K4X.G$ZG- MC6J]%>N_<-P9=GL#& U._^E=?6EIV5A_\NT/[L9T6.T"-7D ?,AU^\W MJ@5JTL4XC/CB"RGRO\!_8?^S.^Z[,T:GX"ZIMY#L@L)@.F4>%46V%V@O[']V MV;YU(ECHL8@$ZRF_?5O.%S.H8@95S*"*\E?,H)YSG)[:,;4Z@QKWC@?CMY_@ MG7MT]*EH2XNVK+#_90VA4!B7LP3>T2!(B@)0)$!A_[,[\-,IU.'5V'_<\WVE2G46LK?,H7:T<_LK3T_?,LK(BM/"]YXRR3BL7X.L2EH0-34:^V] MDZ]MDWXFT/K*0B;8.RWD.LMW7E7)_J8OSNSH%W;^ U!+ P04 " "@0JU8 M+HWJ\V3N #+_@H $0 '!R87@M,C R-# S,S$N:'1M[+UI=^)(MBCZ_?P* M74[?VUEK 49B=E9Q%V635;S.M-W&V=5]OYP52(%1IY H#;;I7__VWA$28C*3 ML"6LL_ID&0VAB#U/L>/G__LRL90G[GJF8__R5[5<^:O";=TQ3/OQE[]V!U?] M_E__;^>_?OY?I=(_?[W_JEP[>C#AMJ]37^L^&.N_.&X/\PGIMQ9 MS!\Y[J14$J]=.=.9:SZ.?46K:+7PL?"N>\F9.AJ-6O42:S3KI5J3LU*KQNNE M"J^J;:95>*-2+3Y>,L;:([VEEAI-32O5VJUAJ:6V:J4ZK[955:]4*\U&T;@T MVKK1YFUFU$>L5F]IS&B-1E7-T-4*:V@-G;X[]F'-L&[;NWP9NI;Y2V'L^]/+ MBXOGY^WKP-]S">LM#1I^(A?\KB^ M\";\+C\Z3[%O7/@NLSU$'?.!&' *@(56J:I&7X='?VP& =X-'_5FJ"%\P M^!(:PF7#C86I (C6C_H:?+1*J:*55"T<9 4\BW/#VT/F16@)O-(C8]-5.,D; M"Q/DNK%^)7!C_N"EQ8!O"]PN?1\4.C^/.3,Z/T^XSQ1\M<3_#,RG7PI7CNT# M#Y<>9E.8C"Y^_5+P^8M_071\T?FO__JOGWW3MW@'\5(*$?'SA;CX\X48>N@8 ML\[/AOFD>/[,XK\4#-.;6FQV:3LVAPF8+Y?X('?%GZ9A<)O^A/LW($A<4Q?? M?_'O^>B7@EX"7-ML@B-Q\[(+HL9 :A0ZN.*D/W,'CCK'XB5:A\W?U\ _T;$#$[ H^ MX3*K;QO\Y6]\%@W>+G0J(!(:K7:]UCK\(U>!ZRY J6<;UR#U"XK@@E\*P#:7 M!EPI36"4,;Y9,MBLQ.UP*M5*H7/-=3X9I;EKP%Y?IR%-*8)MB)G: ;Q26 M9M4C#F2O M3 M2O/R^^!ZW[% M UP$M&8H M,@\^-F5]_'B-;>=B6FO&W97T"P, M<;$X^]=6+>EV_6>G\.=>,)Q*$O M(!?X/3)!O9%8X&NM[*O^WQ95\O++T0P61Y^2Y1#^ JO>]5$!DW52JJCPO_"] M^;UHFD;LT6JIJLX_(>Z$O\./7"RL>ST8M!2 0;@WOEP9^"CM:"!YYY"555.W MLCC.CEE9+5TKJX+!E=#*ZBE8V0)35G=GRFIR3-E('QA4%5R M&@QR-4+9B9\&?.P%+$_=]+\))\]\4$ MTRY\#*Z#&T7&K!CKYXNUGXB@$A'%R'S(E?)L+]R.(Y.3N^*F(I.L_C/DW MYO[@_GFS\-2%JK[Z'*:\'D22GJC4Z=%5RY=CL@OIC>REO/X&G1E/?AVTIQ+&A"4WH!; MBB/5:4!) MBY15P">YM*R[G.\3*'V?FN]J>CW/U"54WPE#6?=3WRXV^DX(RKHC^_ZQT7=" M7-8=X3>.C;X3EG(7>==B^,3"$M7<17Y7^-=R%_F= )^[R.G!1CWD]]I5 M_E?P:H+9[@'VS0MJ@FEAXX?5%% M;?>BBEJI6DF$+%+KEW\Q;6;K)G9<\WR7.KPMHN<;J/:9B&U]"6PC,ZGE6FH] MZJT@_S[XS7GBKDUW'CD\R[UK/O0'HH,0_,H,$E+K,&]%PI7C3E%E\8Q"/K5N M\PZ0GTRXBT_<,5CRC>.#LV %!C?^,/WQ%?/&:%/ ?]#]> )E!IY'5M!23ZTW MO14MY,-EDQGJJ76EOS#3_0>S O[K[)MHW(8#?'')(-)GBQB('HX]ZMTC-D[C M_IRHPU5JZ[=CR(C^_!U&9*X^GGWE3]S:@(^^/0U\CYY0D[*;WXXR#IE2U_.X M?V4QSSL/:[&>VBC(AZ"#-V51+3-$F=K83[J)\F#*J*:70])#E*F-<*6;*,^. M#M(;TLK-N&.)\GPB4/7TA@$_)F7DIMY:,DUOH#359)H)4^^,I&EZH\JI)M/S MIXQ&>@/;*34'-]'$88FG%#)*>F@S"^'_LR>'W/!;2YM9R(;DM/F6IF=Z:#-/ MBJ2 7=)##EE(1V3$Q$N\PB6%K),>PLU"RN)CTTIN'*XEW"SD6'+"S2W'%<+- MLRYIYZ7TT$H64A^I,BLS1+@9+AINY+F.=)EE.5V*,V&SD&DY)[I\RU1QENDR M"UF6%-+E.9)"%I(:'\FD2P]EY"F%=!E5Z:&,+&07SHDR,A-,:F8A?/]A!'CJ M0M*>ZU_>Q!BBW MHY&I\\&4Z< EOSJ>[]C?P"AC^C@ ^W$\32U5*DGA:'4Q5X10U=. )-TIPR M?L,F/ ;X[U>_'BL7\0N 4B/0_5MWP-TGP.0B]WT5W8A.BL0$&U\%WS6B ML;:C:(P_>HQH;*4NG'1FQ'[RH,S[+2UU4844\?&N)HZ:D(G32ITC_^&T8T)F M3BJ# .\/W\3,R*RY\&F46DDY9JW4N>*A;'K_!MF++^I7#CB=EB"?);.EW''SV&+=JIC/YCK N7? MNO?FX]B/???.Y=CAAQORB:RP8SMUOO .$ \?V0W6'U[DME/G8J<'XFD0MJDK MFZ"L&[,?I16(/[^Q%W,23,Y'G*; ^&RG+GZ1N.S-*&)2%\M(J< D]*B-G4-- M\T>/0D_J(A3I0<]R3&@.\:,LB-3%+%+MM+T36WR46$:&K(P3L6-J8R@?W&E+ M$,=J);4QF.XSA4QL6 MR3&=,$^G-L*RP1PB). 9Y/ \;0BYL]@V@VCG;^)8RS41SS#MF?AWP13KVSHN M\HGO,($4<79JXSLYOD_"WZD-%>T#^[O U**5_-$<]/?2N9PTRU>UK/BG[P#R5+!$:MW:]ZP22P5F4NL,@R'J3 ! ML#1\\ZNC4X!R1:%P;._9!1A@^TYGBL_V7J9GVQ%-U5+K2:<>8]7=,59-$F.I M=<-WPMAOW.8NL["'J#$Q;1.4%D,'\;RY++5>? 9P]EY\EMH@0!=&,$PK0!3, M#R[HO8C3JKZXS@1S<('/1!_>'G-MTW[T[K@[&#,7CT-8.\ 'M5FJJ8TXG"F> MWXF?J^D-;[P%GC]$L*2:WF#)^>'XO?@XO=&9-Y?79\K%Z8WOG!N&WXN'4QLG M>J\]\OA=.M+$[SW!/VMJZQ8?.#WGP_^T'3D__NAQ=)'::-3'I8O%)$L"D&0VH#9F0B"G;^;MN8MR0F@U,;W,M^])4/"[GCB,E\N M76Z1Q>^-S:G"7-UUK$6BP5?*COMXH54JU0OYQ,6(Z7YIY#B^[?B\H(S ?;CG M(^^7P@AKY!7\MT;_UNG?!OW;I'];]&\;_]4J!<4R[1_WKW^4OHC/%13?D9^Q M2VI!<5R#N[\4U,+%J=;2H%4T:!5-6E>3KC1I+4U:2TNE?\7?[2-6I$4KTG!% M%[0DSPE>CB9,3?8I#5H9C["*/YSO2R#B,A=96893[:EUA#R5T8T&=#BX?/#VF=)1UX MDTT]?AG^\=DPO:G%9D#! !U>HI<^R]&'CN\[$_H V#"^J3-+?H2^)V[/5U&N MB)7X "_?"+\L;Y?AUL6:ZZURN[+^5J6LKG\E'VKC4!<$>S>\*8FM.O4+] Y@ M':GJET*UL$08$M7JU%<\QS(-Y;\K]'^?Y7TDM-6;4V88(.$O*PKR4/ M=-](W/;,__!+M0%CT\]G08Y->)N$32@+-10;WV_Z#[UK9?#0?>@-%J5?;,KO M.\=![^K[??^AWQLHW9MKI??/J]^[-[_UE*O;;]_Z@T'_]N;-)Z[N-/$_NH/? M^S>_/=S>%)7K*T6KU&OMC5--G6YIE6M-;5_-TCZAM$R$^]Z*E&MK*>+__+?: MJ'P.:>#M6.C+[?TW!6U'V[%O@@D,HBO2/ :SC)RM@F(S=*0,;EY>.WHPD=9^ M@6POL/D*';52^CO99_-1.CD])Z_]#U:D$C3MHDT =>] MI"_^Y__0N__Z+^6^=W=[_Z#/"@/MPK8/0]@W"AJ M5;F]5]3Z)^,GY?:+\O![3XF91)$YU+UZP-MJNUI; ,P^PN-DUNA6< @UY;B* M/^;*GR&%*"*DHW ,7QZ@P.[H]9Z(Y<$Z7<'X- VD6W \N?,[$T.-FR3UBEA>) M[IH4W;7-HEL$VC(KP!_NNS>#/HGI7(+')+@?D4HHPC'>K"3I^>PR(0$-@^N. M2R'S2\R#N?A4Z(N]_;]O#8-"1_&='/(QR*>;A:ZY+:O?\D784JS%Y+[O&1'*62CXTEA5/IIF8*Z.V MRLW&^E?)N[,KQU@,4,"$="SF\_G4=9YPG'EDHEGH7'.+/3.7GSXF)@C] M1/)VO6NZ9*X=M)1,DL<#>^G+\C2QRW?1@&L5.K5FJ:ZVZ^V:]BKFDV:K)(F@ MM1/H/A%W*.!/.N!0NLJ_ ]?T#%,GGQ*4L!GG)'K,?62V^1_Z_5.ZV6 9 F_- M!4FN93=&^-0OWY<'947NG'&513)7;ISR3^L(>,ET:+QB.NQ8ZO'J8ZLO_F5-AB4J(5@N=BJ:J MF\-%IS V$@/8CI:&A !:%5,7",J<,DOA+URG3:!P&=04]W*;(E5( TI5D%37 MF W92)7,HTC_Y[];FMK\["D^M_AT[-AZDW%8IZO MN)3+S:.59UJ8NAL]S3L= #V@7.(N4,DT<+T P]R^H\ 3Z*D)!:)JGX8_H;[$ M7&]7]R_36F+2;I>;VM[$4E7+S48[D6!JI5QK-Q()IJ9V4LU35="D)13U8/H6 M)7XXT\>*CGL_]["@DG8GWF']+L,IT@ZYP6PR=*Q/>UG#V8= F/DC N O0HL2 M/!Q;>1Z;<'4N-K?[1GMJD.Q[FE*]S%1M2,P468P-4>\ 4*0-S45ERESEB5D! M5_Y"*345ZX<4;WQT,?A^J=7*S<2* M3I>AN7[_4]\V,.+/E>$,7!&N_U FN(/D>Q]%(Q M FR@0(].7:YS&V"YU_<6^9.,,/TI:-U3G<.(O79'GP M'I5Y62%?Q".@<&+Z/F">^-EU;!1EUDSA(-9F2A\E'-,IS'C-?"8J_I8(>SY& MW!^[#^#)6J4N"Y("T1-"&90>E$\(V^9GK:J5Y0/^V/30]Y]B7=*I"5S,-R)9 M[OV4&$'&X(7@DO09[12J'$>0YTN*@'VF6+ KC!=!U)T&=(38L=%Z;/VJ@(P M+*V]X4V AN$K;B@8 ',36/FLB,(6A@/AA,!Z5!Y=Y]D?A[?+('LYS#*AS?,-7S2M 6K@>E:TD(5$M<; MY;3&/@YM#M(L:]5JRBK)ZK5R54TF9*&VRRV,'R:SOMH!Y6VIR!=M%3-$.5_7 M"3BS3H[Y4P+8^5&^ \CL@;"E!/B*K+GQ$]I MJ9T%9O?E&8++KX$' WG>UA8*._90.'.!F5Y>.%5=?'I7O!OW]];[9A^2XT-8 M_$:@N!*0V+H%'T]*W;8'/W-1Y-$K,0:LF5H;&C%'ZP)T%)8#F\%V**H6>"(^ M 0L4/4?6;&1W7/J6-<.//YOP:?BL8O-G#'ZX_,GTR :QF:W#2M%YPBT^^#"V MJS68:W@*[NDQC5=++*J?V$]KXPT?)7Y*02MOS"TKQ*WR"3!&H2.QV_+UP,Q/ M924.JG]Q[YC0XP GLC/7;>Y\L5-$O)$5C'8I?/>-S<3DVZ)13G&5TZ+N/5\H M?@OL%-BF #Q*A&^ZH6.VBRJE6:QU8I*(\.I=D3^F9:JBVRU M)[+548XZREI'V>JBXLRGLU.,L)JA&&%66_6F/-S*>.,$YD M4_@GOM+>?#Y#FEIE_@H;PC0"?_65;1W1]VW+WHS:LH\C&I^R1UX:NIS]*+&1 MS]U+9CVSF8>K7]^[O::1]:[ZW:_*S>U#3[GO_=:]O^[?_*9\ MN;W_ _XL?;V]_1O^IE;,WWHW#YO;,<=T!O7Z.ID-L-V3H94]8'8YZNJHB'(! M!?O7@ Y6L&LLZ79FVF!OOTS%7AM7,<&&QK89H*F?P2@N68[S0UK)OJQNH'0S M*%-ER-"HQHV^@0M&HPW4@T]$.R>&'(8:45J/>5XPF8K4(OZ&ETQ;6 -H=N@B M9PSS9$_,M$C;@NV].&Y9Z5K^V D>Q\HS%X,_\7GR&Q8!IKHXA ',G)'T(< B MA;O@0;RR(EP,4+WGV/CEHGPA]@ Q,DUI%/@!/,V?Z#KN<(8YRHO.E(N=S^!@ M8+H^\C;@.JW5UKDH*S'M)\>"R?^PG6>;K@2V^-LUO1]>$7[J8"4 %^&X$@<3!A8[0^\()P%W H:%.%Y@^3!$[*.4 -;'""^)0JIA .!S)#0 MNV'B$25P3[0$0[->+FJG\20!(37,20C\B6V0+R,U;L**),\0AUO)66S+ 0@/ M T&?Z#Y:YL3TJ02BN(#Q(1B".Q7(H\DM=4$)@Q27]=H2=Y=0Z+\I;U,:O''2 MIF7K/KP(![56)IF&O.<%N@[X+P+./)_(U0>X SK!.$?:!,_:"'0?J!4L;VSR M"6[$$[><*6)#H=H1,Z)T';Z+]C&X^3!A;R>O*\?2%BPA%I8DY"/P'>$(AH-PWDY,.::3DM4Q9L?H%G?1D(1Q-P">]I&R M*4:PN8'1=N!1^$@8@=T@'/ 103QH7.;8.P7VI#H=!11SC!1EY"MX\?WDX5,V M1W.*N;-(#'.PF4:!2T[ GO:QA+NX^3"PL9,.;N>5C#O ?0%=.482(KEIA8, MBNP2:K)BR"=;>&232,U1DP1J9!0A9BF2.;EH;YIHF=BV]"7D X,2/;DTD$Y;M-L63J=!=U]($Q47UAPV SMQI.Y $#<+'9 M^]QVD%$.+YABLL'U9+S2#C!# A:'O )8,Q>&DED,A1G\SP#0:,URC"6<8O1\0)6(?Y@G.$7J%0Q \.?*.;LM6O MP$:88T7^\- 4MV@[9HZ1I *WNAX 'F:A-N>>;TY(B\SS,)B>L3W4ZU'J]8G; M 0=W%1C(I]QNK,D 8M3FW!#&=2P3(//..Q:XI:)8H0_?05F@,UK_S G0SE%, MT8]Z]EKN'K/,W)V8-DSP<28VN#,OW$<,Y2%5#/G.DJTD& MA6.)/ J]H-,:8A41;#3"-A^R_*&L?%E?>;%8=8$25Y12Q(>B#)LL<5E,PD8E M"VSB8"965EP#B+RB='\M;&"%<#!D,;8GPB3P+6S:9"B%>P!-.+T"+AI7V+5M MG-=JG<3?HNXDV']2'N)YS76.34-%P; \6K-:5OH@K6RAL!TW1D2$#;R\6*?B MH)2C=@.F$'/B?#&JR8]7 )'+(HM0Z,@ %]94#&$YKZT)H8K@?L)HN >V-O6G MIUHAF;E$*(4U)PXY2O\6I3^B .75\I,;9^7V1J&Y5//VCE5^[UNQMZ0\WE11 M1+@3&Q$> X:E["*((;5FK$YI03X!D(Q=RHBDVZ 8\H!-R?+/*-&H1DKG.Q8D MX4AC]A1V08KBFK%>1_A(M#TB=L@<;H)Y&9M#/+H*9 */I8&L,/TK1R,>"VO: MQ5QCY6"+55S2[MZK\NOPXJ[,F!\/KTJ)';'M<@0316P _$\F?_80C3(02D5/ M8=.?5P"ZT)01&O6#H@?%'"N0I,O\68A18#Q K!Q030+HAXBHKOSO/ MV-^(-"1H^V=.Q" ZFN$FJZDAOK:M5M(72G7JF,B%(C B**:(@Q+!VTZD[\B" M"H/WAD.C.=BND4_IN]'&+G_>KPB(BZ%?KY-=8K'G!49&)Q2 MY.G-4126/<6QA)1/((C!6LYO#^1EB.:WRR_+34OV2T+!;T. M&@9V"&=89^#Y+K8B@E]#N4,Z$K7;LP1@BL1&)Y: Z4<%R+&Y(6& P>.=;N;;4F=\5@T4T7E(9'(70A M;#=8@S$F7GPG"I*0O12K?8U!MZQ\MRT*M"#=/ M>('[Q&<>%N &1F2WA]"G+\+LP0T1K+^,J9&)'LM\B@NYPV)L71-T3)BPZA^Y MS5TL=@F&ECS/")Y]!+O3M\%X],QKE!2IU=*YF+,FP9HVIXCQ:L!Q8VC6>>\)?F=>D+M!ZZ439N;W0" M+VY\%VE9,;(6MKSPM58(?/%1::=$; D!F0XK_DOH MODC_->[$Q+I\)>;*9,"JWWWO#IZPE I7X'TW[SR0>0!\>>60D>&M('GS4M+3 M$:[=+K?JU;V/3BAK[7HB6R&;]7*MN5]KN8V[*M5RN_IZ%[?TME%ZN[-ZSFR;Y\.[VEJ1+)A1=W[!X&A?OF$U!;)R#6K&HV2=#I@56)6!M?E%H%+ M$1Z$IV F[)UGH(Q=[''PWSMHWVJA\Z5_T[VAG:/]FR^W]]^Z#_W;FY\OV.X' MVQVP^3@;]+Q>VO3!8I8]5')Z3AD]-X">H[VJ@[ES\^F[S<":![_EI[U(.V6M MP'*:.( FVG@&"$:GT'F#OT@^42/'7YE%:;W!F',_#)X1?61K>=\PN)#!>2O5 M#$Y:S>"<*7*0P7G7,CAGBC:%H1M%1&TRN RM>I"B/$"CK8G T':^S49=KNJV MB:=5M.6&2]:PB5UU-Q@N,"S?J. MUA?V;';Y&)[#XO2OCB>LL S*G-QP?%_#,8.SSFW=W-;-;=TTS#FW=7-;]VVM MHTUHRVW=S&&SM:.M2X=AC!T+M^G(WMA*[\\ -VAG.O+8RKH!V9[WS9B\ MP:5FT6#$>6?:8,0%9-%@),!GS6#$26?-8,0Y9]%@Q'EGS6 DHLZFP8A3SPW& M3)H8]=Q@/!=LU@J=&P>[&?B.LL%R7+H$ 2!]SC,_>R$]="V7(NB+)($&KS M_"51-9=$Z2(\&*C0^7N 3>5\T0X6I0IZ>#:J\DUT8<*^ M/+FDR23"M0\@:FJYJ$D;Y54I$(_ME44/L3O7T;F!DB67(YG$YCG(D:U-=O(N M.ZDC/;"6;Q]^[]T?W&(G%R%IP:/6RKX(R?L:98[RVH7.5_[(+&&#<(1\;H1D M$X\?0H)T2LCR#3\TQ:ZBBO5>A< M\Q&C?/SWJ6.#$+=-QUV6Y;D\R1I6/X(\R=-E::,\#?<4P#M@&XXXF(2Q1'PN M1S*)S8\@1^JY'$D;Y=4*G5LZ'BUV4%XN03*)QX\@01JY!$D;Y34+G9X\$$'1H;7LWX@:34_ MD%36$RI]VNFC?=YP1%Q\^GL N%%8L]K8R:6-DQT?OGZI\;JGM?LDUYRXN^-2 MV]N7^OF=\7S?_6=_H-S=]Z[Z \"J\JUWW;_JW_0&14#VU4Z'P%???157MS?7 MO9M![UJ!OP:W7_O7W0?X\6OW*]!M3QG\WNL]#+*QE(63ZC(QX>[$"; C#1T( M[@0PEN$5%?ZBUKK5IRDVH=(>^O\?,CI4B*<#O^H#A5>"ZP&$*(SQ?ID$( M)/9^0DRIT'^KJ<0>]MI#,T;'/_B?@?G$+-%$91&/^RRYHJ266O]RU+H^+\== MWG]!/YLOE[9C?W&93LTH MOT[S$&$GA& 8C6QBG3!;T$E&MPW9PPR_NE@+]L M-N'X9.F1L>DETD+7-O _O3DA=/TKYKHS@,$_F!7P@B)R5^ GOOB7=C I&0X% M8W!8X R !2<>05=R5*(><76UV&Y5?KY8G&I'.*?'("3DK9T1DXR*R'DA^[Q0 M>P=>T J=EEJL5M+""@G9)"E6;Z)%AG"T8]5_&TP4;;^EKV7M#++"%K70?6*F MA2#\XKA8'C\OH[SF0W_^2QJ"^S)%M="IUXNU:N-8IGB%.$^A'W:Q.3\H06V1 MK4<1U,A\X4;I/]QUUM!2K="1H?V4$-/Y.Q!W+I\R\'KYRQ3;,XJ&(@Z5.>D+ MGN%!4G=7@RJ#3+)%ZDJX]@18P12ATC$13#E0TM8+G5JQVFJEQ/I(,E;S06EH MBZ ] 0TU"IUJL9X:9RY)"U:KIU&^/C@^LY(0I7+EVT.6Y\0@VTS;8U@!J[E4 MM=BJU!(R-G9#309LVH]%8]NLW6-HK%7HM&K%UO'R]N0D=@;YJ_6D\-6Q'TL^ M=R?*)+%@PAF;) D%$VX<6S^,9=I@H=2+K68U)29*;N:F)9ZPB:9>"RG4*HF% M%-)E\J9/T-ZYSA3F,*,( F8BIUBE6%1L[N<1VSUC!P*2=Q:S?7#[>B$P;[B_ MAL3Q:*%F'GX]&^K8&A78BSJT0J=^?,PH7?'4] D_>6B$_:A8G'E<(3B4G%$I M@!]Y /4 (1A!]"L"]!X_"& MX6*E<72<*+<@MPA12CL!@$O)Q4O/D?:W2:3U-QN/!NRV"82 M=R2+1IK((LD$?)H31.L%W?'UZ^=6PKCCBC/.R3NEO?:U8C#?5:\4:Y5V0G;, M^^>[CJCQS5GG/%EGIVS>OJR#:;QFL5U+JO0F16F\]/D&Z[>A?379T+0H#T ! M9L]W]!]CQP(X>O+@3PHZ^[-C=C#%$%,%Z!M.@-G"X_:J);2Y:9^IG6V8+=RL M9LVIX; =:PEM($S\_?,OZ>_JNMB7/V4S3/H=XU&MZZ,*^%M]JLD@3M! M 8?5UM3:A4X;K-FDJK=2$,#(23_[I+_-_DR"].N50J=>;*GUE)#^^>^2 +2Y M 9_ODLAS>?L*? 1?S(8_D/#50J=1;!]?[)#G\=)".=OE93*4HQ4ZS6("<>UT MY?!2+#*7*R)B+EN>SSNB$B)DA=F!C$"E$&H]+15!>=[O;4LACB6?&I&/=H[Y MP73*T3#D-75<1=/NW/Y$[>#E1#*1[+ 0 M[A[+%G5D"ZV>%O,B-TQ/WF#F!$340"*JMK64$-%'VYR;D(7ZL79/;I&UQSMN M36"*5K'9SG?I?F@ZVR*.CZ>S%C:Z*S9K1U?'G)S.SC:[.]^JF^=W,QOWN8F5 M;\=\%B$7JGB-#!%-2HD./22$IUID1!9D_( MYH&ATP6&7MLST5 +G=;Q C0/_J2%4(X)_APN1C6*K3?4E-#11XG_Y'&?D\9] M]N6":J&C58K-Q%),>< GDP2V>\!G7P*K4411:^:1GO=+:CJ3B>G3*8;B]!)X M R;,;1WW=WRZ<7RN-'Y*+O*SKVA[\,1 _&I1S16 M%^A[[XC5OAQW]+H;T;K/8"?2>MH=;-QYE!^>=(SPB9VU*(ZX.\#3(U^UCVIK.CN+;Q QW3'WUJ5S70TZEV0^IM1= ME8B_FJ^S]*;9U$XSFU:A0Z=2KGHL*Q>4*7.5)QSOL[)Q!70.I_?JY/LW7UZ? M/LW5ZP;^V'$!Z<9NUL%\3>U7(+Q^?M6WG%\38VV5(@ =_W\'N(LY*RSZ("G< M-UABW_."Y>6M:=4X7YGZ)I"_#7S/!Q" ?-EC;MK>9TIT'A[:N7!K?G+G_,3X/.BU MPXD6,:)8*E5IS;ZN-CA7;Q6PK'N*?[,T;1\ A>7,[(?(!@QL+ M9=5BJYD4?A(WG\^XZ&9K<4&$9&D*+9L\+=Q$O!!3WS-.VP,)O M:]6B6DM+04P>,CAYNX=D* <N!Y/ 0G(?G4\[X;[MZ,']K*&$_ T MM908$+E%^0;-WD3E'+K=$#!*K!1Z9N'G:,6L:,B4]'B4\/)@U_ M+3/&/?<9?,GH,=<&('@QV%X+T.YI8;2Q$5F[6JPU5[@W9F8/V#V#(M1 M;,='2\"%R[9BPGP>74K2NCX6J?AC[G$D$@-[\]-F0H(;A941^Q6KVE,:,U&E4U0U&GLSHM5'WEIZ'+VH\1&L*Q+9CVSF8T[P'+E;#*"Y=U]]Y_]@7)WW[OJ#_JW-\JWWG7_JG_3&Q25_LW59G)[)ZY; MOXJKVYOKWLV@=ZW 7X/;K_WK[@/\&#S ?[[U;AX&RNT7Y?:N=]]]@#4.LK&H M3]]M%A@F2(*?,C+A[D0A-NM-2UMRKE]=KK7IR MDVJ].M06Y__5H%)[Y;$U-K$@B/<_ZO%A['*N?(/GQI[2 ZUND J@6F&EJA87 M+*YCH!)S6G8UN]((+ZR:WF7G^=8UGCF0JOL03I9[:X#$!EPQ\J0V=(+;T4OY M>*[UF3O/ZNO.\[V@%F^-']PL=&K5I"HQSR$HE?/&F?%&_6#>:!4Z":0I\\/! MCS]K+#R@,6_%DZUJMWON<;+OT;\E1"4C@@^X"& ]E!94.EZE6\[T89T-!6T1ITA0D MNR\T5QM>9'\#1II+T9P5U^(8D_1C56YN$;*1UR9Y8M]&SFJE6NC4M&)536J; M9ZK#4CF='2B*CZ>S6J%3;16;:S;[I(W.SC;$@QL7E9'K3$*)[-@?_+2&O?8W MK8CB#?N;(EZ9;Q?=FUOJ()758JNU>H##[AN:\BT;F2:W%8E\0G)KD'"NM(_9 M/Y>5G1OID\NTT5QV=\B/ZLQ6N"B.NZ)B\\.B[6?LXV]S8!!^-X[M+$JQ0UW\ M9J&CY3&B3MDT2O@' .#R2H M:J%3;1?K]55-DJ) 0@)6>/]_![JS1J2YR?WQ1&3+/U$4)IHE[EXT080G,O%YNU7>8_)H] MUXC^4K6LKME>"!/F.,+J?N;]K;/EK?AG)^SV7'+6I-VF$W\6C =MH] +._J% MPUP+#E@]9T-57SL!)/F)_(I,N6X:-7!\RVNJ^%$IUU>;S:2:J=_A:+PWI- _Z >>D03S88\\LIW$ 4JQ M4Y/.T8(ZH,IA>V^CO>5R2H35G@=_+6C\RK)8".FJ*\CJ)L"3MFY'4CH<>TZ9 MJKYV0F*"\UV9J)2R>\ZV107.[4JM6%U39Y=L:\[C"#0#R=2<$5]1U&_.B/L? MIWG0?)-A1*U2Z%2+]5JEJ+960SA9Y\.=N^ E=\INO:R%)$T#7>*)1J;^.I%K MF_4X^'ROJW' T,AQ?&R:)Y!JHV!' C/M *C&%Y?P8OC:)5*]<*%VQ?ALX6.0E00_HYZL\$U^1'1>B3\=DE-!I"M@\!( M>XL#R_>4,=AORI!S;(KBNPX2\!.W9@HS_AUX:-_Y#MP965SWL:>@HI: V78+6=%O.6C&??DE%+I"5C/6_)^+%:,E[=?H-E_@[/]?_14[[>#O+6 MC">:\+K6C'GGQ;SS8@8Z+VXG\;SU8MYZ\61 ^B"M%_R4/V4 M1V;:'L;:P._YP:7?Q/7 I8->:/,BQ9W82[Z'P?YWQT*@_ 88 M0+:ZM0<1W&$E'MRZAI_VXQTLQ3$VGT6N:K7\,/(S(JQ=-C>^$6'5L;W:TYIZ#>DQK7;3.]34RT]?S-GU M0[#KKKY8DNS:),^L6CFFQ4]6CE_,D_T?(ME?3239WTHDV7]DIO^]B/?#9_X' M#[=7?_O]]NMU[WX0'HO>^_OW_L._LK'(\Z@ 6#J<,6/',0+'ERN"Z_>I"JBV MRHUV,E4!K7*]U4RH*$#;L[P@GU,^IS>:4[NV2XW)DB&DJ52%?%3=24IK!YH[ MU0Y%[SD:F;FYMGYO#<&9Z*:$DJR'0AW-Q_O?U>+@(V="\D M4 YB73ZDHT#7>W\&IC];5YNUI(?4@_50ZFO8=H.EV%OU@4O]=F1E\H]V -.. MP#C528AO&8S>#7*_,HO9.O;I4:ZY+K83556QG>A'RZ?_-E M35P:+$J2B$?O[,3X6ZO8;*O%5O-#G$&3X0J\W8CM+"KPCN2K-4F?YNNU'G'[ M0M@4Z[(X;=SAGW-)SB7GRB6M_;EDOT1HM5+H-+5JL9YKFYR/LL5'>]48M'>L M,4B H]1"IU&O%MM:I:16CM-*(_.%&Z7_<-=9QSY:H4,!)>US MKI!R'CI7'JJ=W+"K@AIJ%QN-=NK9*(.G3NQ&$(3%$C92PH5-\'00T<=('OR< M[8U%N\% RO)\3TZ.DQPG21E@6W;@=:G]&!7&/CCSM#UF[/NVS-53I)I$TU5, M,MUS4#:>Z?,!=Y],G8N-4O=<=QYM&N4?S KV/E"K6BMTU%JQUES=!YO38(IH M,)<+.4YRG+SI9NG4B>IZRD1U5H_5V8V2^IX74)+>&2V&K$69N2X#>HI:&.!E]QFW0<.#ANGI M5'%>I ^:G@>X]6C :'3=\7P/W_S+7I2NK2?UJA$,;KO8*Q]^;,ND@@V)K MS3&*1[297T,MF90\&[JO5[>4+D1HX49\9[PH8[CASW1K1U3-BQBJN+NNV*IH MQ8IVM!QYY8C?%!^5FA6".LR\R'&2&O-BET#B*H.3;; G?\=$,9ZLT%"+C5I2 MP<6#F7M:B=M.F\3-Z@%=2?AES"_Y8UX2C>.6?;.YWV6& M@Z!S-7>V#G6O-G3'VNA>K1!1#<]A:2;J/IU+X&:#^]1X%_>IIF*'XW:Q5==2 M$H3)XX!Y;#8C.-E+I.Y2A)ZT*J]IA4ZCJ!Y?EY'34<[;.4YRG&1(WFYI\'H: M>5M-E[P]@_VF!_E,N%B+#1U7E,"A3P1N$Y;!*>S1Y=3'[9AMJ9EGF T^2.M] M?)!:H5.K58O:FB,@\M!5BL@I#R>F#R=[Z<25G4EOH1.QRJ-9U!IY=C;5A)0S M=XZ3'"?)"EQME]UKB0O<1LH$[MGNN?D']ZC.#9P0L']]UZ0CM84C@F2QN>/2 M1W#*U_L8FGJ,CW$?@9D>ZSXSU_C-W?FXK)C/T00F48N5=EIJ3_.03QZ&RW&2 MXR3'28Z3'"?GB9.S#<<+XTQY-OWQF%L&VF)XF"53F(F9\QMW-Q!Z% [ MF5[#S5M?'/>!O?R!P!=G$L(%NOOK\CZNO:WD%FZN:+16\UE[=Q?*HQ$IDF;=1]8^U/,*5V5]S538_NBLO.%!&0Q^*3CL73S5L!W)Z$NK&OAU%7R<.H MIN7X\SQLDKZP28Z3DW?Q>BT1O8'/5S6?ANU:G),_%DZ.J]4;<_6Q4E6+ MBE;1:L>$RN7A@&(UEU6 M^$$&)6G P*/.,0R);RR;Q%/;4L1SQ752%&F213N MW :^YS,;@;%WN0YV8\=./:UBI9;P*=Y'(?2= B?O1JOI<*0//7#U.'ADB6?7 M&:H'G,>ZJKZHD#]GP)P!;L,MRY6KU=;Y49;77NK4EY_ M?=-0K7*]U=QKI,W7-;61SRF?4QKGU*Z].I+,\(0WI;S7:J#\-]D.KZ8&VW,3 M8U>!N<_I=^'@F\3@FR2/1-Y"(1T62MP$/EXKU^L[?/_SU/'H:/M+%YL"F$_\ M,\*XI)5KM57).V0>QQ$*'77+"7?5/3"W%O4P@.L\KV3+#B$#@=/W3Q-V888( M:F:1>L6>5J6^37]?L:GIP_5-^<)#H?%A0*OKP22@KA8$SVL^,G5S\^$G.3QW MAJ="9<&*(--X<;#R];7:TEP K$+UP?$E[\<]%BKD:7ZFZ\)[60#J>IVJ:H?J MU'T0DV)8BAS_2V';>59.5. W>F-''3KIM_=C/C<+M"\Y@=/CFSI(""/A"S[,4K6_JA)*!PVH5. MLU%4*XW4FW!GVZR"L%C"!",N;-Y[7.$O^#?/FUCLA^%\2V^.DW/%R5[:8TOM M8.Q8A =GGJ''Y'S?EFEYBDH/ET]%N.>@;#S3YP/N/IDZ%TV/[KGN/-HT"K4^ MW5<7-2N@BXKU=EJ:H.8DF(N%'""O_>C) V M'H7OO+7M;$ MADWM4Y>]S#N@XSROO+!ZKU8T[ON>'/=&O' MQCGS0H)FE?!4U-9TSLD;H&:!G-:Q[RY;XC><81"CI%6FKE%%=$XF9T(FN^PW MVTXF>YH3=:"A5K'23JH@(R>D%'D9.4YRG'PLG"3H^9U&WC:DO$TJZ9.G=C90 MPC^XY\,$T=D"B]QW31VWENXC,--CW6?F&K^Y.[VJX*YN>G17 M7':FB( \%I]T+)YNW@K@]B34C7T]C):*'D:[N5HWEH=-4D18>2@K?3AYJ\*? M#7R^JODTT'R5HZO%^1+O]=Q'-_8Z:-/=YO[4&DR&$I'MR*6V@W MW+\=/;"7=?88[HNJKW9QRVDKH[2UQ89_2]*JIXFTSC:+ !@@R_XCI 7R $.. MDQPG.4ZRB)/]BJE6CK/=T'T4I+]0X%]WWCL4T]"-0J?:+-;JQY1%YE23<_+' MPLEQ-3LG8>1F>ACY#&+J6X\;^L9-51-X*RAY,_23@FO[%O(\Y8G$;5: M>!)1JU$K5M;4N67K4.D$(B?O1JKI\*/S8]\/B60F<<91JUWH)-S7.^>_G/\^ M!/^=_/2D=@68LZH5ZZVC*UMS%LU9]#Q8="\/L/9VYS*U56R)B2V3VHD=-9/S M:3'CRHZ3:53!H:\5:(^'30-^<0RG0>D%U MO&%35[RI@]<67( MN:VXW'<=I+\G;LT41EMXN:'X#MP965SW%7_,%;4$1%Y2ZW 1H.5QN2/4FUJF MKP 1FR,N <+@/@-&IB8W"?F997CL@\!MOM=!2G M3YT#Y[K) %2M;!,E!+\'@ 73\?0Q9L^P%0_.VE.8"Y=MQ83Y/+K,4J;,%;7L M8PZP @ECX %EJ-%L8D#<&ZV,3)O9.DP)I@X7:-_T'"K+<)#3J-5AGJO4_&P: M_C@4=[&WI%"HS%]A0YA!X&]^Y7T!7%LZY2#V+\X1><\TVKK1YFUFU$>L5F]I MS&B-1E7-T-4*:V@-_7^JX(;(E\9N..\I>^2EH_C'(QJ(^?;=98)@@!G[*R(2[$S ]0'.8 M-D@U)X"Q#.^HN+L.MB]7K3;6L:MK:6Y6RNO;ZIJ%4K5QK-_8: M:O/U:JN6W*1:KPZU)9_^:M%%>^6Q-=Z2H(A3N@GMG?+K#V,7+)5O\-S84WJ@ ML@T2\5&N?<$N/P8J,7=V5^,\C? "ZZZVL?1@GS6>.9"J^Q!.&LM3=EOI%?/& MRLARGCUQX)8SY2ZC=I7D75 !_^4N]++%SSV"D [:QY'LS#*X#6 9_?MM SBZ MZ"X=R]L]F+9N76\:%-MM07N%IG>-3!]51-BN%SK5=K&^YCBU+%8#YX1_!H3_ M)M6S[125P9^!>;(>[;'FA"*X"8C63?! ;:FX\"K^K:,=$V"T#ES=Q(V8]S95 M3F60" %632/FK_D4L&U2GTF%OV#/29[MS8J[K?LH!;\HWN(@7"? Z P@+25- M=3[D2G6F.?5RCIKI'";O4M"AX M/W(Z^>[SK>=SO3AQ8Z7^(,WH"O.MX M )M9:T>W;LD-RK20S+:N0 F0C(;)EC-K[)EBH1G'"I8Z@4@ZA';7-NXD&OHV'A9'X:YUS%(M M=%JKXC4_O"@=-'.*"'5RM%,K=&II<6H^D'%*)5%#QQ42%Z6L9>JH#!7VZ'(J M'\T-UEW$:CUDC:G+7BZOXF %)O@J@-H-80KP1_!'AL>>SEP=3V6I5_)36\MI0'1(_&D^&5#T\I3@J^2 ME%9/(VK!TIDRTPCUI<"G@ZUI%7!07%2E M$?09,FZ:'T;; RP86_YN*_?5N" M^IJ/. #6D*(/9"-U B8'?ZV5V00/I;*Z12Z+E4#G2#2G<%$.)9X]33+,3A:; MS7,,%:53VH+K*8)!4S;#,-!'"/N<5*:& +T3\-R; ]K8=Z[>6NT.D&67?]= M1-^!SDS6W3 ^L45_+"PC:KW-_;AW%JX5.(S=( MSX-6#K=(U]'*GJ)3 T(JUMHI(*7S-SUOERHZ8C&;CV"%)BI *<*YRA&+N?LM M0K0*9L,:SRM//&:07K8)T23HI0;T4EM-GKPYO9R_?1G&6*C#CQU\B!SB&]F7 M5S .?N$/TQ]?!1XLDKLAW:]IW:>I]4*G5CU&2N:F9FK(YG!31,L@O>W!W+[\>0E MP;L3R7-+ENJCS$VTWQ&T?NVXD!6N7.=)]/@QJ^S M[P#_F/_3%.!$5:I5"IZH5 M6[75?<8IHL(S:*>Q6[S<=1>X^IAA%9PS6K]9)X\%[5>Q<<=F MM'OBP>GJ?P:FR[M/S+00J%\<=P"";'ZD_34?^GN+/K70::M%$('O[^OG(:)3 M.T)'$=.K[I"FG6E1>?ID[#?F2QPE*V3/.#ZP3<:Z#JS=\+Z ]8%39 M[>A;!. Y<^S#&-6TQ0GR>-/)Q>QQ]+2#UJZ!PU(K5H[?"Y;'GO:-/7V2P:>? ME*GT1)7A;*W/DD>BWBH2U0^A?T0,H)Z<(9Q'HE)#A0E*]1/27B,I<9X'H9(* M0LD3E?(@5/:"4'W/"P!W'-TCW9E,'/PL'C$F$.M8@.427)P&0\O4X:D1? 81 M;1N+!W)-75X:!7AZA_+,7)>!YTR]9G!@O.P^H_D&#T8]:HKT0=/S@'?E3M!P M=-WQ/L8>T+WT_I8C$N.6=(C6V]$5(95:5>XM:K&];$,M-FI'[UC*HUYIH:): M-5$J>MV?3R[OGP>ZCI'C^O8>-GD8;)%/M)73VT\M;47CVF8C+3V>\MC7\<*V M]G;"MEI)6_#T;(WF$&U"N#*_Y(]Y2207(AMV;OV:H6A&N3LW>7,C=ZV1NT>X M.!&QBV?6-HK5ZFI156[B9I2&JLE*W1UH2 /5W2I6VF=V]D(*):],RM,AW^Q% M>3;]\=BQ<-*>0J=RBS/4PP0#/.;"GZY)YZ0+BQA)YT-D?4]16G,O8/S@/+"7 M/^; QY*(#5WX5[FE"MRR1M[FFPDR2#8[%M$D038U(!LM!63S0,H?=M/%_9 M?,(JB?6,"#9 M.3;\2WG=3;S:9EUR]ACK]V/5.6R1V!OJ'+Z$,#^\SJ&*R;>65FRNV>YU6#CO M_2MM$C*D/Q8%'E9IDP0%MD14HYE4X62**FVR8I*'W2EP R]*]J*0[_S/P'P" M=-FR)7HLQH'W/W8Q98+B'3D+_[\WA_=]!&J\ 7;2XH78DW

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end XML 69 prax-20240331_htm.xml IDEA: XBRL DOCUMENT 0001689548 2024-01-01 2024-03-31 0001689548 2024-05-09 0001689548 2024-03-31 0001689548 2023-12-31 0001689548 2023-01-01 2023-03-31 0001689548 2023-11-28 2023-11-28 0001689548 us-gaap:CommonStockMember 2023-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001689548 us-gaap:RetainedEarningsMember 2023-12-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001689548 prax:FollowOnOfferingMember 2024-01-01 2024-03-31 0001689548 us-gaap:CommonStockMember prax:FollowOnOfferingMember 2024-01-01 2024-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember prax:FollowOnOfferingMember 2024-01-01 2024-03-31 0001689548 prax:AtTheMarketOfferingMember 2024-01-01 2024-03-31 0001689548 us-gaap:CommonStockMember prax:AtTheMarketOfferingMember 2024-01-01 2024-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember prax:AtTheMarketOfferingMember 2024-01-01 2024-03-31 0001689548 us-gaap:CommonStockMember prax:LicenseAndCollaborationAgreementMember 2024-01-01 2024-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember prax:LicenseAndCollaborationAgreementMember 2024-01-01 2024-03-31 0001689548 prax:LicenseAndCollaborationAgreementMember 2024-01-01 2024-03-31 0001689548 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001689548 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001689548 us-gaap:CommonStockMember 2024-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001689548 us-gaap:RetainedEarningsMember 2024-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001689548 us-gaap:CommonStockMember 2022-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001689548 us-gaap:RetainedEarningsMember 2022-12-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001689548 2022-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001689548 prax:AtTheMarketOfferingMember 2023-01-01 2023-03-31 0001689548 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001689548 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001689548 us-gaap:CommonStockMember 2023-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001689548 us-gaap:RetainedEarningsMember 2023-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001689548 2023-03-31 0001689548 prax:FollowOnOfferingMember 2023-01-01 2023-03-31 0001689548 prax:LicenseAndCollaborationAgreementMember 2023-01-01 2023-03-31 0001689548 us-gaap:SubsequentEventMember prax:FollowOnOfferingMember 2024-04-01 2024-04-30 0001689548 us-gaap:MoneyMarketFundsMember 2024-03-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001689548 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001689548 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-03-31 0001689548 us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001689548 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001689548 prax:OfficeSpaceInBostonMassachusettsMember 2021-05-31 0001689548 prax:UCBMember us-gaap:LicenseMember 2022-12-31 0001689548 prax:UCBMember us-gaap:LicenseMember 2024-01-01 2024-03-31 0001689548 prax:UCBMember us-gaap:LicenseMember 2024-03-31 0001689548 prax:TenaciaMember us-gaap:LicenseMember 2024-01-04 0001689548 prax:TenaciaMember 2024-01-04 2024-01-04 0001689548 prax:TenaciaMember 2024-01-04 0001689548 2024-01-04 0001689548 prax:TenaciaMember 2024-01-01 2024-01-31 0001689548 prax:TenaciaMember us-gaap:LicenseMember 2024-01-31 0001689548 prax:TenaciaMember 2024-03-31 0001689548 prax:TenaciaMember 2024-01-01 2024-03-31 0001689548 prax:FollowOnOfferingMember 2023-06-21 0001689548 us-gaap:OverAllotmentOptionMember 2023-06-21 2023-06-21 0001689548 prax:PreFundedWarrantMember prax:FollowOnOfferingMember 2023-06-21 0001689548 us-gaap:WarrantMember prax:FollowOnOfferingMember 2023-06-21 0001689548 prax:FollowOnOfferingMember 2023-06-21 2023-06-21 0001689548 srt:MaximumMember prax:PreFundedWarrantMember 2024-01-01 2024-03-31 0001689548 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001689548 prax:FollowOnOfferingMember 2024-01-16 2024-01-16 0001689548 prax:FollowOnOfferingMember 2024-01-16 0001689548 us-gaap:OverAllotmentOptionMember 2024-01-16 2024-01-16 0001689548 prax:PreFundedWarrantMember prax:FollowOnOfferingMember 2024-01-16 0001689548 us-gaap:WarrantMember prax:FollowOnOfferingMember 2024-01-16 0001689548 us-gaap:EmployeeStockOptionMember 2024-03-31 0001689548 us-gaap:EmployeeStockOptionMember 2023-12-31 0001689548 prax:PreFundedWarrantMember prax:June2023FollowOnOfferingMember 2024-03-31 0001689548 prax:PreFundedWarrantMember prax:June2023FollowOnOfferingMember 2023-12-31 0001689548 prax:PreFundedWarrantMember prax:January2024FollowOnOfferingMember 2024-03-31 0001689548 prax:PreFundedWarrantMember prax:January2024FollowOnOfferingMember 2023-12-31 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockIncentivePlanMember 2024-03-31 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockIncentivePlanMember 2023-12-31 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockPurchasePlanMember 2024-03-31 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockPurchasePlanMember 2023-12-31 0001689548 us-gaap:StockCompensationPlanMember prax:InducementPlanMember 2024-03-31 0001689548 us-gaap:StockCompensationPlanMember prax:InducementPlanMember 2023-12-31 0001689548 us-gaap:RestrictedStockMember 2024-03-31 0001689548 us-gaap:RestrictedStockMember 2023-12-31 0001689548 prax:InducementPlanMember 2024-03-31 0001689548 prax:A2020EmployeeStockIncentivePlanMember 2024-03-31 0001689548 prax:A2020EmployeeStockIncentivePlanMember 2023-12-31 0001689548 prax:A2017EmployeeStockIncentivePlanMember 2024-03-31 0001689548 prax:A2017EmployeeStockIncentivePlanMember 2023-12-31 0001689548 prax:TwentyTwentyEmployeeStockPurchasePlanMember 2024-03-31 0001689548 prax:TwentyTwentyEmployeeStockPurchasePlanMember 2023-12-31 0001689548 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001689548 prax:UnvestedRestrictedStockUnitsMember 2024-03-31 0001689548 prax:UnvestedRestrictedStockUnitsMember 2024-01-01 2024-03-31 0001689548 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001689548 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001689548 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001689548 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001689548 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001689548 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001689548 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001689548 us-gaap:SubsequentEventMember prax:FollowOnOfferingMember 2024-04-02 2024-04-02 0001689548 us-gaap:SubsequentEventMember prax:FollowOnOfferingMember 2024-04-02 0001689548 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-04-02 2024-04-02 0001689548 prax:PreFundedWarrantMember us-gaap:SubsequentEventMember prax:FollowOnOfferingMember 2024-04-02 0001689548 us-gaap:WarrantMember us-gaap:SubsequentEventMember prax:FollowOnOfferingMember 2024-04-02 shares iso4217:USD iso4217:USD shares pure prax:platform prax:candidate prax:segment prax:security prax:obligation false 2024 Q1 0001689548 --12-31 0.0667 0.0667 0.0667 0.0667 10-Q true 2024-03-31 false 001-39620 PRAXIS PRECISION MEDICINES, INC. DE 47-5195942 99 High Street 30th Floor Boston MA 02110 617 300-8460 Common Stock, par value $0.0001 per share PRAX NASDAQ Yes Yes Non-accelerated Filer true false false 17107887 151980000 81300000 55436000 0 4388000 3580000 211804000 84880000 35873000 0 476000 588000 1840000 2064000 416000 416000 250409000 87948000 9404000 5815000 6976000 7416000 1158000 1126000 1256000 1392000 18794000 15749000 1066000 1369000 866000 1161000 20726000 18279000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 150000000 150000000 13258047 13258047 8791877 8791877 13000 13000 923141000 723577000 3000 0 -693474000 -653921000 229683000 69669000 250409000 87948000 431000 683000 26984000 25504000 15333000 13270000 42317000 38774000 -41886000 -38091000 2333000 636000 2333000 636000 -39553000 -37455000 -2.84 -2.84 -10.58 -10.58 13904374 13904374 3540185 3540185 -39553000 -37455000 3000 154000 -39550000 -37301000 8791877 13000 723577000 -653921000 0 69669000 14475000 14475000 10836000 3802025 161649000 161649000 376000 209852 6169000 6169000 443253 17265000 17265000 11095 3689 137000 137000 3634 143000 143000 3000 3000 -39553000 -39553000 13258047 13000 923141000 -693474000 3000 229683000 3292163 5000 606918000 -530644000 -173000 76106000 7593000 7593000 560000 560253 1000 18095000 18096000 11516 2875 127000 127000 2970 101000 101000 154000 154000 -37455000 -37455000 3864027 6000 632580000 -568099000 -19000 64468000 -39553000 -37455000 112000 106000 14475000 7593000 224000 201000 84000 -45000 2500000 0 808000 -1771000 3589000 2314000 -608000 -6498000 -271000 -240000 -431000 -683000 -2000 0 -20857000 -32846000 91220000 0 0 34000000 -91220000 34000000 161649000 0 14765000 0 6337000 18096000 137000 127000 143000 101000 182757000 18070000 70680000 19224000 81716000 62031000 152396000 81255000 151980000 80839000 416000 416000 152396000 81255000 168000 0 Nature of the Business<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system ("CNS"), disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using its understanding of shared biological targets and circuits in the brain. Each platform has multiple programs currently, with significant potential for additional program and indication expansion: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Cerebrum</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™, the Company's small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Solidus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™, the Company's antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For the Company's most advanced product candidate under the Cerebrum™ platform, ulixacaltamide (formerly known as PRAX-944), it expects to announce topline results from the ongoing Phase 3 Essential3 clinical trials in essential tremor in the second half of 2024. Within the Company's PRAX-628 program, it announced positive results from its Photo-Paroxysmal Response ("PPR") study in the first quarter of 2024 and plans to initiate the first of two efficacy studies of PRAX-628 in focal onset seizures in the second half of 2024, with topline results expected in 2025. The Company plans to initiate a second PRAX-628 efficacy study in focal onset seizures in the first half of 2025, with topline results expected in the first half of 2026. The Company's PRAX-562 Phase 2 EMBOLD study was initiated in the first quarter of 2023, with cohorts in SCN2A-DEE and SCN8A-DEE; topline results are expected for both cohorts in the third quarter of 2024. For the Company's most advanced product candidate under the Solidus™ platform, elsunersen (formerly known as PRAX-222), it shared results from Part 1 of the EMBRAVE study in the fourth quarter of 2023, and is currently completing multiple global regulatory interactions in anticipation of starting the pivotal phase of the program later in 2024. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, from the sale of common stock through an initial public offering and at-the-market offerings under its shelf registration statement, and from follow-on public offerings of common stock and pre-funded warrants to purchase common stock. From inception through March 31, 2024, the Company raised $785.3 million in aggregate cash proceeds from these transactions, net of issuance costs. In April 2024, the Company raised net proceeds of $215.8 million from a follow-on public offering of common stock and pre-funded warrants. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses since its inception, including a net loss of $39.6 million for the three months ended March 31, 2024. In addition, as of March 31, 2024, the Company had an accumulated deficit of $693.5 million. The Company expects to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2024 of $243.3 million will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div> 2 4 785300000 215800000 -39600000 -693500000 243300000 Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the "Effective Time").</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities Classification</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses in accumulated other comprehensive loss, a component of stockholders’ equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more-likely-than-not that the Company will hold these assets through to their maturity dates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of March 31, 2024, the condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 and the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. Financial statement disclosures for the three months ended March 31, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 480) and ASC No. 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2023, the FASB issued ASU No. 2023-07,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the "Effective Time").</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities Classification</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses in accumulated other comprehensive loss, a component of stockholders’ equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more-likely-than-not that the Company will hold these assets through to their maturity dates.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of March 31, 2024, the condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023, the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 and the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. Financial statement disclosures for the three months ended March 31, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 480) and ASC No. 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2023, the FASB issued ASU No. 2023-07,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.</span></div> 1 Cash Equivalents and Marketable Securities<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's investment portfolio as of March 31, 2024. The Company did not hold any cash equivalents or marketable securities as of December 31, 2023 (in thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,626 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company had 33 securities with a total fair market value of $42.6 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. The Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three months ended March 31, 2024 and 2023.</span></div> <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's investment portfolio as of March 31, 2024. The Company did not hold any cash equivalents or marketable securities as of December 31, 2023 (in thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,626 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 15971000 0 0 15971000 17889000 0 0 17889000 12009000 0 1000 12008000 2450000 0 1000 2449000 59722000 12000 0 59734000 26602000 0 2000 26600000 1934000 0 3000 1931000 3046000 0 2000 3044000 139623000 12000 9000 139626000 33 42600000 87782000 0 35873000 0 123655000 0 0 0 Fair Value Measurements<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of December 31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,594 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of December 31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,594 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 15971000 0 0 15971000 17889000 0 0 17889000 0 12008000 0 12008000 0 2449000 0 2449000 59734000 0 0 59734000 0 26600000 0 26600000 0 1931000 0 1931000 0 3044000 0 3044000 93594000 46032000 0 139626000 Accrued Expenses<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,717 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,957 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,717 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,957 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4717000 2957000 1661000 3716000 598000 743000 6976000 7416000 Commitments and Contingencies<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023. This lease qualifies as an operating lease.</span></div> 0.02 Collaboration and License Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB Option and License Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company entered into an Option and License Agreement (“the Collaboration Agreement”) with UCB Biopharma SRL (“UCB”) for the discovery of small molecule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a $5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to $98.5 million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that UCB is a customer, and as such, the arrangement falls within the scope of Topic 606. At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be $5.0 million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for its research services performance obligation over time using an input method over the duration of the research services. During the three months ended March 31, 2024, the Company recognized $0.4 million in collaboration revenue related to the Collaboration Agreement in the condensed consolidated statement of operations. As of March 31, 2024, $2.1 million was included in deferred revenue in the condensed consolidated balance sheet, of which $1.3 million was classified as current. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tenacia Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2024, the Company entered into an exclusive collaboration and license Agreement (“the License Agreement”) with Tenacia Biotechnology (Shanghai) Co., Ltd. (“Tenacia”), a China-based portfolio company of Bain Capital, which provides Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company also entered into a Stock Purchase Agreement (“the Stock Purchase Agreement”) with BCPE Tenet Holdings Cayman, Ltd. (“BCPE”), a related party of Tenacia. Pursuant to the terms of the License Agreement, the Company was entitled to an up-front, non-refundable and non-creditable cash payment of $5.0 million, net of certain tax withholdings. In addition, the Company is eligible to receive $264.0 million in success-based development and commercialization milestone payments as well as tiered royalties on net sales. Pursuant to the terms of the Stock Purchase Agreement, the Company issued and sold 443,253 shares of its common stock to BCPE at a price per share of $22.5605 for aggregate gross proceeds of $10.0 million. The per share price was based on a 20% premium over the 30-day volume-weighted average price.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the License Agreement, the Company granted to Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the License Agreement and the Stock Purchase Agreement is a combined arrangement since they were executed at the same time and in contemplation of each other with the same counterparty or a related party thereof and the combined arrangement falls within the scope of Topic 606. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s obligations under the arrangement comprise a single promise, or one performance obligation, related to the exclusive development and commercialization license granted to Tenacia. Total proceeds associated with the combined arrangement at inception were $14.8 million consisting of the following: (i) $10.0 million gross proceeds from the sale of common stock under the Stock Purchase Agreement and (ii) $4.8 million, net of tax, related to the up-front payment under the License Agreement, both of which were received in January 2024. During the three months ended March 31, 2024, the Company had not achieved any development or sales milestones or earned any royalties under the License Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the common stock sold to BCPE at its issuance date fair value of $38.95 per share, or $17.3 million in the aggregate, which exceeded the proceeds received which were calculated based on the 20% premium over the prior 30-day volume-weighted average price. Accordingly, there is no transaction price allocable to the performance obligation as of March 31, 2024. The Company accounted for the excess of the fair value of the equity securities issued over the total proceeds received as consideration paid to a customer for which no distinct good or service was transferred in exchange. As a result, the transaction gives rise to negative revenue on a cumulative basis in the amount of $2.5 million, which was recorded in research and development expense in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2024. For agreements where the licenses are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time that the Company effectively grants the license, as the licenses or assignments represent functional intellectual property.</span></div>As of March 31, 2024, the Company did not have any receivables or deferred revenue related to the arrangement with Tenacia. The Company did not recognize any contract assets related to costs to obtain a contract with a customer or costs to fulfill a contract with a customer through March 31, 2024 because no qualifying costs were incurred. During the three months ended March 31, 2024, the Company did not recognize any revenue associated with the combined arrangement. 5000000.0 98500000 1 5000000.0 400000 2100000 1300000 5000000.0 264000000.0 443253 22.5605 10000000.0 0.20 P30D 1 14800000 10000000 4800000 38.95 17300000 0.20 P30D 2500000 Common Stock and Preferred Stock<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the period prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company did not hold any treasury shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-On Public Offerings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2023 Public Offering</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2023, the Company completed a public offering of: (i) an aggregate of 4,296,646 shares of its common stock at a public offering price of $14.25 per share, including the underwriters’ full exercise of their option to purchase 619,979 additional shares of common stock, and (ii) pre-funded warrants to purchase 470,000 shares of common stock at a public offering price of $14.2485 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0015 per share exercise price for each underlying share. Total net proceeds generated from the offering were approximately $63.4 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause either the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 9.99%, or the combined voting power of the securities beneficially owned by such holder, together with its affiliates, to exceed 9.99%. A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company. The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. In the event of certain fundamental transactions where the consideration payable to the holders of shares of common stock consists solely of cash and/or marketable securities, the pre-funded warrants will automatically be deemed to be exercised in full pursuant to a cashless exercise effective immediately prior to and contingent upon the consummation of such transaction. As of March 31, 2024, none of the pre-funded warrants had been exercised and all remain outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">January 2024 Public Offering </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2024, the Company completed a public offering of: (i) an aggregate of 3,802,025 shares of its common stock at a public offering price of $35.50 per share, including the underwriters' full exercise of their option to purchase 633,750 additional shares of commons stock, and (ii) pre-funded warrants to purchase 1,056,725 shares of common stock at a public offering price of $35.4999 per share of common stock underlying the warrants. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $161.6 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause either the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%), or the combined voting power of the securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. As of March 31, 2024, none of the pre-funded warrants had been exercised and all remained outstanding.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the pre-funded warrants related to both the June 2023 and January 2024 public offerings are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity’s Own Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved the following shares of common stock for future issuance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of pre-funded warrants related to the June 2023 Financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of pre-funded warrants related to the January 2024 Financing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2024 Inducement Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">996,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of authorized common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,957,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,384,683 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, $0.0001 par value.</span></div> 150000000 150000000 0.0001 0.0001 0 0 4296646 14.25 619979 470000 14.2485 0.0015 63400000 0.0999 0.0999 0.1999 P61D 3802025 35.50 633750 1056725 35.4999 0.0001 161600000 0.0499 0.0999 0.0499 0.0999 0.1999 P61D <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved the following shares of common stock for future issuance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of pre-funded warrants related to the June 2023 Financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of pre-funded warrants related to the January 2024 Financing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2024 Inducement Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">996,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of authorized common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,957,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,384,683 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1084026 666163 470000 470000 1056725 0 111028 148264 141029 53111 996950 0 97601 47145 3957359 1384683 10000000 10000000 0.0001 0.0001 Stock-Based Compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Inducement Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Board of Directors ("the Board") adopted the 2024 Inducement Plan (the "Inducement Plan") without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules ("Rule 5635(c)(4)"). In accordance with Rule 5635(c)(4), the Inducement Plan allows the Company to grant awards only to a newly hired employee who was not previously an employee or non-employee director or to an employee who is being rehired following a bona fide period of non-employment if such award is a material inducement to such employee entering into employment. The total number of shares of common stock authorized for issuance under the Inducement Plan as of March 31, 2024 was 1,000,000 shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of March 31, 2024 and December 31, 2023 was 1,100,833 shares and 661,240 shares, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan") as of March 31, 2024 and December 31, 2023 was 395,850 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of March 31, 2024 and December 31, 2023 was 175,145 shares and 87,227 shares, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s restricted stock unit activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.63 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, total unrecognized compensation cost related to unvested restricted stock units was $7.8 million, which is expected to be recognized over a weighted-average period of 2.34 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689,361 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.09 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock Options</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three months ended March 31, 2024:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average grant-date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, total unrecognized compensation cost related to unvested stock options was $24.8 million, which is expected to be recognized over a weighted-average period of 1.88 years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was allocated as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1000000 1100833 661240 395850 395850 175145 87227 <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s restricted stock unit activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.63 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 47145 202.27 65333 43.35 11346 316.60 3531 35.63 97601 88.63 7800000 P2Y4M2D <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689,361 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.09 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 666163 160.19 428850 43.36 3634 39.30 38000 7353 124.58 1084026 114.62 P8Y4M17D 14197000 689361 129.09 P8Y21D 7632000 1084026 114.62 P8Y4M17D 14197000 <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three months ended March 31, 2024:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average grant-date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.0388 P6Y3D 0.8875 0 32.70 24800000 P1Y10M17D <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was allocated as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5598000 2223000 8877000 5370000 14475000 7593000 Net Loss per Share<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential shares issuable under the 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,038 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares issuable upon exercise of the pre-funded warrants that were sold in connection with the June 2023 and the January 2024 underwritten public offering are included in the calculation of basic weighted average number of common shares outstanding for the three months ended March 31, 2024. Consistent with the guidance in ASC 260-10-45-13, the underlying common shares are issuable for little to no consideration and there are no vesting conditions or contingencies associated with the warrants. Accordingly, the aggregate number of common shares underlying the pre-funded warrants have been considered outstanding for purposes of the calculation of basic net loss per share from the date of issuance.</span></div> <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential shares issuable under the 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,038 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1084026 712737 97601 50317 27827 11984 1209454 775038 Related Party Transactions<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, the Company entered into a Cooperation and License Agreement (the “License Agreement”) with RogCon Inc. (“RogCon”). Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon's intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Pursuant to the terms of the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the associated research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. One of the founders of RogCon became the Company's General Counsel in June 2020. The Company continues to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. Expenses incurred during all periods presented were not material.</span></div> Subsequent Events<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2024 Financing</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 2, 2024 the Company completed a public offering of: (i) an aggregate of 3,849,558 shares of its common stock at a public offering price of $56.50 per share, including the underwriters' full exercise of their option to purchase 530,973 additional shares of common stock, and (ii) pre-funded warrants to purchase 221,238 shares of common stock at a public offering price of $56.4999 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the $0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately $215.8 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.</span></div> 3849558 56.50 530973 221238 56.4999 0.0001 215800000 false false false false Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details. Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.